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Abstract· 
Resveratrol, a polyphenol found in red wine, has been reported to have 
antithrombotic, antiatherogenic, and anticancer properties both in vitro and III VIVO. 
However, possible antidiabetic properties of resveratrol have not been examined. The 
objective of this study was to investigate the direct effects of resveratrol on basal and 
insulin-stimulated glucose uptake and to elucidate its mechanism of action in skeletal 
muscle cells. In addition, the effects of resveratrol on basal and insulin- stimulated amino 
acid transport and mitogenesis were also examined. 
Fully differentiated L6 rat skeletal muscle cells were incubated with resveratrol 
concentrations ranging from 1 to 250 IlM for 15 to 120 min. Maximum stimulation, 201 
± 8.90% of untreated control, (p<0.001), of2eH] deoxy- D- glucose (2DG) uptake was 
seen with 100 IlM resveratrol after 120 min. Acute, 30 min, exposure of the cells to 100 
nM insulin stimulated 2DG uptake to 226 ± 12.52% of untreated control (p<0.001). This 
appears to be a specific property of resveratrol that is not shared by structurally similar 
antioxidants such as quercetin and rutin, both of which did not have any stimulatory 
effect. Resveratrol increased the response of the cells to submaximal insulin 
concentrations but did not alter the maximum insulin response. Resveratrol action did not 
require insulin and was not blocked by the protein synthesis inhibitor cycloheximide. 
L Y294002 and wortmannin, inhibitors of PI3K, abolished both insulin and resveratrol-
stimulated glucose uptake while phosphorylation of AktlPKB, ERK1I2, JNK1I2, and p38 
MAPK were not increased by resveratrol. Resveratrol did not stimulate GLUT4 
transporter translocation in GLUT4cmyc overexpressing cells, in contrast to the 
significant translocation observed with insulin. Furthermore, resveratrol- stimulated 
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glucose transport was not blocked by the presence of the protein kinase C (PKC) 
inhibitors BIMI and G06983. Despite that, resveratrol- induced glucose transport 
required an intact actin network, similar to insulin. 
In contrast to the stimulatory effect seen with resveratrol for glucose transport, 
e4C]methylaminoisobutyric acid (MeAIB) transport was inhibited. Significant reduction 
of MeAIB uptake was seen only with 100uM resveratrol (74.2 ± 6.55% of untreated 
control, p<0.05), which appeared to be maximum. In parallel experiments, insulin (100 
nM, 30 min) increased MeAIB transport by 147 ± 5.77% (p<0.00l) compared to 
untreated control. In addition, resveratrol (100 JlM, 120 min) completely abolished 
insulin- stimulated amino acid transport (103 ± 7.35% of untreated control,p>0.05). 
Resveratrol also inhibited cell proliferation in L6 myoblasts with maximal 
inhibition of eH]thymidine incorporation observed with resveratrol at 50 J.LM after 24 
hours (8 ± 1.59% of untreated control, p<O.OOI). Insulin (100 nM, 24 h) significantly 
increased thymidine incorporation (280 ± 9.92% of untreated control, p<O.OOI) and 
media containing 10% FBS resulted in stimulation of thymidine incorporation to 691 ± 
36.92% of untreated control, p<O.OO1. Resveratrol (50JlM) completely abolished both 
insulin- (11 ± 1.26% of untreated control,p<O.OOI) and FBS- stimulated (36 ± 5.16% of 
untreated control, p<0.05) cell proliferation. 
These results suggest that resveratrol increases glucose transport in L6 skeletal 
muscle cells by a mechanism that is in4ependent of insulin and protein synthesis. 
Resveratrol- stimulated glucose uptake may be PI3K and actin cytoskeleton- dependent 
and independent of AktIPKB, PKC, ERK1I2, JNK1I2, p38 MAPK, and GLUT4 
Resveratrol 6 
translocation. However, unlike glucose transport, resveratrol inhibits both basal and 
insulin- stimulated amino acid transport and mitogenesis. 
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CHAPTER 1: BACKGROUND INFORMATION 
1.1 INSULIN AND INSULIN SIGNALLING 
1.1.1 Insulin 
Insulin is a major anabolic protein hormone regulating numerous physiological 
processes in the liver, adipose tissue, and muscle (1). It is composed of two amino acid 
chains, an alpha (a) chain and a betaW) chain, connected by disulfide bridges. Insulin is 
produced by the beta cells of the islets of Langerhans in the pancreas and is degraded by 
insulinase in the liver and kidney. Initially, insulin is secreted into the portal vein and is 
immediately exposed to liver insulinase. As a result, approximately one half of the insulin 
produced is degraded before entering the peripheral circulation. 
Insulin is an important regulator of amino acid uptake, cell growth, development, 
and survival, lipid metabolism in muscle and adipose tissue, and transcription and 
translation rates as a mitogen, although it is best known for regulation of whole- body 
glucose homeostasis (Figure 1) (2). Plasma glucose elevations cause a rise in insulin 
secretion, which stimulates muscle and fat tissue glucose uptake and glycogen synthesis 
and inhibits liver glycogenolysis and gluconeogenesis, thereby maintaining glucose 
homeostasis (Figure 2). Very recent evidence indicates that insulin is also produced in 
nerve brain cells, although the function is not clear. The major target tissues of insulin 
action are the liver, adipose tissue, and skeletal muscle (Figure 2). 
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1.1.2 Glucose Transporters 
The plasma membrane of cells is composed of a lipid bilayer that is impermeable 
to carbohydrates. Therefore, glucose does not freely travel across the plasma membrane 
and requires membrane- associated carrier proteins for transport. The glucose transporters 
are large integral proteins with 12 membrane- spanning domains. The structure of each 
transporter contains a cytoplasmic carboxyl (C)- and amino (N)- terminal. There are two 
known main groups of glucose transporters, including the sodium- glucose transporters 
(SGLTs) and facilitated diffusion transporters (GLUTs). The SGLTl- sodium dependent 
transporter is found in the intestinal epithelial and renal tubular cells and is responsible 
for sodium- dependent secondary active transport of glucose. When sodium is absent, 
these transporters have a higher affinity for fructose, however when sodium is present, 
the transporter is activated, which increases its affinity for glucose and therefore 
transports glucose against its concentration gradient. 
Glucose is cleared from the bloodstream by a group of facilitative transporters 
known as the GLUTs. There are currently 12 known subtypes of this facilitative 
transporter, but GLUT1- 6 are most commonly discussed (3;4). In contrast to SGLTs, 
these proteins transport glucose down its concentration gradient. The GLUT transporters 
have distinct substrate specificities, tissue distribution, and kinetic properties that define 
their role. GLUTI (46kDa) is ubiquitously expressed with high concentrations in human 
erythrocytes and in endothelial cells lining blood vessels in the brain. The GLUTl 
transporter is essential since it has been characterized as the basal glucose transporter and 
is the major glucose transporter in adipocytes (5). GLUTI has a high affinity (Krn) for 
Resveratrol 16 
glucose at 20mM. GLUT2 is a low affinity transporter (Km = 42mM) found in the liver, 
intestine, kidney, and pancreatic beta cells. This transporter is part of the glucose sensory 
system in beta cells and functions in the basolateral transport of intestinal epithelial cells. 
GLUT3 (45 kDa, Km = 10mM) initially was thought to be expressed in fetal embryonic 
tissues like the placenta. It is also expressed in neurons, allowing glucose to cross the 
blood brain barrier (6). GLUT5, on the other hand, is a fructose transporter located in the 
jejunum of the small intestine with a very low affinity for glucose. The GLUT6 gene 
encodes a pseudogene with no corresponding protein (6;7). 
GLUT4 (48 kDa, Km = 2- 10mM) is an insulin- responsive glucose transporter 
present in skeletal muscle, cardiac muscle, and adipose tissue. Insulin- stimulated glucose 
transporter translocation was initially demonstrated in 1980 by Cushman and Wardzala 
(8) and has been documented in several fat and muscle cell lines since then (9;10). The 
importance of GLUT4 in insulin- stimulated glucose transport was demonstrated in mice 
in which one allele encoding the GLUT4 gene was disrupted. These mice exhibited 
severe insulin resistance (11). During the basal state, GLUT4 is continually cycled 
between the plasma membrane and several intracellular compartments, where the 
majority of the transporters are located inside the cell (~90%) (12). Rapid translocation of 
GLUT4 from an internal pool to the plasma membrane occurs in response to acute insulin 
stimulation in both fat cells and muscle fibres (13). 
1.2 The Insulin Signalling Cascade 
Signal transduction begins with an extracellular signal that produces an 
intracellular response. Molecules that are unable to penetrate the plasma membrane of the 
cell must bind to receptors, which then activates intrinsic enzymatic activity or modulates 
Resveratrol 17 
transducing proteins. This stimulation eventually leads to either the activation or 
inhibition of effector proteins and subsequent alteration of gene expression. Signal 
transduction relies on signalling cascades to convey information to effectors within the 
cell, coordinate information from parallel pathways, and amplify signals (Figure 3). 
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1.2.1 The Insulin Receptor 
The insulin receptor (90kDa) is a heterotetrameric glycoprotein consisting of two 
extracellular alpha subunits containing the insulin binding sites and two beta subunits that 
span the plasma membrane containing cytoplasmic tyrosine kinase domains (14). The 
involvement of the receptor as an early event in insulin action was discovered when the 
occupied insulin receptor demonstrated by specific tyrosine phosphorylation of the beta 
subunit by insulin in a dose- dependent manner (15). 
Insulin binding to the receptor causes a conformational change and leads to the 
autophosphorylation of the intrinsic tyrosine residues on the beta subunits to initiate the 
signalling cascade. Tyrosine autophosphorylation of the receptor is one of the earliest 
cellular responses to insulin stimulation. This causes an increase in tyrosine kinase 
activity leading to activation of insulin receptor substrate- 1 (IRS-I). However, insulin 
binding to its receptor is not essential for insulin receptor signalling since anti- insulin 
receptor antibodies may activate glucose transport (16). It is an active receptor tyrosine 
kinase that is essential for subsequent insulin signalling as evidenced by mutated human 
insulin receptors at the ATP- binding site of the tyrosine kinase domain that failed to 
mediate the post- receptor effects of insulin in both Chinese hamster ovary (CHO) (17) 
cells and NIH 3T3 fibroblasts (18). 
1.2.2 Insulin Receptor Substrates 
The insulin receptor substrates are cytoplasmic proteins that contain 22 potential 
tyrosine phosphorylation sites that serve as recognition sites for cellular substrates 
containing SH2 domains (19;20). Insulin receptor substrates 1 (180kDa) and 2 (185kDa) 
(IRS 1- 4), are phosphorylated on their tyrosine residues by receptor tyrosine kinase, 
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which creates new binding sites on the substrate (19). IRS-l is the major substrate of the 
insulin receptor kinase (19). The amino acids surrounding the phosphotyrosine define the 
specificity of the binding site. IRS-I, in particular, contains multiple tyrosine 
phosphorylation motifs that serve as docking sites for proteins containing a Src homology 
2 (SH2) domain. 
IRS-l and IRS-2 are best characterized for their role in insulin action and glucose 
transport as mediators between insulin receptors and the downstream effector molecules 
(21 ;22). The primary involvement ofIRS- 1 is in somatic cell growth and insulin action 
in muscle and adipose tissue. When IRS- 1 is phosphorylated, it binds with proteins like 
the p85 regulatory subunit of phosphatidylinositol 3- kinase (PBK), to mediate insulin 
action (23;24). Additionally, phosphorylation at Serll0! ofIRS-l by PKCe, results in an 
inhibition of the insulin signalling pathway and suggests a potential mechanism for 
insulin resistance (25). IRS-2 functions as a scaffolding protein to coordinate branches of 
insulin signalling cascades and is important in beta cell survival and growth, insulin 
action in the liver, brain growth, reproduction, and food intake. Therefore, IRS-2 
knockout mice fail to maintain sufficient compensatory insulin secretion and develop 
diabetes (26). Glucose transport activity in IRS-l knockout mice is still increased by 
insulin but with reduced maximum stimulation (27;28). It is suggested that IRS-2 
compensates for IRS-l by binding to a-p85 but it is possible that other substrates are 
upregulated as well. 
Two other alternative insulin receptor substrates are IRS-3, which is expressed in 
adipose tissue, and IRS-4, which is expressed in neuroendocrine tissue. Both IRS-3 and 
IRS-4 are not essential in insulin signalling (29). Studies involving IRS-3 and IRS-4 
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knockout mice showed that in IRS-3 deficient mice plasma glucose and insulin levels 
were similar to the normal mice and did not display defects in growth (29) while the IRS-
4 deficient mice had only minor problems with glucose homeostasis, growth, and 
reproduction (30). 
1.2.3 Chi 
In addition to IRS-1 and IRS-2, the cytoplasmic adaptor protein Cbl (120 kDa) is 
activated through the insulin receptor (31). The structure of Cbl contains an amino-
terminal phosphotyrosine binding domain (TKB) and a C3HC4 RING finger motif. The 
TKB domain recognizes both phosphorylated tyro sines on activated receptor tyrosine 
kinases and non- receptor tyrosine kinases. The RING finger recruits ubiquitin-
conjugating enzymes. 
Activation of Cbl begins with the association of the insulin receptor with the APS 
adaptor protein that contains both a plechstrin homology (PH) and SH2 domain. This 
association is followed by subsequent phosphorylation of the associated protein substrate 
(APS) by the insulin receptor at tyrosine residue 618. Activated APS recruits Cbl to the 
insulin receptor for tyrosine phosphorylation, which is wortmannin- independent (32). 
Then Cbl- associated protein (CAP) binds to Cbl through the SH3 domain (33), allowing 
the complex to migrate to caveolae through interaction with the hydrophobic protein 
flotillin, which is also known as the lipid raft (32). At this point, it is able to bind to the 
SH2 domain of the adaptor protein CrKL (39kDa) leading to the activation of the small 
GTP- binding protein TC10 (32;34) to increase glucose transport through GLUT4 
translocation and possible regulation of the actin cytoskeleton. ChI activation is required 
but not sufficient for insulin- stimulated glucose transport since expression of mutant 
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CAP (CAP LlSH3) that lacks the SH3 domain, reduced the stimulation of glucose 
transport (50%) by insulin without affecting PI3K- dependent signalling events in 3T3-
Ll adipocytes (32;35). 
1.3 THE PI3K1AKT/PKB PATHWAY 
1.3.1 PI3K 
Phosphoinositide 3 kinase (PI3K) is a lipid kinase that is a downstream effector 
protein in the insulin-signalling cascade (23). It is a heterodimer composed of a II0kDa 
catalytic subunit and an 85kDa regulatory subunit. Class lA and Class IB PI3K are 
activated by tyrosine kinase and G- protein coupled receptors respectively. Class lA 
PI3Ks form heterodimeric enzymes that consist of a catalytic and regulatory subunit. The 
catalytic subunit can be further divided into two subclasses, IA and lB. Subclass IA 
contains 110 kDa catalytic subunits of p 11 Oa and p 11 O~, whereas subclass IB contains 
pIlOy. Each catalytic subunit contains an amino- terminal Ras- binding domain and a 
carboxyl- terminal phosphatidylinositol kinase domain. 
Class lA enzymes possess an arninoterminal regulatory subunit- binding domain 
and may bind to five types of regulatory subunits; 85a, p55a, p50a, p85~, and p55y. 
Class lAPI3K enzymes contain SH2 domains in their amino- and carboxyl- terminals 
and bind PYXXM of phosphotyrosine motifs that exist in receptor tyrosine kinases 
themselves and their substrates, such as IRS- 1 (36). In contrast, the pI I Or and subclass 
oflB isoforms ofPI3K bind only one regulatory subunit, plOI, which binds to a trimeric 
GTP- binding protein (G- protein), the target ofG- protein coupled receptors (GPCRs). 
The docking of PI3K near the plasma membrane through p85 recognition of the 
receptor phosphorylated YXXM activates the PI3K pathway. PI3K activation catalyzes 
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the phosphorylation of the inositol phospholipid phosphatidylinositol-4,5-bisphosphate 
(PI(4, 5)P2) to generate phosphatidylinositol-3,4,5-triphosphate (PI(3, 4, 5)P3), which 
attracts various kinases and regulators to the plasma membrane and eventually leads to 
cell growth and survival. 
Involvement of PI3K in insulin- stimulated glucose uptake was initially indicated 
when activation was blocked by wortmannin to inhibit glucose uptake and transport in 
skeletal muscle (37). Wortmannin is a fungal metabolite that binds to the plIO catalytic 
subunit oftype 1 PI3K to exert inhibition (38;39). Similar results were also obtained with 
L Y294002 (40), a quercetin derivative that acts as a competitive inhibitor of the A TP 
binding site ofPI3K (41). In addition, the mutant Llp85, which lacks a binding site for the 
pI to catalytic subunit, greatly inhibited insulin- stimulated glucose uptake in CHO cells 
(42), suggesting that PI3K is necessary for glucose transport. Therefore, PI3K activation 
is required for insulin- stimulated glucose transport but its' sufficiency is uncertain. 
Activation of PI3K by other growth factors such as platelet- derived growth factor 
(PDGF) are unable to stimulate glucose transport or GLUT4 translocation (43). However, 
active- PI3K overexpression increases both GLUT4 translocation and glucose uptake to 
50- 100% of full insulin stimulation, yet insulin is able to further increase glucose 
transport (44;45). These studies suggest that an alternative insulin signalling pathway 
exists that is PI3 K - independent. 
1.3.2 Phosphoinositides 
The inositol phospholipid, PIP2, is phosphorylated on its 3- OH group by PI3K to 
generate the lipid products and second messengers phosphatidyl- inositol-3- phosphate 
(PI3P), PI(3, 4)P2, and PIP3• PI3P is localized on endosomes (46) and does not change in 
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response to cellular stimulation. However, recent studies in L6 cells and 3T3- Ll 
adipocytes with exogenous Pl}P suggest that PI3P is produced in response to insulin-
stimulated TC10 activation (a small GTP- binding protein) to promote plasma membrane 
translocation of GLUT4 (47). PI(3, 4)P2 has been shown to be generated through 
. integrin- dependent signalling in human platelets (48). 
PIP3 attracts signalling molecules, such as 3'- phosphoinositide- dependent 
kinase-l (PDKl) (14), PDK2, AktlPKB (49), mTOR (50), and atypical protein kinase Cs 
(PKCs) (51), to the plasma membrane by interacting with plechstrin homology (PH) 
domains. PIP3 is required for maximum PDK1 activity (52). PIP3 does not directly alter 
Akt/PKB but recruits it to the plasma membrane (53) and alters its conformation to allow 
subsequent phosphorylation by PDKI. 
PIP2 and PIP3 are the main substrates of phosphatase and tensin homologue 
deleted on chromosome ten (PTEN), which is a negative regulator of the PI3K1Akt 
pathway (54). PTEN removes a phosphate group from the 3- OH position of PIP3 (55). 
Alternatively, SH2-containing inositol phosphatase 1 (SHIP-I) catalyzes the 
dephosphorylation of PIP3 at the 5- OH position to regenerate PIP2 in order to potentially 
promote Akt/PKB activation (56). 
1.3.3 PDKlIPDK2 
PDKI is a 63-kDa serine/threonine kinase that contains a carboxyl terminal PH 
domain and was originally identified by two different groups (57;58). PDKI localizes to 
the plasma membrane in response to PIP3 in order to activate Akt/PKB. Colocalization, 
which is mediated by the phosphoinositides acting as scaffolding molecules (59), of 
PDKI and AktlPKB at the plasma membrane results in the phosphorylation of AktlPKB 
Resveratrol 24 
at the threonine residue by PDK1 (57) and Ser473 phosphorylation (60). It appears that 
PDK1 interacts with the Ser473- phosphorylated hydrophobic motif (HM) of AktIPKB in 
order to bring PDK1 closer to the Thr308 residue to catalyze its phosphorylation (61). 
The function of PDKI was confinned in a study by Williams et al. (2000)(62), 
where PDK1 was genetically disrupted and resulted in AktIPKB not responding to 
mitogens because Thr308 was not phosphorylated. PDK1 is also substrate specific as 
evidenced by deletion of PDKI in mouse embryonic cells, which demonstrated full 
inhibition of AktIPKB (62). 
1.3.4 AktJPKB 
AktIPKB (56 kDa) is a serinel threonine kinase and shares sequence homology 
with protein kinase A (PKA) and protein kinase C (PKC). Experiments with wortmannin 
and L Y294002, both PI3K inhibitors, and by overexpression of a deletion mutant of the 
regulatory subunit of PI3K, demonstrate that AktIPKB is a downstream target of PI3K 
(49;53). Identification of the AktIPKB signalling pathway began with the 'isolation of the 
Akt1 and Akt2 genes, which are human homologues of the viral oncogene v- akt that 
causes a fonn of leukemia in mice (63). Subsequent studies revealed that v- akt and its 
mammalian homologues encoded a protein kinase that was similar to the already 
discovered PKC and PKA, which is why it was originally termed Related to A and C-
Protein Kinase (RAC- PK) and then changed to PKB (64). The AktIPKB kinase 
expresses three different isofonns, which include PKBal Aktl and PKBW Akt2 that are 
broadly expressed, and PKBy/Akt3 that has a more restricted tissue distribution (65;66). 
Akt3 is expressed mainly in the brain and testes while Akt2 is predominantly expressed 
in insulin target tissues like fat cells, the liver, and skeletal muscle. 
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There are three distinct functional regions on AktIPKB; the N- terminal plechstrin 
homology (PH) domain, the kinase domain, and the C- terminal hydrophobic motif (HM) 
(Figure 4). The PH domain mediates the binding of AktIPKB to the 3- phosphoinositides, 
PI (3,4,5)P3 and PI (3,4)P2 that are generated by PI3K, and binds to both molecules with 
equal affinity (67). The PH domain is common to many signalling proteins and acts as the 
plasma membrane recruitment mechanism for AktIPKB, which is the hallmark of 
AktIPKB activation. The kinase domain is the second region of the PKB molecule and is 
located in the central catalytic domain, which is similar to that ofPKA (68). 
The third area is the C- terminal hydrophobic motif (HM) that contains the second 
regulatory phosphorylation site, Ser473 in PKBalAktl for example. Specifically, the HM 
provides a docking site for the upstream activating kinase 3- phosphoinositide- dependent 
kinase- 1 (PDKl) (69). When this docking interaction is interrupted, phosphorylation of 
the activating loop (T - loop) is attenuated. The main phosphorylation site of AktlPKB is 
within the activation T- loop at the Threonine 308 residue site (for PKBa). 
Phosphorylation of this residue causes a charge- induced change in conformation that 
allows substrate binding and increases the catalytic rate required for enzymatic activity 
(68). 
The HM domain is also an allosteric regulator of catalytic activity (70). The 
catalytic core located in the kinase domain, is stabilized when the HM associates with 
hydrophobic and phosphate- binding pockets created by a cleft formed at the junction of 
the aB- helix, aC- helix, and the 135- sheet in the N- lobe. This pocket is also referred to 
as the PRK2- interacting fragment (PIF)- pocket. Stabilization of the N- lobe increases 
the phosphotransfer rate by ten- fold. 
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Kinase domaln---......... 
Figure 4: Structure of the AktlPKB protein. 
In order for full activation of AktlPKB to occur, the Ser473 residue must be 
phosphorylated at the plasma membrane to increase the HM affinity for the PIF- pocket, 
unfortunately identification of this mechanism is still controversial (71). One theory 
suggests that PDK1 converts to a Ser473 kinase after Thr308 phosphorylation because it 
interacts with Akt/PKB and PRK-2, a protein fragment. Since Ser473 phosphorylation is 
dependent on PI3K and Thr308 activity, it was thought that PDKI was the Ser473 kinase 
(72). However, ES PDK1 knockout mouse cells disproved this theory when Ser473 
phosphorylation was similar to the wildtype and Thr308 phosphorylation was completely 
abolished. On the other hand, PDK1 overexpression in transfected cells increased 
AktlPKB phosphorylation on Ser473, which indicated that PDK1 might have an indirect 
contribution to Ser473 phosphorylation (62). 
Toker and Newton (2000) (73) argue that Ser473 is modified through 
autophosphorylation of AktIPKB. Another possibility is that Ser473 may be 
phosphorylated by serine kinases like integrin- linked kinase- 1 (ILK- 1) (74). ILK- 1 is 
activated by insulin in a PI3K- dependent manner, which is in accordance with AktlPKB 
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signalling. ILK- 1 could alternatively act as a facilitator instead of phosphorylating 
Akt/PKB directly since ILK- 1 kinase dead mutants were able to induce Ser473 
phosphorylation (75). Persad et al. (2001) (76) also demonstrated that an ILK- inhibitor 
blocked Ser473 phosphorylation of AktlPKB, suggesting that ILK- 1 could be an 
important upstream kinase for the regulation of Akt/PKB. It appears that PDKI 
phosphorylates Thr30S and an unidentified PDK2 phosphorylates Ser473 on Akt/PKB. 
Recently, Hill et al. (2002) (77) isolated a protein kinase that specifically phosphorylated 
Ser473 but identification requires further investigation. 
PI3K is also required for phosphorylation of Ser473 but the mechanism is distinct 
from Akt/PKB membrane localization. The role of PI3K has several possibilities such as 
PI3K- derived lipids activating a distinct Ser473 kinase, inhibiting a phosphatase, or even 
regulating the binding of a Ser473 regulatory protein (7S). Scheid et al. (2002b) (79) also 
found that PI3K is important in Ser473 phosphorylation. In this study, mast cells derived 
from SHIP- knockout mice showed that Ser473 activity was sensitive to PI3K inhibition 
even though PIP3 levels were high, Thr30S phosphorylation was normal, and AktlPKB 
membrane localization was strong. PIP2 may also have a role in promoting Ser473 
phosphorylation because cells lacking SHIP pool PIP3, which decreases PI3K activity and 
abolishes PIP2. The addition of PIP2 restored Ser473 phosphorylation and subsequent 
AktlPKB activation (SO). 
Akt/PKB may also be phosphorylated on Serl24 and Thr450 residues but these 
sites do not regulate AktlPKB and their phosphorylation is unchanged after stimulation 
(71). When PKBylAkt3 is spliced to PKByl, which lacks the Ser472 phosphorylation site 
and only requires Threonine 305 phosphorylation for activation, Thr 305 phosphorylation 
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is decreased after pervanadate stimulation and insulin- induced PKBy1 translocation is 
reduced, suggesting that the second phosphorylation site limits its maximum potential for 
membrane translocation and catalytic activation (81). In summary, in the resting non-
stimulated cell, the majority of AktIPKB is located in the cytoplasm and when activated, 
it is translocated to the plasma membrane and then followed by translocation to the 
cytosol and the nucleus to elicit a response (61). 
Phosphorylated AktIPKB has many functions, which is partly attributed to the 
variation and specificity of its substrates. Mouse gene knockouts for each isoform of 
AktJPKB provide significant insights into their specific functions. AktIPKB is a regulator 
of several cellular processes, including apoptosis, proliferation, differentiation, and 
metabolism. For example, downstream of AktJPKB, glycogen synthase kinase- 3 (GSK-
3), the pro- apoptotic protein Bad, caspase- 9, Forkhead transcription factor (82), p70 
ribosomal S6 kinase, Id3 kirtase- a (IKKa) (83), and endothelial nitric oxide synthase 
(eNOS) (84) are activated. 
Glycogen synthase kinase- 3 (GSK- 3) inactivates glycogen synthase in order to 
build up cellular glycogen stores in response to insulin stimulation and was the first 
substrate identified for AktIPKB (49). The PI3K1 PDKI Akt pathway enhances cyclin DI 
protein stability by inactivating GSK- 3(3 through phosphorylation at Ser21, thereby 
preventing it from causing ubiquitin- mediated degradation of cyclin DI (85). 
Phosphodiesterase 3B is also phosphorylated by AktIPKB to its active form and 
regulates intracellular cAMP and cGMP in response to insulin (86) while 6-
phosphofructo- 2- kinase is activated by AktJPKB to promote glycolysis (87). The 
mammalian target of rapamycin (mTOR) regulates mRNA translation in signalling 
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pathways and is phosphorylated by AktlPKB (88). However, p70 S6 kinase activity, a 
downstream target ofmTOR, is not increased (89). Protein tyrosine phosphatase (PTPIB) 
negatively regulates insulin sensitivity by acting as a phosphatase to dephosphorylate the 
insulin receptor. AktIPKB phosphorylates PTPIB to inhibit PTPIB phosphatase activity 
and enhances insulin signalling (90). 
The most well known function of AktIPKB is its involvement in insulin-
stimulated glucose transport where AktIPKB is translocated to the plasma membrane in 
response to insulin stimulation (91). For example, overexpression of AktIPKBa in 3T3-
Ll rat adipocytes increases glucose transport by stimulating GLUT4 translocation to the 
plasma membrane (92). AktlPKB co- localization with GLUT4- containing vesicles in 
3T3-Ll adipocytes is suggested to be involved in GLUT4 translocation (93). 
Additionally, Carvalho et al. (2000) (94) demonstrated that obese Zucker rats with 
impaired translocation of GLUT4 had defects in PI3K and AktlPKB that reduced 
activation. 
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Figure 5: GLUT4 translocation in response to insulin stimulation via PI3K1 Akt. 
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1.4 THE RAS/MAPK PATHWAY 
1.4.1 RAS 
Ras (21kDa) is a guanine- nucleotide binding protein that is activated by receptor 
tyrosine kinases and G- protein coupled receptors. Activation of the insulin receptor 
results in the interaction of the adaptor protein growth factor receptor- binding protein 2 
(Grb2)- Son of sevenless (Sos) complex with tyrosine phosphorylated IRS- 1, through the 
cytosolic scaffold protein Shc, to link the insulin receptor to the Ras- signalling pathway 
leading to ERK1I2 activation. The Grb2- Sos complex is formed by Sos, a guanine 
nucleotide exchange factor, binding to the SH3 domain of Grb2, which enhances GTP 
binding to Ras to make it active (Figure 6) (95;96). 
1.4.2 . RAF 
The Ras- Raf physical interaction was a significant breakthrough in the ERK1I2 
signalling cascade. GTP- Ras, which is the active form, binds to both sites of Raf (65-
75kDa), which include the Ras binding domain (RBD) and the cysteine- rich domain 
(CRD). Activated Ras can bind to anyone of the three isoforms of Raf; Raf- 1 (c- Rat), 
B- Raf, or A- Raf, to induce phosphorylation at multiple sites and then translocates to the 
plasma membrane where protein kinase activity is increased and the kinase cascade is 
activated (97). Different Ras isoforms activate Raf to varying degrees but only Raf- 1 and 
B- Raf phosphorylate MEKlI 2 (98). 
1.4.3 MEK1I2 
Subsequently, Raf phosphorylates the serine residues (positions 217 and 221) of 
the dual specificity protein kinases, MEKI (45 kDa) and MEK2 (99). This step involves 
amplification of the signalling cascade because Raf is present at much lower 
concentrations than MEKI and MEk2. MEK1I2 activates ERK1I2 MAP kinase by 
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phosphorylating both threonine and tyrosine residues at sites located within the activation 
loop of kinase sub domain VIII (100). 
1.4.4 ERK1I2 MAPK 
Since ERKI (44 kDa) and ERK2 (42 kDa) have overlapping signal capabilities, 
they are often listed as ERK1I2 and are the only well established substrates of MEKl12. 
Other ERK isoforms have been identified by molecular cloning but are not as well 
understood and include ERK3 (62 kDa), ERK4, ERK5 (110 kDa), ERK6 (38 kDa), and 
ERK7 (61 kDa) (101). ERK3 is similar to ERK1I2 but is more highly concentrated in the 
nucleus (102) as opposed to the cytoplasm, while ERK5 is implicated in cell 
transformation and cell cycle control (103). In addition, ERK7 is involved in cell 
proliferation but requires further investigation (104). 
ERKs are the most well studied MAPK family members and were the first 
signalling MAP kinase cascade to be recognized. ERK was originally termed "MAPK" 
and was first described in 1986 (105). Original identification of ERK was as a protein 
kinase that phosphorylated microtubule- associated protein 2 (MAP2), a cytoskeletal 
protein, in response to receptor protein tyrosine kinase activation by insulin (105). 
Additionally p42/ 44 MAPKs were found to regulate the protein kinase p90rsk (106). 
Later studies identified the 44 kDa isoform ofMAPK called ERKI (107). 
Mitogenic stimuli, cytokines, neurotrophic and growth factors, neurotransmitters, 
and hormones such as insulin activate ERKII 2. More recently, oxidative stress that 
induces apoptosis was found to mediate ERK1I2 phosphorylation (108). Phosphorylation 
of both tyrosine and threonine residues of ERKI and ERK2 is catalyzed by MEKI and 
MEK2. Dual phosphorylation is required in order to achieve high activity. No 
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amplification is needed in this step since the concentrations ofboth·ERKll2 and MEKII2 
are equivalent. The relatively high intracellular concentration of these enzymes is partly 
responsible for the rapid activation observed. 
Downstream ERK112 activation leads to nuclear translocation from the cytoplasm 
and altered gene expression. ERK1I2 phosphorylates numerous enzymes and proteins 
that are involved in a variety of cellular processes. A specific example of ERK1I2 
phosphorylation involves the induction of the c- fos gene via Elk- 1. This results in the 
activation of a variety of transcriptional factors like activating protein- 1 (AP- 1) (109). 
ERK1I2 also phosphorylates the c- myc and c- jun transcription factors that control 
protein expression involved in cell growth (110). Additional substrates of ERKI and 
ERK2 include factors involved in translation (PHAS- I), proteins· involved in 
phosphorylation and dephosphorylation reactions (protein phosphatase 2C), and various 
signalling enzymes (cytoplasmic phospholipase A2). 
Specific ERK pathway inhibitors are commonly used to determine ERK 
requirements and functions. ERKl/2 plays a critical role in the regulation of cell growth 
and differentiation. Insulin is a pleiotropic hormone and therefore, in addition to glucose 
uptake, insulin stimulates mitogenesis to promote cell proliferation and differentiation. It 
has been previously documented that L6 myoblasts exhibit a proliferative response when 
stimulated with either insulin or insulin-like growth factor- 1 (IGF-l) (111;112) and that 
the mechanism of insulin- stimulated cell proliferation involves the activation of the Ras-
Raf- ERK1I2 pathway, which is similar to many other growth factors (96) (Figure 6). In 
order to promote DNA synthesis, insulin activates the Grb2/Ras/RaflERK1I2 pathway, 
which requires an intact cytoskeleton but is independent ofPKC (113). 
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ERKl12 activation also mediates cell cycle arrest (114). Constitutively activated 
MEK1, which is an upstream kinase of ERK1I2, has been shown to accelerate cell entry 
into the S phase of the cell cycle. In addition, 4- OH- tamoxifen- stimulated MEK1 
down- regulated p27 and up- regulated cyclin D1 protein expression in NIH 3T3 cells, 
indicating a link between the ERKl12 signalling pathway and the cell cycle (115). 
Another possible target ofERK is the pro- apoptotic Bcl- 2 family protein Bad (116). Bad 
influences mitochondrial membrane integrity and the release of cytochrome c from the 
mitochondria indirectly by associating with Bcl- 2 and Bcl- XL and inhibiting their anti-
apoptotic function. 
ERK1I2 activation inhibits apoptosis induced by vanous stimuli including 
hypoxia (117), growth factor withdrawal (118), hydrogen peroxide (119), and 
chemotherapeutic agents and mediates non- apoptotic cell death as well (120). Xia et al. 
(1995) (121) observed that growth factor withdrawal- induced apoptosis inhibited ERK in 
rat PC 12 cells. In Raf- 1 knockout mice, B- Raf was discovered to compensate for Raf- 1 
concerning MEK1I2 activation however these cells were more susceptible to apoptotic 
stimuli despite the presence of A- and B- Raf (122). 
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Figure 6: Insulin signalling- the Ras/Raf7MAPK pathway. 
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1.4.5 p38 MAPK 
Another major subgroup of the MAPK family is p38 MAPK, which was initially 
discovered by several independent labs (123). p38 MAPK or p38a MAPK (38 kDa), 
which is the mammalian homologue of the yeast HOG kinase, was first identified in 
budding yeast as a kinase activated by hyperosmolarity. Han et al., 1994 (124) 
determined p38 MAPK to be a MAPK family member through molecular cloning. 
Homologues of p38a MAPK, including p38~ MAPK (39 kDa) (125), p38y 
MAPK (43 kDa) (ERK6, SAPK3) (126), and p38() MAPK (40 kDa) (SAPK4) (127), 
were later cloned in mammals. p38a MAPK and p38~ MAPK genes are ubiquitously 
expressed (127) while p38y MAPK expression is induced during muscle differentiation in 
skeletal muscle (126). In addition,p388 MAPK expression is developmentally regulated 
in the lung, kidney, testis, pancreas, and small intestine tissues (128). The most widely 
studied isoform is p38a MAPK and still very little information exists on the activation of 
the other homologues. 
p38 MAPK is activated by growth factors (129), muscle contraction (130) and 
numerous other environmental stresses like oxidative stress and pro- inflammatory 
cytokines such as interleukin- 1 (IL- 1), tumour necrosis factor- alpha (TNFa), TNF~, 
and CD40 ligand (131;132). Initiation of the p38 MAPK cascade begins with G- proteins 
like Rac1 and Cdc42 that phosphorylate and activate various MAPKKKs (133;134). p38 
MAPK has divergent signalling pathways, which has been demonstrated through 
knockout mice of certain activators. MKK3 (135) and mitogen activated protein kinase-
activated protein kinase- 2 (MAPKAPK2 or M2) (136) knockout mice were both viable 
but p38a MAPK disruption proved to be lethal, indicating that the p38 MAPK cascade is 
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not a classical step- wise chain reaction. The upstream signalling pathway of p38 MAPK 
is very diverse, which partially explains why activation is stimulated by many stimuli like 
Ask- 1 (137), Msk- 1, Mlk- 3(138), and Tak- 1 (139) for example. Overexpression of any 
ofthese enzymes may activate the p38 MAPK pathway. 
The next step in this signalling cascade is phosphorylation of the group of 
MAPKKs by the MAPKKKs previously listed. The MAPKK family includes kinases like 
MKK3 (140), MKK4 (141), MKK6 (142), and MKK7. Stimulation of these MAPKKs 
activates p38 MAPK through phosphorylation at both the threonine (Thr 180) and 
tyrosine (Tyr 182) residues. These dual kinases have exhibited selective activation of the 
different isoforms of p38 MAPK. For example, MKK6 activates all four isoforms, 
MKK3 activates p38a MAPK, p38y MAPK, and p380 MAPK (125), MKK4 activates 
p38a MAPK and p380 MAPK (143), and MKK7 activates only p380 MAPK (144). Both 
MKK3 and MKK6 are regulated by dual serine and threonine phosphorylation. 
Phosphorylated p38 MAPK may activate either transcription factor or non-
transcription factor targets. Examples of non- transcription factor targets include 
MAPKAPKs -2, -3, -5, and MAP kinase interaction protein kinase (MNK1). MAPKAP 
kinase- 3 was identified as a substrate of p38a MAPK in vitro and was then 
demonstrated in vivo when SB203580, a p38a MAPK and p38p MAPK inhibitor (145) 
blocked its activation. Another non- transcription factor target ofp38 MAPK is MNK1, 
which is able to bind to both p38 MAPK and ERKl, was suggested to have a potential 
link with translational initiation (146). More recently, PRAK (p38 MAPK regulated! 
activated kinase) was identified as a stress activated protein stimulated by p38a MAPK 
and p38p MAPK (147). MSKli2 (mitogen- and stress- activated kinase), which activates 
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another transcription factor called CREB, is also activated by p38a MAPK (148) and 
protects cells from growth factor deprivation- induced apoptosis. 
p38 MAPK mediates the phosphorylation of numerous transcription factors and 
regulates downstream gene transcription (149). Phosphorylation of ATF- 2 and Sap- la 
by p38a MAPK and p3813 MAPK stimulate growth arrest while the transcription factor 
153 (GADDI53) promotes DNA damage (150). p38 MAPK is primarily involved in the 
mediation of apoptosis and inflammation but recent evidence has shown biological 
importance in regulating other cellular processes such as cell proliferation, 
differentiation, inflammation, and developmental processes like actin cytoskeleton 
organization (151). Pro- apoptotic activity ofp38 MAPK was shown by induction with 
NGF withdrawal and Fas ligation (152). However, overexpression of MKK6b induced 
caspase activation and cell death downstream ofp38 MAPK. It appears that p38 MAPK 
functions both upstream and downstream of caspases in the apoptotic response. 
Insulin also activates p38 MAPK in L6 myotubes to increase glucose transport 
through GLUT4 activation (10). Discrepancies have been observed between the 
magnitude of GLUT4 translocation and glucose transport, suggesting that in addition to 
GLUT4 translocation, there is also an increase in the intrinsic activity of GLUT4. 
Sweeney et al. (1999) (153) demonstrated that insulin- stimulated glucose uptake was 
reduced (60%) in both muscle and adipose tissue with the addition ofp38 MAPK family 
inhibitor, SB203580. However, insulin- stimulated GLUT4myc translocation was 
unaffected. SB203580 is one of the most widely used inhibitors ofp38a MAPK and p3813 
MAPK (154) and exerts its inhibition by acting as a competitive inhibitor of the ATP 
binding site of p38 MAPK. In addition, pre~ incubation of L6 myotubes with the 
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azaazulene p38 MAPK inhibitors, A291077 and A304000, produced similar results and 
strengthened the concept that p38 MAPK inhibition reduces insulin- stimulated glucose 
transport (155). Mutant p38 MAPK (p38 MAPKAGF), where the regulatory serine and 
threonine residues were replaced with alanine and phenylalanine, in 3T3- Ll adipocytes 
also reduced insulin- stimulated glucose transport by 40% with no affect on GLUT4 
translocation (155). 
Further study revealed that insulin rapidly phosphorylates p38 MAPK to 
maximum (2.3- fold) within 5- 10 minutes and then declines after 15 minutes (156) and 
that both MKK3 and MKK6 are also activated by insulin upstream ofp38 MAPK (157). 
Similar results were also obtained in mature skeletal muscle (quadriceps and soleus) 
(130). It was suggested that p38 MAPK could activate GLUT4 intrinsic activity and may 
be involved in the activation of newly recruited transporters or be required to complete 
the fusion event. Since GLUT4 translocation precedes maximal glucose uptake, it was 
thought that GLUT4 activation occurs at the plasma membrane and that p38 MAPK 
migrates to the plasma membrane in response to insulin stimulation. Higher levels of 
immunodetectable p38 MAPK lawns were detected at the plasma membrane after insulin 
stimulation in L6 myotubes (Sweeney et al. unpublished data reviewed in (158)), 
supporting the idea that p38 MAPK migrates to the plasma membrane after insulin 
stimulation. 
Whether p38 MAPK directly interacts with GLUT4 still needs to be established 
but it is possible that the mechanism of GLUT4 activity regulation will involve 
phosphorylation of GLUT4 by p38 MAPK or association/dissociation of a ligand by p38 
MAPK. On the other hand, several studies have demonstrated increases in glucose uptake 
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due to insulin, osmotic shock, or hyperosmolarity, which are unaffected by p38 MAPK 
inhibitor treatment (159;160). Fujishiro et al. (2001) (161) found that p38 MAPK 
activation was not necessary for glucose uptake induced by insulin and that it regulated 
glucose transporter expression. Therefore, the effect ofp38 MAPKa and p38 MAPK~ on 
stimulated glucose transport is still unresolved. 
As in many other signalling cascades, it seems that the involvement of p38 
MAPK in apoptosis is cell type and stimulus dependent. p38 MAPK regulation of 
apoptosis induction remains a controversial issue because both anti- apoptotic (162) and 
pro- apoptotic (163) results have been established. 
Another essential role of p38 MAPK activation involves the inflammatory 
response. p38 MAPK is involved in the production of inflammatory cytokines such as IL-
1~, TNF-a, and IL-6 (164;165) and in the induction of enzymes like cyclooxygenase- 2 
(COX-2) that control connective tissue remodelling. More specifically, p38 MAPK is 
suggested to be involved in the translation of both TNFa and IL- 1~, since p38 MAPK 
inhibitors block protein synthesis but do not change the corresponding mRNA levels. 
Consequently, p38 MAPK demonstrated control of pro- inflammatory mRNA translation 
(166). p38 MAPK inhibitors at protein and mRNA levels, blocked expression of COX- 2, 
an additional pro- inflammatory mediator, suggesting that p38 MAPK functioned through 
more than translational regulation (165). 
p38MAPK is strongly activated by pro- inflammatory stimuli (123). p38 MAPK 
inhibitors also destabilized COX- 2 mRNA in IL- 1 stimulated HeLa cells (167) and in 
lipopolysaccharide (LPS)- stimulated primary human monocytes (168) where p38 MAPK 
inhibitors similarly blocked TNFa. As part of the inflammatory response, platelet 
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aggregation is also mediated by p38 MAPK (169). In addition, intracellular enzyme 
expression of iN OS that regulates oxidation and adherent protein induction ofVCAM-l 
is affected. Since initial studies ofp38 MAPK focused on the involvement ofp38 MAPK 
in inflammatory responses, it was also found to be involved in the proliferation and 
differentiation of cells in the immune system (170). 
The involvement of p38 MAPK in cell cycle control was established in 
mammalian cells treated with SB203580. Activated p38 MAPKa was seen in mammalian 
cultured cells arrested in the M phase by spindle disruption with nocodazole (171). In the 
somatic cell cycle, p38 MAPKa activation was involved in the spindle assembly 
checkpoint. G 1 arrest of NIH3T3 cells caused by microinjection of cdc42 was p38 
MAPKa- dependent (172). As a result, it is possible that positive and inhibitory effects 
are exerted by p38 MAPK at different stages of the cell cycle. p38 MAPK is involved in 
the regulation of cell differentiation (173). Morooka et al. (1998) (174) and Engelman et 
al. (1999) (175) demonstrated that the differentiation of3T3- Ll cells into adipocytes and 
PC12 cells into neurons, required p38 MAPKa and! or p38 MAPK~. 
1.4.6 JNK MAPK 
The c- JUll N- terminal protein kinase (JNK) (54kDa) is a serine! threonine protein 
kinase from the family of MAPKs. Kyriakis and Avruch first identified this protein 
kinase in 1990 (176), as a protein kinase activated in the liver of rodents exposed to the 
protein synthesis inhibitor cycloheximide through intraperitoneal injection. 
Cycloheximide activated JNK or stress activated protein kinase (SAPK), which it was 
originally termed, and demonstrated activity with microtubule- associated protein- 2. 
Subsequent studies lead to the isolation and molecular cloning of JNK and demonstration 
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that it belonged to the MAPK family where SAPK and JNK were identical enzymes 
(177). JNK has three encoding genes, JNKI (178), JNK2 (179), and JNK3 (180). JNKI 
and JNK2 are ubiquitously expressed and JNK3 is mainly located in the tissue of the 
brain and testes. Currently 10 different JNK isoforms in the 46 to 55 kDa range have 
been identified in the human brain through molecular cloning. The distinguishing factor 
of each ofthe isoforms is their varying substrate affinities (180). 
There are 11 protein kinase subdomains of JNK (181) that bind adenosine 
triphosphate (ATP) and peptide substrates to maintain the three-dimensional folding 
structure. The N- terminal lobe binds ATP and aids in orientation while the C- terminal is 
involved in substrate recognition and anchoring the phosphate of Mg2+ ATP (182). 
JNK may be activated by cytokines (TNF, IL- 1, other interleukins) and growth 
factors (insulin) through specific receptors and by environmental stresses such as heat 
shock (183), ultraviolet radiation (184), ischemia! reperfusion, hypoxia, glucose 
deprivation, or hyper- osmolarity (185). The mechanism of activation by cellular stresses 
is still unknown, however a study by Rosette and Karin (1996) (186) demonstrated that 
ultraviolet light and osmotic shock stimulation of JNKll2 activation involved clustering 
and internalisation of cell surface receptors for epidermal growth factor (EGF), tumour 
necrosis factor (TNF), and interleukin- 1 (IL- I), playing an important role in the 
mediation of signal transduction. 
The pathway of JNK activation is extremely complex and still incompletely 
understood. Initial receptor activation leads to the recruitment of adaptor molecules (Nck, 
Crk, Shc, or TRAFs) and activation of G- proteins or GTP- binding proteins like Ste20 
homologues and low molecular weight GTP- binding proteins like Cdc42 (187), and 
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members of the- Rho and Rac (Rac-l) family. It is still unclear how growth factor 
receptors activate JNK. One example is through the epidermal growth factor (EGF) 
receptor in order to activate the Rho family and subsequently the Ras proto- oncogene. 
Alternatively, PI3K and/ or PKC isoform activation could be involved (188). It is 
suggested that agonists acting through the TNFa receptor via sphingomyelinase enzymes 
could generate the lipid second messenger ceramide, which could then activate the JNK 
pathway by mechanisms through the Rho family of GTPases. 
Stimulated MAPKKKKs (P AKs, Gck, and HPK) phosphorylate and activate 
MAPKKKs (MLKI- 3, DLK, Tp12, ASK- 1, and TAK- 1). Subsequently, the MAPKKs, 
MKK4 (SEK1) (189) and MKK7 (MAP2K7), which is an isoform of MKK4 (190), are 
phosphorylated and therefore activated on their tyrosine and threonine residues 
respectively, as a catalyst for JNK phosphorylation. MKK4 and MKK7 are analogous to 
MKK1I2 and mutually required for full activation of JNK MAPK through the 
phosphorylation of both threonine and tyrosine residues. JNK inactivation is controlled 
by serine and tyrosine phosphatases and dual specificity MAPK phosphatase. 
JNK1I2 phosphorylates the transcription factor c- lun at Serine 63 (Ser63) and 
Serine 73 (Ser73) and subsequently activates the c- Jun gene. Phosphorylation of c- Jun 
increases its ability to activate activator protein- 1 (AP- 1) enhancer elements in the 
promoters of many genes. JNK ultimately activates specific target proteins like members 
of the AP- 1 transcription factor family and other factors involved in regulating gene 
expression, cell survival, and proliferation. Alternative target substrates of activated 
JNKs include transcription factors such as Elk- 1, Sap- la, NFAT4, p53, ATF2, c- Myc, 
and non- nuclear targets like Bcl- 2, tau, and neurofilament H. Gene disruption studies in 
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mice showed JNK to be required for TNFa stimulated c- Jun phosphorylation and AP- 1 
transcription factor activity (191). ATF2 and Elk- 1 may also be activated by p38 MAPK 
and in addition, ERK has been shown to activate Elk- 1. This demonstrates the possibility 
of cross- talk between the MAPK family pathways since more than one MAPK may 
activate several transcription factors. 
Since there is more than one JNK activator, specificity is required in order to 
achieve the appropriate cellular response. One theory of specific activation involves 
scaffolding proteins that assemble functional signalling molecules. Scaffolding proteins 
lack enzymatic activity and instead act as organizers of specific pathways. An excellent 
example of this organizing ability involves JNK- interacting proteins (JIPs), specifically 
JIP- 1 (192), that are transported by the microtubule motor protein kinesin. Signal 
transduction components are concentrated in a specific area of the cell in order to regulate 
localized activation of JNK within cells and enhance activity. 
Another alternative for signal transduction specificity of JNK is through protein-
protein interaction mediation. A docking site on JNK, distant from the active site, is able 
to bind to the docking motifs, D- domain, and FXFP, located in the interacting proteins or 
substrates, MAPKKs and MAPK phosphatases (193). Irradiation was found to stimulate 
JNK activity in cultured human thyroid cells but not in WI- 38 fibroblasts, which 
indicates that there are distinct activation and regulation mechanisms involved in the JNK 
cascade (184). The types of cells involved, the context of the stimuli, and the duration of 
the activation signal are possible factors hypothesized as determinants of the nature of 
JNK - mediated signals. 
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A wide range of physiological functions is mediated via signalling through the 
JNK family, which include apoptosis, cell survival, and growth. More recently JNK has 
been shown to be involved in obesity- and TNFu- mediated insulin resistance by negative 
regulation of insulin- stimulated PI3K activity (194). Insulin has been shown to activate 
JNK in L6 myotubes, in addition to ERK1I2, p38 MAPK, and Akt/PKB. Originally JNK 
activation was thought to mediate glycogen synthase activation by insulin in skeletal 
muscle in vivo (195). In a later study, a JNK activity assay showed that RO 31-8220, a 
PKC inhibitor, also activates JNK but when added to insulin, JNK activity was not 
increased. However, this combination was additive for glycogen synthase activity, 
suggesting that JNK does not playa role in insulin- induced activation of glycogen 
synthase (196). 
The involvement of JNK activation III apoptosis was first demonstrated in 
neuronal cells. Overexpression of the wild- type c- Jun induced apoptosis of cultured 
sympathetic neurons, while in the c- Jun mutant that lacked the transactivation domain; 
apoptosis was inhibited when induced by nerve growth factor (NGF) withdrawal (197). 
In rat PC- 12 pheochromocytoma cells following NGF withdrawal again, apoptosis was 
blocked in JNK mutants while MEKKI overexpression stimulated apoptosis (121). The 
pro- apoptotic properties of JNK were further supported by mouse embryonic fibroblasts 
deficient injnkl andjnk2 when the cells resisted UV radiation induced apoptosis (198). 
The same results were reported in neuronal and melanoma cells (199). Previously, Xia et 
al. (1995) (121) and Brenner et al. (1997) (200) had also established the role of JNK in 
stress- induced programmed cell death. 
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In contrast, several studies have also demonstrated that JNK is involved in cell 
survival as opposed to apoptosis. Hilberg et al. (1993) (201) did not observe any defect in 
neuronal apoptosis in c- jun -1- mice. Apoptosis was also shown to take place even in the 
absence of c- Jun (202). Similarly, Sabapathy et al. (1999) (203) established thatjnk- 1 -l-
and jnk- 2 -/- mice had increased apoptosis in both the hindbrain and forebrain, suggesting 
that JNK activation is required for survival. The evidence suggests that JNK acts as 
modulator of apoptosis instead of as an intrinsic component, since both pro- and anti-
apoptotic roles have been demonstrated extensively (204). 
JNK control of cell proliferation by regulating gene expreSSIOn VIa 
phosphorylating the transcription factor c- Jun was also established as a major role of the 
JNK signal transduction pathway (178). Recent research also suggested that JNK 
phosphorylation of the NH2- terminus of c- Myc plays a role in cell proliferation and 
apoptosis (205). However, the primary consequence of gene disruption in the JNK 
pathway is apoptosis in a wide variety of cell types (206) where overexpression of ASK-
1, MEKK- 1, MLK, or TAK-l induces cell death. Activation of AP- 1, which is 
stimulated by JNK, has also been shown to lead to apoptosis and inflammation (207). A 
summary of the MAPK pathways is presented in Figure 7. 
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Figure 7: Summary of the MAPK family signalling pathway characteristics. 
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1.5 CROSSTALK 
Crosstalk between signalling pathways has also been demonstrated with the 
AktIPKB cascade. The first implication of crosstalk between the PI3K1 AktIPKB-
signalling pathway and ERK1I2 was observed after treatment with PI3K inhibitors, which 
decreased ERK1I2 activity (208). In addition, heterotrimeric guanosine triphosphate-
binding protein- activated PI3Ky stimulates ERK1I2 activation through MEK 
phosphorylation (209). In the TNFu- signalling pathway, Rac was shown to be 
downstream ofPI3K, leading to nuclear activation of JNK (210). In addition, a dominant 
negative mutant of the p85 subunit of PI3K reduced MEKI and ERK1I2 activity with a 
subsequent decrease in cell proliferation (211). AktIPKB has also been shown to inhibit 
apoptosis signal- regulating kinase-l (ASK1) phosphorylation and its subsequent JNK 
activity, resulting in a reduction in apoptosis (212). Another implication of crosstalk 
activity was demonstrated when PI3K activated through the fibronectin receptor 
increased Raf activity (213). 
As previously mentioned, ROS activate both the ERK1I2 and AktIPKB pathways, 
which supports current crosstalk theories. It was discovered that the two pathways 
communicate via a Raf and AktIPKB interaction, which might be dependent on the 
muscle cell differentiation stage (214). For example, AktIPKB activation inhibits ERKII2 
in differentiated myotubes but not in myoblasts (215), which also demonstrates cross-
regulation. On the other hand, Ras is phosphorylated by AktIPKB to inactivate Raf 
signalling but is not a common occurrence because PI3K inhibition did not inactivate 
MAPK (216). The PI3K1 AktIPKB pathway affects Raf through AktlPKB interaction, 
Resveratrol 49 
which was demonstrated when Raf- 1 activity was reduced by Akt/PKB- mediated S259 
phosphorylation (215). Rommel et al. (1999) (216) found that Akt/PKB decreased Raf- 1 
activity, which was specific to differentiation in skeletal muscle culture models. 
Therefore, it is important to realize that signalling cascades are not linear sequences but 
exist as components of an interactive branching network where not all components are 
equivalent in their effects. 
1.6 PROTEIN KINASE C 
The protein kinase C (PKC) family is a group of phospholipid- dependent serine-
threonine protein kinases. The mammalian isoforms of PKC are divided into three groups 
according to activation, which include the conventional a, ~l, ~2, and y, novel 5, e, e, and 
11, and atypical S, and tI A (217). Conventional PKCs require both calcium (Ca2l and 
diacylglycerol (DAG) for activation. However novel PKC isoforms require only DAG 
and the atypical isoforms are both DAG- and calcium- independent (218). Originally, 
atypical PKCs were known to be activated by phosphatidyserine or unsaturated fatty 
acids like arachidonic acid (219). In addition to AktlPKB, PBK regulates PKC5, e, S, and 
p70 S6 kinase, which play an important role in cell signalling leading to proliferation, 
survival, motility, and secretion in numerous cell types (69;220). 
Phorbol- myristate- acetate (PMA) stimulates glucose transport in L6 myotubes 
independent of insulin, however the role of PKC activation in insulin- stimulated glucose 
transport remains controversial. In L6 myotubes, insulin has been shown to increase 
DAG (221) and DAG- sensitive PKCs (221;222). Insulin activates certain isoforms of 
PKC in a similar manner to Akt/PKB to increase glucose uptake, in particular, PKCS (78 
kDa) (223;224). The lipid products of PBK regulate the atypical PKC isoforms, PKCA 
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and PKCS (225) through PKC activation loop phosphoryiatien, which modulate GLUT4 
translocation. Expression of kinase- inactive forms of the conventional (a and ~) and 
novel (0 and c) isoforms had no effect on GLUT4 translocation (226) and have been 
shown to negatively regulate components of the insulin- signalling pathway (227). There 
is evidence to support that PKC- ~ has an inhibitory effect on GLUT4 translocation when 
PKC- ~ null mice displayed lowered blood glucose concentrations as a result of elevated 
basal and insulin- stimulated cell surface GLUT4 protein (228). Additionally, increased 
conventional and novel PKC expression and activity are involved in the pathogenesis of 
insulin resistance and type 2 diabetes (229). This issue is still debated and supports the 
need for caution when studying PKC where multiple approaches should be used. 
More recently, protein kinase D (PKD), which is also known as PKCJl, has been 
added to the PKC superfamily based on homology within the catalytic domain. However, 
PKD is distinguished by its transmembrane domain and PH domain and by its unique 
substrate recognition and Golgi localization. DAG also regulates PKD. New evidence 
suggests that PKD is responsible for insulin- independent increases in basal glucose 
uptake in L6 myotubes as demonstrated by siRNAs, dominant- negative PKD isoform 
expression, and PKD3 overexpression (230). 
1.7 THE ACTIN CYTOSKELETON 
The actin cytoskeleton also plays an important role in the metabolic effects of 
insulin (231). Rapid actin reorganization and plasma membrane ruffling induced by 
insulin, have been observed in both L6 myotubes (232;233) and in mouse 3T3-Ll 
adipocytes (234). PI3K is involved in the control of membrane ruffling as evidenced by 
the inhibition of insulin- induced actin reorganization (235) and membrane ruffling (236) 
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with the PI3K inhibitor wortmannin. Vesicles containing glucose transporters accumulate 
in these membrane ruffles for pinocytosis. Further investigation revealed that early 
insulin signalling events, including the activation of PI3K, do not require an intact 
cytoskeleton (231 ;232;234). 
Downstream however, PI3K- signalling complex association with GLUT4-
containing vesicles is actin- dependent. In addition, activation ofp38 MAPK and ERK1I2 
by insulin does appear to be cytoskeletal- dependent (113). Treatment with cytochalasin 
D, a compound that disassembles the actin cytoskeleton, demonstrated that translocation 
ofthe glucose transporters, GLUT1, GLUT3, and GLUT4, from the intracellular storage 
compartment to the plasma membrane is mediated by an intact actin cytoskeleton (232). 
Therefore, it is apparent that the actin cytoskeleton plays an important role in glucose 
transport for both the regulation of signalling molecules and transporter translocation. 
1.8 DIABETES 
Diabetes mellitus is a heterogeneous disease with many different fonus and a 
variety of causes. The major types are type 1 diabetes (insulin- dependent diabetes 
mellitus) and type 2 diabetes (non- insulin- dependent diabetes mellitus). Type 1 diabetes 
is characterized by the lack of pancreatic insulin production caused by the destruction of 
pancreatic beta cells. Heredity is a risk factor for development and the majority of cases 
develop during childhood. It may be virally induced or caused by an autoimmune 
disorder. Autoimmune insulinitis with pancreatic mononuclear cell infiltration is 
characteristic at onset and islet cell autoantibodies are produced. Treatment for type 1 
diabetes involves exogenous insulin injections in order to regulate and maintain glucose 
homeostasis. 
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The characteristics oftype 2 diabetes are diminished insulin secretion and reduced 
insulin sensitivity or insulin resistance (237), which is defined as reduced target cell 
response to a given insulin concentration compared to normal. Beta cell destruction and 
dysfunction is responsible for the decrease in insulin secretion. In type 2 diabetes the 
glucose-consuming tissues, like skeletal muscle, become insensitive to insulin. The 
failure to increase glucose disposal into peripheral tissues in response to insulin is 
responsible for chronically elevated levels of glucose in the circulation followed by a 
compensatory rise in insulin (238). The combination of increased insulin and glucose 
levels promote exacerbated insulin resistance, contributing to the pathogenesis of the 
disease (239). 
Obesity facilitates the development of this disease Slllce it induces insulin 
resistance (240). As a result of chronically uncontrolled blood glucose levels, 
complications develop in approximately 40% of those with diabetes, including kidney 
failure, blindness, and lower- extremity amputations. Vascular damage also develops 
over time in response to hyperglycaemia, leading to cardiovascular disease. 
Control of type 2 diabetes usually begins with diet and exercise modifications to 
achieve increased weight loss, reduce fat body mass, and increase insulin sensitivity. 
Additionally, pharmacological agents such as thiazolidinediones (TZDs) or metformin 
may be given to improve insulin sensitivity or sulfonylureas (SUs) may be administered 
to stimulate beta cell insulin secretion. The biguanide metformin is an insulin sensitizer 
that reverses insulin resistance and hyperglycaemia primarily by inhibiting 
gluconeogenesis and glycogenolysis in the liver, and by increasing insulin- stimulated 
glucose uptake in muscle and adipocytes (241). The sulfonylureas glyburide, glipizide, 
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and glimepiride interact with the sulfonylurea receptors on beta cells (242) to reduce 
blood glucose levels through stimulation of insulin secretion by the pancreas (243). 
Thiazolidinediones (TZDs) such as rosiglitazone, may be given to improve insulin 
sensitivity and also reduce insulin resistance and decrease hepatic glucose production by 
activating the nuclear receptor peroxisome- proliferators- activated receptor y (PPARy) 
(reviewed in (244)). In addition, exogenous insulin administration is also used to control 
plasma glucose levels. 
Diabetes mellitus is a disease with high prevalence in society. Type 2 diabetes is 
estimated to account for 90% to 95% of all cases of diabetes. It is projected that the total 
number of persons in the world with diagnosed diabetes will reach 300 million by the 
year 2025. In addition, the World Health Organization (WHO) estimates that between 2.5 
and 15% of health budgets are depleted by diabetes related illnesses, depending on local 
prevalence. Specifically in Canada it is estimated that between five and six billion dollars 
is spent on diabetes treatment every year, while in the United States the total cost is 
approximately $44 billion. 
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1.9 AMINO ACID TRANSPORT 
1.9.1 Importance of Amino Acids 
Amino acids circulate in the bloodstream and are absorbed by all tissues to 
support protein synthesis. Approximately one half of the required amino acids to build 
protein may be synthesized by the body. After a meal there is a compensatory rise in 
plasma amino acid levels, however when the amino acid concentration in the plasma 
decreases below normal physiological levels, amino acids are transported out of the cell 
to replenish plasma levels while intracellular proteins are degraded. 
Skeletal muscle is the main storage tissue for both free amino acids and protein, 
while the liver regulates blood amino acid levels (35- 65 mg/dl) and is the most active 
site for amino acid catabolism to produce energy in the form of adenosine triphosphate 
(ATP). The liver also removes excess amino acids from the blood in order to synthesize 
proteins or convert them to lipids or glucose for additional storage. Deamination in the 
liver generates highly toxic ammonia molecules that are converted to the harmless water 
soluble compound urea. However in the presence of disease ammonia molecules 
accumulate in the bloodstream resulting in hepatic coma. Additionally, dysregulation of 
skeletal muscle amino acid balance may contribute to diseased states like diabetes 
mellitus and cancer (245;246). 
Absorption of amino acids requires transport across the cell membrane and may 
be stimulated by adaptive regulation (247), cell stresses (248), growth factors (249), and 
several hormones, including androgens/ estrogens, and insulin (250), which is the 
primary hormone involved in the transport of amino acids into skeletal muscle. These 
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stimuli induce amino acid transport· through an increase in maximum transport capacity 
(V max) without affecting transporter affinity (Km) or the synthesis of new carriers (249). 
There are multiple amino acid transport systems in humans; including Systems A, 
ASC, L, Nm , y+, bO,+, BO,+, lL, and XAG, which differ by their substrate specificity, ion 
dependence, and kinetics. Furthermore, these systems may be categorized by the type of 
amino acids they transport and whether they are acidic, basic, or neutral (251). 
System ASC, which is Na+- dependent, transports the small neutral amino acids 
alanine, cysteine, and serine (252). System Nm mediates glutamine transport, which isa 
neutral nonessential amino acid and is also Na+- dependent (253). System XAG- , again 
Na + - dependent, has a widespread tissue distribution but is localized in the brain and 
epithelial tissues (254). System BO,+ is also Na+- dependent and transports cationic and 
neutral amino acids (253). System lL is a more recently discovered transporter that 
binds to both cationic and neutral amino acids, such as leucine and arginine, but with 
specificity that depends on ionic composition (255). 
Unlike the previous transport systems, System L is Na+- independent and 
transports nonpolar, long chain, and aromatic amino acids like isoleucine, leucine, 
phenylalanine, and tyrosine (256;257). This system is also responsible for mediating the 
transport of essential neutral amino acids and is ubiquitously expressed. System T is 
functionally similar to System L but selects for benzenoid substrates and is expressed in 
human kidney (258). System y+ transports basic cationic amino acids and arginine, 
lysine, and ornithine. System y+ is Na+- independent as well and is ubiquitously 
expressed (259). The other basic amino acid transport system, System bO,+, is Na+-
independent and may be located in the kidney and intestine. It transports dibasic and 
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neutral amino acids like alanine, arginine, and cysteine (260). The neutral amino acid 
System A is most commonly studied in skeletal muscle tissue and cell culture and is 
predominantly regulated by insulin (261). Therefore, it is the focus of study in this thesis 
regarding questions on amino acid transport. 
1.9.2 System A Amino Acid Transport 
System A amino acid transport III mammalian cells involves the sodium-
coupled neutral amino acid transporters (SNATl, 2, and 4) of the SLC38 family, which 
are widely expressed (262).SNATl (GlnT), a neuronal Na+ -dependent glutamine 
transporter was first cloned and proposed as a member ofthe System A transporter family 
but its expression is restricted to the brain and, given that System A activity is 
ubiquitously expressed, it seemed likely that there must be additional transporters 
(263;264). The SNAT2 isoform (also known as ATA2) is a membrane bound carrier and 
transports short polar straight- chain amino acids like alanine, proline, and the non-
metabolizable amino acid analogue 2- methyl-aminoisobutyric acid (MeAIB) (263;265). 
MeAIB is specifically transported by this system, which makes it ideal for transport 
studies (253). System A transport is dependent on the Na+ electrochemical gradient, pH 
levels, amino acid availability, and exercise (266). For example, SNAT2 utilizes the Na + 
electrochemical gradient to move amino acids into the cytosol. 
Furthermore, insulin stimulates the translocation of SNAT2 from an endosomal 
compartment to the plasma membrane, which accounts for the increase in System A 
activity after acute insulin stimulation (267). Insulin stimulation of glucose and amino 
acid transport share certain characteristics, however there are also significant differences 
between the two. For example, both insulin- stimulated System A activity and glucose 
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transport are PI3K and AktlPKB- dependent, which was demonstrated with 
pharmacological PI3K inhibition (248;268) and expression of a constitutively active form 
of Akt/PKB (269) that mimicked insulin action on amino acid transport. On the other 
hand, cytochalasin D, an actin disassembling drug, inhibits insulin- stimulated glucose 
uptake but not System A activity. See Table 1 for further details. However, the link 
between activation of these signalling molecules and System A activity is not yet fully 
understood. 
Table 1: Comparison of glucose and System A transport in L6 cells. 
Glucose Transport System A Amino Acid Transport 
Similarities a) wortmannin sensitive a) wortmannin sensitive 
b) rapamycin insensitive b) rapamycin insensitive 
c) PD098059 insensitive c) PD098059 insensitive 
Differences a) constitutively active Akt a) constitutively active Akt does not 
maintains glucose transport in the maintain System A in the presence 
presence of ceramide (270) of cerami de 
b) CD blocks Akt activation and b) System A unaffected by CD 
glucose transport (232;271) (267) 
c) insulin signalling mimicked by c) phorbol esters attenuate insulin 
phorbol esters stimulation in System A (272) 
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1.10 THE BIOLOGICAL EFFECTS OFRESVERATROL 
1.10.1 The Chemical Properties of Resveratrol 
Resveratrol (trans- 3, 4" 5- trihydroxystilbene) is a polyphenolic compound that 
has been discovered in 72 different plant species of mulberries, peanuts, and grapes 
(273). In grapes, resveratrol is concentrated in the skin and seed, where fresh grape skins 
contain 50- 100 mg ofresveratrol per gram of grape skin (274). The dominant source of 
resveratrol is the root Polygonum cuspidatum, which was originally used in traditional 
Chinese and Japanese medicine as a treatment for heart disease, stroke, suppurative 
dermatitis, gonorrhea, favus, and athlete's foot (275;276). Resveratrol is known as a 
phytoalexin because it is produced in response to fungal infections and plays an 
important role in inhibiting fungal cell growth and proliferation. 
Environmental stress is a significant factor contributing to plant resveratrol 
concentration where ultraviolet radiation and fungal attack are common stressors that 
stimulate resveratrol production in order to increase resistance to pathogens. Therefore 
plants located in colder climates that provide optimal conditions for fungal cell growth, 
often exhibit higher concentrations of resveratrol because of the increased incidence of 
fungal attack. As a result, the high content of resveratrol in grapes makes wine the 
leading source of resveratrol in the human diet. The average concentration of resveratrol 
in red wine ranges from 0.84 to 7.33mg/L (277). 
The concentration of resveratrol is considerably higher in red wine than in white 
wine because of the different fermentation processes. During red wine fermentation, the 
seed and the skin remain in contact with the must for longer periods of time, which 
increases the absorption of resveratrol. In contrast, during white wine fermentation, the 
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must is separated from the skin and the seed much sooner. The significantly higher 
quantity of resveratrol in red wine has been speCUlated to be responsible for the positive 
health benefits associated with red wine consumption. 
The structure of resveratrol is shown in Figure 8. The simplicity of the chemical 
structure allows it to interact with numerous receptors and enzymes so that it can be 
involved in many different pathways, which will be discussed later. Another advantage of 
the simple structure is that it is not difficult to synthesize, which makes it more readily 
available for experimentation (278). Both synthetic and pi ant- derived resveratrol 
demonstrate the same biological activity. 
_Figure 8: Chemical structure of trans- resveratrol (3, 4', 5-
trihydroxystilbene ). 
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Thcre are two known isomers of the resveratrol molecule, the trans and cis forms, 
shown in Figure 9. The trans isoform is the primary isomer found in most resveratrol 
sources and is the biologically active form. Trans- resveratrol is readily isomerised to the 
cis state upon light exposure (279). Resveratrol is quite stable but when exposed to heat 
or extreme pH levels it is reactive. Both the cis and trans isomers are stable between pH 
3- 8 but are completely degraded at a pH of ten (279). 
Resveratrol contains 1, 2- diphenylethylene in its functional group and is 
classified as a stilbene (276). Phenylpropanoids are the precursors for stilbenes like 
resveratrol, flavonoids, and even furanocoumarins. Stilbenes, in particular, are 
synthesized by coumaryl- CoA and three molecules of malonyl- CoA under the cleavage 
of four carbon dioxide,molecules (280). 
Figure 9: Isomerization of resveratrol that is induced by light exposure. 
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1.10.2 Bioavailability of Resveratrol 
Resveratrol is a lipophillic molecule and can easily cross the blood brain barrier 
and affect the central nervous system. Studies in hepatocytes, HepG2 (281), and intestinal 
cells (282) have shown that resveratrol (30- 150IlM) enters the cell by simple diffusion to 
significant levels within 5 minutes. 
The biological effectiveness of resveratrol is dependent upon its bioavailability 
after it enters an in vivo system. Studies on the bioavailability of orally ingested 
resveratrol demonstrate that 50- 75% of the dose is absorbed in rats (283). Vitrac et al. 
(2003) (284) studied the distribution of radioactive resveratrol in Balb/c mice after oral 
administration via whole- body autoradiography.· e4C]trans-resveratrol was most 
concentrated in the digestive system, including the stomach, liver, kidney, intestine, bile, 
and urine, where the majority of resveratrol remained intact. It is possible that resveratrol 
will also be deposited in adipose tissue since it is lipid soluble or accumulate in skeletal 
muscle, both of which have not been examined. 
High performance liquid chromatography (HPLC) analysis with diode array 
detection can be used to determine trans resveratrollevels in plasma. Oral administration 
of resveratrol (2mg! kg) to male Sprague- Dawley rats was analyzed at 15, 30, and 45 
minutes and after only 15 minutes, trans resveratrol was detected in the plasma at a 
concentration ofO.175mg! L (285). 
There are several natural and synthetic analogues of resveratrol with different 
isomers, derivatives, and conjugates/ metabolic products. The most common types are 
piceid (resveratrol glycosides), glucuronide, and sulphate conjugate (resveratrol-3-
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sulphate) (286). Each of these conjugates/metabolic products seem to have distinct 
biological properties, however their specific effects have not been as extensively 
explored. 
Despite the vast amount of resveratrol data available in vitro and in VIVO 
(animals), few studies have examined any effects in humans. Oral doses of resveratrol 
(25 mg 170 kg) to healthy humans, in 100 ml of either white wine, grape juice, or 
vegetable juice, revealed high concentrations in the serum and urine predominantly as 
glucuronide and sulphate conjugates peaking after 30 minutes, whereas the serum 
concentration of free resveratrol was only 1.7- 1.9% of the total concentration (287). It 
was also determined that only 16.5% of the administered dose of resveratrol was seen 
after 24 hours in the urine. The transient increase of plasma resveratrol suggests that 
much larger oral doses of resveratrol would be required in order to sustain an adequate 
concentration to control disease processes. 
Similarly, Walle et al. (2004) (288) administered e4C]resveratrol orally and 
through i.v. to six healthy humans. Absorption reached 70% with peak plasma levels of 
resveratrol and its metabolites at 491 ± 90 ng/ml (~2!lM), but again with only trace 
amounts of unconjugated resveratrol «5 ng/ml) present. Sulfate conjugation by the 
intestine and liver seems to be the rate- limiting step in resveratrol bioavailability with 
considerable accumulation in the epithelial cells along the aerodigestive tract. These 
studies conclude that resveratrol is well absorbed and metabolized by the intestine. 
1.10.3 The Antioxidant Properties of Resveratrol 
Oxidizers produce free radicals, also called reactive oxygen species (ROS), which 
are electron-accepting molecules that have unpaired electrons and are extremely harmful 
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and highly reactive. Examples of ROS include the superoxide anion (02), the hydroxyl 
ion (OH), nitric oxide (NO), and molecules like hydrogen peroxide (H202). Antioxidants 
behave as reducers and donate electrons to these free radicals in order to make them 
harmless unreactive compounds. Increased ROS production or oxidative stress can cause 
deoxyribonucleic acid (DNA) damage, protein oxidation, and lipid peroxidation, which 
can lead to mutagenesis, carcinogenesis, membrane damage, atherosclerosis, and 
neoplasia (289). Other free radicals that cause oxidative damage in the body are produced 
by pollutants in the air, water, and food supply and from oxidation- reduction reactions of 
lipids and metal ions, and mitochondrial electron transport reactions in the body itself. 
There are several methods used to measure antioxidant activity. For example, the 
antioxidant activity of resveratrol and other phenolic compounds may be examined via 
the spectrophotometric method of Rice- Evans and Miller, where cation radical 
absorption inhibition indicates antioxidant activity (290). 
The most well known characteristic of resveratrol is its antioxidant properties. 
Polyphenolic compounds like resveratrol either donate hydrogen or react with superoxide 
anions, lipid peroxyl radicals, and hydroxyl radicals. For example, deletion of the 
hydroxyl group at position B4 (Figure 8) reduces antioxidant activity (291). When the 
hydroxyl group is a free radical, it is a potent oxidizer but is unreactive when attached to 
a polyphenol like resveratrol. Resveratrol converts these radicals to unreactive 
compounds that are harmless to human tissues (292). 
DNA damage is an indicator of oxidative damage from ROS. De Salvia et al. 
(2002) (293) examined the antioxidant capacity of resveratrol against ROS in Chinese 
hamster ovary cells. In this model, ROS activity was generated by H20 2 treatment. 
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Simultaneous administration of resveratrol and H20 2 produced a small significant 
reduction in intracellular oxidation, but when pre-treated with resveratrol (3 hours), 
increased oxidative damage was observed. Resveratrol had no effect on primary DNA 
damage when administered alone or simultaneously, but when applied for three hours 
before hydrogen peroxide, all damage was abolished. Additionally, resveratrol protected 
against fixed DNA damage during the combined treatment but enhanced oxidative 
damage with pre-treatment. Therefore, resveratrol exhibits both anti- and pro- oxidant 
activity, depending on the type of treatment. 
Polyphenols containing a phenol ring, as opposed to a catechol ring, have been 
shown to generate reactive oxygen species (ROS) when metabolized by peroxidase as 
evidenced by NADH cooxidation (294). Compounds like resveratrol that act as 
antioxidants towards lipids, may also be pro- oxidant towards DNA and protein (295). 
For example, resveratrol increased ROS production in T- lymphoblastic leukemia CEM-
C7H2 (296) and rat pheochromocytoma (PC12) (297) cells, playing a role in apoptosis 
induction. On the other hand, resveratrol decreased ROS production in MCF-7 breast 
cancer (298) and hepatoma cells (299;300). 
Recently, several studies have focused on understanding the cancer 
chemopreventive and cardioprotective effects of resveratrol. It seems that the effects seen 
in both disease processes have a common aetiology that includes antioxidative, cell cycle 
control, and mitogen- activated protein· kinase (MAPK) activation mechanisms. In 
addition, a possible role in estrogenic activity is also being explored where resveratrol has 
demonstrated both agonistic and antagonistic effects. Therefore, resveratrol is capable of 
affecting numerous biological activities involved in major disease processes. 
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1.10.4 The Anti- Cardiovascular Effects of Resveratrol 
Research has demonstrated the cardiovascular benefits of resveratrol treatment in 
numerous ways, which include antioxidant, decreased smooth muscle cell proliferation, 
vasorelaxation, and anti- thrombotic theories. Each aspect will be considered in this 
section. 
1.10.4a Antioxidant Properties 
ROS are essential in cell signalling and regulation at low concentrations, affecting 
gene transcription, protein synthesis, and cell function. In the cardiovascular system, 
ROS play a role in maintaining cardiac and vascular integrity. However, an 
overabundance of ROS causes oxidative stress, which is one of the most important 
contributors to vascular damage. Therefore it is imperative that a pro-oxidant and anti-
oxidant balance be maintained (289). An excellent example of oxidative stress is the 
production of superoxide anions (02-) and nitric oxide (NO-) by endothelial cells, 
activated macrophages, and neutrophils during the inflammatory response. These two 
oxidants are the main sources for production of the oxidant peroxynitrite (ONOO-), 
which is involved in the development of atherosclerosis and rheumatoid arthritis. 
Oxidative stress and associated oxidative damage are mediators of vascular injury 
and inflammation in many cardiovascular diseases including atherosclerosis. Under 
pathological conditions, increased ROS production leads to endothelial dysfunction, 
increased qontractility, VSMC proliferation and migration, apoptosis, inflammation, and 
increased deposition of extracellular matrix proteins, all contributing to vascular damage 
and cardiovascular disease. 
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Several in vitro and in vivo studies have demonstrated that resveratrol is a potent 
antioxidant. The antioxidant and superoxide anion scavenging activity of resveratrol was 
demonstrated in rat cardiac muscle cells at 7.8J.tM and 245.1J.tM concentrations 
respectively. Conjugated dienes and TBARS (thiobarbituric acid- reactive substance) 
formation and electrophoretic mobility of oxidized LDL showed that resveratrol inhibited 
Cu2+- induced LDL oxidation by 50% (291). Resveratrol (5 0 J.tglml, 30 min) also 
significantly inhibited ROS and TBARS production in pig blood platelets stimulated by 
lipopolysaccharide (SI959) or thrombin (301). 
As previously mentioned, lipid peroxidation may lead to a variety of disease 
processes. Therefore, inhibition of lipid peroxidation would be of great benefit and may 
be achieved with antioxidanttreatment. Stojanovic et al. (2001) (302) compared the free 
radical scavenging activity of resveratrol and several other antioxidants via HPLC 
analysis and the iodometric method. Liposomes, in the absence of antioxidants, were 
used as a control and liposomes containing a particular antioxidant were y- irradiated at 
various doses. As expected, the highest content of lipid hydroperoxide was seen in the 
control. HPLC analysis showed that resveratrol was a stronger inhibitor of lipid 
peroxidation (95% efficiency) than both Vitamin C and Vitamin E, which was consistent 
throughout the process. For confirmation, the procedure was repeated using the 
iodometric technique, which revealed that resveratrol was the most potent antioxidant 
(95%). 
Low- density lipoprotein (LDL) oxidation is associated with the accumulation of 
LDLs in subendothelial cells of the heart and vessels and increased platelet adhesion to 
the epithelium (280). Ferrylmyoglobin and peroxynitrite are the main oxidants involved 
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in the pathophysiology of cardiovascular disease (278). Resveratrol protected human 
plasma isolated LDLs from oxidation by ferrylmyoglobin in vitro in a concentration-
dependent manner and inhibited the protein modification effects of peroxynitrite. 
Resveratrol (10IlM, 10 min) infusion in Langendorff- perfused normoxic rat 
hearts, significantly increased coronary flow (46.3%) and adenosine release (95.5%). To 
confirm that the increase in coronary flow was mediated by adenosine, the adenosine 
receptor antagonist, 8- (p- sulfophenyl) theophylline (SPT), was administered in 
combination with resveratrol. The increase in blood flow was completely inhibited by the 
antagonist, which established the acute action of resveratrol. Chronic oral administration 
of resveratrol (25mgl I in tap water, 15 days) to male Sprague- Dawley rats induced 
significant vasodilatation and improved heart functional recovery. Administration of NG_ 
nitro-L-arginine methyl ester (L-NAME) (30IlM), a nitric oxide synthase inhibitor, 
reversed the resveratrol- induced effects. This inhibitor is not specific so the source of the 
nitric oxide (NO), whether intracellular nitric oxide synthase (iNOS) or endothelial nitric 
oxide synthase (eNOS), is uncertain. Resveratrol (10IlM) has been shown in previous 
studies to have no significant effect on eNOS expression (303), however studies in iNOS 
knockout mice have shown that eNOS is upregulated (304). Therefore, resveratrol seems 
to improve cardiac function through a NO- mediated mechanism (305). 
1.10.4b Anti- thrombotic Properties 
The cyc100xygenase pathway promotes the formation of prostaglandins from 
unsaturated fatty acids. Prostaglandins initiate contraction of the smooth muscle of blood 
vessels and promote fever and pain as part of the inflammatory response to injury. 
Thromboxanes, which are produced by blood platelets, work with prostaglandins to 
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promote vasoconstriction and activate platelet coagulation in blood vessels that restricts· 
blood flow to fonn a thrombus. 
Resveratrol inhibits thrombus fonnation by inhibiting thromboxane B2! 12-
hydroxyeicosatraenoate, which is specifically responsible for platelet aggregation 
induction and contraction of arteries (306). In addition, when both synthetic and natural 
resveratrol (3.56flg/l) were administered to platelet- rich plasma for ten minutes, platelet 
aggregation was reduced by 50.3%, thereby reducing the risk of cardiovascular 
complications (307). Platelet aggregation inhibition was again demonstrated both in vivo 
and in vitro by resveratrol (10- 1000flM) in a concentration- dependent manner in 
platelets isolated from human plasma and III experimentally induced 
hypercholesterolemic rabbits (308). 
Alternatively, thrombus fonnation may be prevented through an inhibition of cell 
adhesion to the endothelial lining of blood vessels. Resveratrol significantly inhibited 
U937 monocytoid cell adhesion to lipopolysaccharide- stimulated human saphenous vein 
endothelial cells and neutrophil adhesion to TNF-a-stimulated NIH!3T3 ICAM-l-
transfected cells, resulting in decreased blood clotting activity (309). 
Overnight treatment with resveratrol (100nM) in combination with TNFa, a pro-
inflammatory mediator and coagulant, significantly decreased vascular cell adhesion 
molecule- 1 (VCAM- 1) expression but had no effect alone (310). This result would help 
decrease leukocyte adhesion to the vascular endothelium and perhaps reduce 
cardiovascular disease progression. The effects of TNFa are controlled by the NF-kB 
signalling pathway, which is mediated by Ililla phosphorylation. Human umbilical vein 
endothelial cells stimulated with TNFa and resveratrol (100nM and 1 flM) overnight 
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increased p50-NFkB and p65-NF-kB nuclear appearance. Acute (30 minute) resveratrol 
treatment increased IkBa tyrosine phosphorylation of immunoprecipitated NF-kB, which 
is indicative of an alteration in transcription (311). 
Fulgenzi et al. (2001) (312) used TNFa to induce endothelial permeability in a 
Balb/c mouse model. Resveratrol (30 minutes) alone did not affect vascular permeability, 
but when given in combination with TNFa, vascular leakage values were significantly 
lower than TNFa alone. This confirmed previous in vitro data that suggested resveratrol 
affects endothelial function. 
1.10Ac Vasodilation 
Another way to prevent cardiovascular damage is through vessel dilatation to 
facilitate an increase in blood flow and oxygen transport to the tissues. Angiotensin-
converting enzyme (ACE) and neutral endopeptidase (NEP) inhibition decreases 
vasoconstriction. When there is a reduction in the concentration of these two compounds, 
vasodilatation and blood flow increases, peripheral vascular resistance and blood pressure 
are reduced, and the sodium- water balance is restored. When cells of the neuroblastoma 
line, SK- N- SH, were incubated with 10IlM resveratrol for four days, there was weak 
inhibition of ACE and no effect on NEP, suggesting that resveratrol is a mild vasodilator 
(313). 
To explore the mechanism behind the production of vas ore laxation by resveratrol, 
Li et al. (2000) (314) looked at possible actions on the ionic currents in endothelial cells. 
The effect of resveratrol on whole cell potassium outward currents in cultured human 
umbilical vein endothelial cells and calcium activated potassium channels in pancreatic 
endothelial cells (MS 1) were examined. Resveratrol (30IlM) increased the amplitude of 
the outward currents within only one minute of administration and increased the activity 
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of large- conductance calcium- activated potassium channels, which was explained by a 
lengthening of the open time of the channels. In MS 1 endothelial cells, resveratrol 
stimulated membrane hyperpolarization in intermediate- conductance calcium- activated 
potassium channels, which subsequently affected endothelial function and induced 
vasorelaxation. 
1.I0.4d Cell Proliferation and Migration 
Smooth muscle cell (SMC) proliferation IS a known prerequisite for 
atherosclerosis and other cardiovascular disorders. Atherosclerosis is characterized by the 
thickening of arterial walls due to lipid deposits that obstruct the lumen and deteriorate 
the arterial wall. Arteriosclerosis is a characteristic of advanced atherosclerosis where the 
arterial walls lose elasticity and become rigid. It has also been documented that vascular 
smooth muscle cell migration, proliferation, and hypertrophy are involved in the 
pathogenesis of atherosclerosis. In particular, vascular smooth muscle cell proliferation is 
involved in the formation of atherosclerotic plaques that decrease the elasticity of the 
blood vessels (315). 
Initial studies in newborn calf thoracic aorta in vitro (316) showed that resveratrol 
had the ability to control cell proliferation. Vascular smooth muscle cell proliferation and 
migration in vitro were reduced by 70- 90% after resveratrol administration in a dose-
dependent manner, particularly at 50 and 100~M concentrations. The underlying 
mechanism was discovered to be a disruption in the cell cycle where the number of cells 
in the S phase (37%) was reduced, followed by a subsequent increase of the number of 
cells in the Gl phase (23%). From these results it was determined that resveratrol blocked 
the cell cycle at the G 11 S transition as opposed to inducing apoptosis. As a result, cell 
cycle control could potentially prevent the progression of atherosclerosis. 
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Subsequent studies also continned that vascular smooth muscle cell proliferation 
was inhibited by resveratrol treatment. Vascular smooth muscle cells from newborn calf 
thoracic aorta were incubated with resveratrol (6 hours) at concentrations of 10 and 
1 OO~m. (3H]thymidine incorporation assays were used to measure smooth muscle cell 
proliferation. The results showed a 43.9% and 96.2% decrease in (3H]thymidine 
incorporation, respectively, which is indicative of decreased DNA synthesis that nonnally 
occurs during the S phase of the cell cycle (317). 
Vascular smooth muscle cell proliferation was also inhibited by resveratrol in 
human aortic vascular smooth muscle cells (HA VSMC) in a dose- and time- dependent 
manner. Concentrations as low as 1.1~M (120 h), demonstrated a reduction in the growth 
of HAVSMCs (6.5%). In addition, resveratrol inhibited DNA synthesis, as detennined 
through thymidine uptake, by as much as 91.6% (12.5~M). It was discovered that 
resveratrol (6.25~M) was associated with increased intracellular p53 levels, which was 
dose- dependent. p53 was absent when resveratrol was not present, which continned that 
resveratrol induced p53 signalling. It is also important to note that in higher 
concentrations of resveratrol (25~M), apoptosis was induced in cells that were actively 
proliferating. Together, these results suggest that resveratrol exhibits a selective 
mechanism (318). 
Endothelin- 1 is a known mediator of cardiovascular disease and is an upstream 
promoter of MAPK. MAPK induces smooth muscle cell proliferation and contraction in 
blood vessels, which leads to cardiovascular disease development. EI- Mowafy et al. 
(1999) (319) examined the underlying mechanisms involved in resveratrol' s protective 
effect on coronary heart disease and atherosclerosis. Resveratrol (37~M) down- regulated 
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endothelin- 1 evoked tyrosine phosphorylation in endothelia removed from the left 
anterior descending artery of pig hearts. The subsequent effect of this inhibition was a 
significant reduction in MAPK activity. Endothelin- 1 also augmented ERKII2, JNKl, 
and p38 MAPK kinase phosphorylation, whereas resveratrol (50 11M) counteracted these 
effects. 
MAP kinase activation induced by collagen, thrombin, and ADP, was inhibited by 
resveratrol (10- 50JlM) in washed platelets (320). Resveratrol (50JlM) inhibited 
aggregation induced by collagen (91%), thrombin, and ADP. Exogenous fibrinogen 
added to the assay did not affect resveratrol, which indicated that the inactivation of 
MAPK was a possible mechanism causing reduced aggregation. The same effect was 
tested in whole blood to simulate in vivo conditions but more than 200JlM of resveratrol 
was needed for a 30- 60% decrease in platelet aggregation. 
It is well documented that angiotensin II induces smooth muscle cell hypertrophy. 
In a recent study in rat aortic smooth muscle cells it was shown that angiotensin II-
induced (3H]leucine incorporation, which is an indicator of SMC hypertrophy, was 
inhibited by 71 % by resveratrol (50JlM). This result was associated with the inhibition of 
the PBK- Akt/PKB signalling pathway. Angiotensin II- induced activation of both PBK 
and Akt/PKB phosphorylation was significantly reduced with resveratrol at 
concentrations as low as 10JlM. Additionally, ERK1I2 phosphorylation was dose-
dependently inhibited by resveratrol with a maximum effect seen at 50JlM (321). 
Resveratrol 73 
1.10.5 The Anti- Cancer Effects of Resveratrol 
1.10.5a Anti- Tumour Effects 
The relationship between resveratrol and its role in cancer prevention is less 
debated and has been more extensively studied. There are three major stages documented 
in cancer progression, initiation, promotion, and progression. Chemoprevention involves 
. the ingestion of chemical agents that are targeted at specific stages of tumour progression, 
some of which are harmful to more than just cancer cells. One of the landmark studies 
linking resveratrol administration to cancer chemoprevention is from J ang et al. (1997) 
(273). In this in vivo study, resveratrol inhibited preneoplastic lesions in carcinogen 
treated mammary glands of mice, and tumorigenesis in a mouse skin cancer model 
(88%), showing that resveratrol inhibited the initiation phase of· carcinogenesis. 
Resveratrol inhibits carcinogenesis in human promyelocytic leukemia cells (HL-60) 
through a reduction in COX1I2 activity, which is responsible for the inhibition of tumour 
promotion and progression. 
Later studies (322) demonstrated that resveratrol could decrease tumour incidence 
and multiplicity in female mice of specific pathogen- free ICR strain. Resveratrol (8SnM) 
was applied topically one week before DMBA and TP A induced carcinogenesis and 
continually until week 20. In the control group there was 100% tumour incidence after 10 
weeks, whereas the resveratrol group demonstrated an incidence of only 20%. After 20 
weeks, resveratrol still showed a 30% inhibition of tumour growth. The number of 
tumours seen on each mouse was also evaluated, which showed that in the control group 
each mouse had an average of 10 tumours as opposed to the four-tumour average seen in 
those treated with resveratrol. 
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An in vivo study on male Donryu rats implanted with AHI09A hepatoma cells 
showed a positive effect with resveratrol treatment (323). In the untreated group, tumour 
size increased throughout the entire study (20 days). Resveratrol (50ppm) administered 
orally in the diet arrested tumour growth at day 12 and decreased hepatoma weight, the 
number of metastases, and metastases tumour weight. The control group expressed 60% 
incidence of metastases while the resveratrol treated group (50ppm) exhibited only 37.5% 
incidence. Serum TBARS and triglyceride levels also declined in the resveratrol group 
when compared to the hypercholesterolemia and hypertriglyceridemia expressed in the 
untreated group. 
Resveratrol also inhibited tumour formation in a CD- 1 mouse model, which was 
indicated by a decrease in the number of tumours developed and by the number of mice 
that developed tumours (324). In contrast, Bove et al. (2002) (325) did not find any 
inhibition by resveratrol of 4Tl breast cancer tumour growth in a BALB/c female mouse 
model. Daily injections were given at 1, 3, and Smg/kg for 23 days and did not present 
any toxic effects as indicated by the absence of weight or behavioural changes. However, 
an in vitro model of 4Tl mammary carcinoma cells (Era/~ positive) did show that 
resveratrol (30IlM) completely inhibited cell growth in a dose- dependent manner after 
only 24 hours incubation. Therefore, caution should be used during extrapolation of data 
from an in vitro model to in vivo. 
1.10.5b Cell Proliferation 
Resveratrol reduces tumour formation through cell cycle control, which is 
paralleled with the effect on vascular smooth muscle cells in cardiovascular disease. Flow 
cytometry analysis is one of the most widely used methods for counting the number of 
cells in the various phases of the cell cycle. Ragione et al. (1998) (326) had confirmed 
Resveratrol 75 
through flow cytometry analysis that HL-60 promyelocytic cells were completely 
inhibited by resveratrol (30~M) at the Sf G2 phase checkpoint, which was accompanied 
by an S phase elongation that prevented further cell proliferation (Figure 10). 
G2 
Resveratrol 
s 
Figure 10: Cell cycle progression demonstrating the inhibition of resveratrol at Sf 
G2 phase. 
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One explanation of the disruptive activity on cell proliferation by resveratrol 
involves gap- junction intercellular communication (GJIC) (327). TPA (12-0-
tetradecanoylphorbol-13-acetate) and DDT (1, 1-bis (p-chlorophenyl)-2, 2, 2-
trichlorethane), which are tumour promoters, are known to block GJIC. These tumour 
promoters were added to WB- F344 rat liver epithelial cells along with resveratrol to 
examine GJIC through dye- coupling. As expected, pre- incubation with resveratrol 
(25JlM) on cells treated with either TPA or DDT showed a remarkable increase in GJIC 
after only 30 minutes. Maximum dye- coupling was observed after 6 hours of pre-
incubation with resveratrol. Resveratrol (5 h) also counteracted both TPA and DDT in a 
concentration- dependent manner. Resveratrol (35JlM) enhanced TPA- inhibited GJIC 
activity to 71 %, while DDT- inhibited GJIC activity was enhanced to 100% of the control 
cells by 17JlM resveratrol. Resveratrol up- regulated GJIC through connexin43 
phosphorylation control and reversed phosphorylation of connexin43 without affecting its 
expression. In conclusion, GJIC regulation by resveratrol may be an important anti-
tumour mechanism. 
Resveratrol blocked the cell cycle at the SI G2 phase transition in SW 480 
colorectal tumour cells (328), which is illustrated in Figure 10. When resveratrol (30JlM, 
24 h) was administered, cell growth was inhibited by 50% and the number of cells in the 
S phase increased. This effect was reversible and both dose- and time- dependent. The 
mechanism of action involved the inhibition of cdkl and cdk2 that regulate proteins in 
the cell cycle to activate maturation-promoting factor and cyclin- dependent kinases. The 
effect was an elongation of the S phase, which therefore prevented cells from beginning 
the G2! M phases where cell growth and mitosis occur. 
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. Similarly Latruffe et al. (2002) (276) also found that resveratrol inhibited 
proliferation of human hepatoblastoma HepG2 and colonic cancer cells SW480. 
Resveratrol prevented cell cycle progression past the S phase, which was indicated by the 
large increase in cell number in the S phase and the increase in (3HJthymidine 
incorporation. Cell cycle inhibition prevented growth and decreased the number of viable 
cells. The mechanism of action was evaluated with Western blot analysis, where 
increased cdkl and cdk2 levels were observed. Carbo et al. (1999) (329) also confirmed 
these results, where resveratrol decreased tumour growth by 25% in rats inoculated with 
Yoshida AH -130 ascites hepatoma. The effect was again attributed to cell cycle arrest. 
Resveratrol (50IlM, 12 h) also completely arrested MCF- 7 cell proliferation 
(330) through suppression of the cell cycle at the G21 M phase and stimulation of cells 
accumulating in the S phase (48% vs. 11 % in control). A dose- dependent inhibition of 
cell proliferation by resveratrol (25- IOOIlM) was also found in human peripheral blood 
lymphocytes, where a 99% prevention of entry into the cell cycle was observed at 
IOOIlM. This effect was not attributed to apoptosis induction because fractional DNA 
content showed that the frequency of apoptosis was reduced with resveratrol. The 
mechanism of cell cycle control was recognized to be cyclin regulation where a 
significant inhibition of cyclin E was observed at 6 hours after cyclin D2 and D3 
induction, which indicated cell cycle arrest at the G Oil stage (331). 
1.10.Sc Apoptosis 
A controversy remains with regard to apoptosis induction by resveratrol. 
Evidence exists that supports both the cell cycle control and apoptosis induction effect of 
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cell proliferation and growth. The action of resveratrol seems to be dependent on the cell 
line. 
Surh et al. (1999) (332) examined cell proliferation in human promyelocytic 
leukemia (HL-60) cells. Resveratrol (50~M, 8 h) inhibited cell growth and reduced cell 
viability by 45% through apoptosis induction, which was confirmed by an increase in 
DNA fragmentation and morphological characteristics such as broken nuclei, which are 
associated with apoptosis. A 66% increase in DNA loss was also observed after 48-hour 
resveratrol (1 OO~M) administration. Resveratrol increased Bcl- 2 content, an anti-
apoptotic oncoprotein commonly observed in cells undergoing cell death. Therefore, in 
this study, resveratrol inhibited cancer cell growth through apoptosis induction. 
In the JB6P+ mouse epidermal celllineCI 41, resveratrol (2.5- 40~M) induced 
apoptosis through an increase in p53 activity (333). Apoptosis was not observed with 
resveratrol (24 h) treatment in a p53 deficient cell line (p53-1.). It was only in the wild-
type (p53+1+) cells that apoptosis occurred. Therefore, the p53 pathway is involved in 
resveratrol- induced apoptosis and may help to explain why resveratrol exhibits anti-
tumour activity. 
Further investigation of the mechanism of apoptosis induction by resveratrol was 
completed in the JB6P+ mouse epidermal cell line Cl 41 (334). Resveratrol (20~M) 
activated apoptosis and increased p53 phosphorylation at the serine 15 residue. MDM2, a 
feedback inhibitor of p53, was also induced by resveratrol but was interfered with by 
serine 15, which dissociated MDM2 and stabilized p53. ERKII2 and p38 MAPK 
activation were required for p53 phosphorylation at serine 15, which again suggested that 
MAPKs are also affected by resveratrol. 
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To further elucidate the involvement of MAPK in resveratrol action, Niles et al. 
(2003) (335) examined cell proliferation and apoptosis in SK- me128 and A375 human 
melanoma cells. Resveratrol (50IlM, 2 days) significantly inhibited proliferation in both 
cell lines and increased apoptosis. Increased phosphorylation ofp38 MAPK or JNK was 
not observed in either cell line but ERK1I2 phosphorylation was induced in the A375 cell 
line. This data suggests that MAP kinase pathways are involved in apoptosis mediation, 
particularly through the p38 MAPK and JNK pathways. 
Previous studies have demonstrated that ERK1I2 and p38 MAPK mediate p53 
activation and the subsequent apoptosis that is responsible for antitumour activity. 
Current research now suggests that JNK is also involved in resveratrol- induced p53 
activation. She et al. (2002) (336) found that resveratrol (10- 40IlM, 1- 4 h) activated 
JNK isoforms in a JB6 Cl 41 mouse epidermal cell line, resulting in p53 
phosphorylation. Apoptosis was repressed in a knockout experiment with resveratrol 
administration to a negative mutant JNKI. Consequently, JNK is also an important 
mediator ofresveratrol- induced apoptosis in addition to ERK and p38 MAPK. 
When MAPK is activated, p53 and subsequent apoptosis is stimulated, as shown 
in human thyroid cancer cells (337). The same researchers found that short- term 
activation of MAPK was required for apoptosis to occur in normal cells and that normal 
p53 function is a requirement for apoptosis. Resveratrol (0.1 to 1001lM) treatment, for 4 
and 24 hours, activated MAPK and induced p53 accumulation leading to apoptosis of 
papillary thyroid carcinoma and follicular thyroid carcinoma cell lines. Resveratrol has 
also demonstrated apoptosis induction in prostate, breast, lymphoblast, and leukemia 
cancer cell lines. 
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Hsieh & Wu (1999) (338) compared androgen- responSIve (LNCaP) and 
androgen- nonresponsive (DU-145, PC-3, and JCA-I) human prostate cancer cells 
concerning the effect of resveratrol on cell growth, cell cycle distribution, and apoptosis. 
Mitogenesis was negatively affected by resveratrol (25JlM) treatment. Cell growth was 
decreased in LNCaP, PC-3, and DU-145 cells with only a mild effect on JCA-l cells. 
Resveratrol also disrupted the GlIS phase transition in all cell lines except for LNCaP. 
Alternatively, resveratrol treatment induced apoptosis in the LNCaP cells. It is interesting 
to note that it was the androgen- responsive cells, LNCaP, that underwent apoptosis. 
Prostate- specific antigens (PSA) respond to androgens via the androgen receptor (AR) 
and are responsible for prostate cell growth. Resveratrol reduced PSA expression by 
almost 80% but did not change AR expression, which is upstream from PSA. Therefore, 
resveratrol regulated PSA gene expression independently of the androgen receptor, which 
may account for the decreased cell growth. 
In another study on LNCaP cells, which are hormone sensitive, resveratrol was 
again found to induce apoptosis. Cell death was assessed via examination of cell 
morphology and caspase activity. In apoptotic cells, caspases are processed from their 
inactive to active state, which is widely accepted as an irreversible step in programmed 
cell death. After resveratrol administration, nuclear condensation and cell shrinkage were 
observed, which indicated that apoptosis had occurred. More evidence for apoptosis was 
shown through an increase in caspase- 3 activity (20nmollminlmg) after 72-hour 
incubation with resveratrol (100JlM) (339). 
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1.10.6 The Effect of Resveratrol on Estrogen Receptor Activity 
Both alpha and beta estrogen receptors are overexpressed in breast cancer (340) 
and targeting their inhibition is a popular therapeutic approach to inhibit breast cancer 
progression. The structure of resveratrol is remarkably similar to that of the synthetic 
estrogen diethylstilbestrol, which is a non- steroidal estrogen used for treatment in 
menopausal disorders. It has been established that resveratrol is a phytoestrogen that 
mimics the effects of human estrogen through the binding and activation of alpha and 
beta estrogen receptors but is less reactive than endogenous estrogen (292). The 
modulatory effects of resveratrol on the estrogen receptor remain controversial since 
resveratrol activity has been shown to be both agonistic and antagonistic for both the 
alpha and beta-receptors, depending on the presence of endogenous estrogen (341). 
Additional factors have been documented to influence the activity of resveratrol, 
including cell type and the type of estrogen receptor expressed (342). 
In the absence of estrogen, resveratrol promoted estrogen receptor (ER) - positive 
breast cancer cell proliferation. In the presence of estrogen however, resveratrol inhibited 
ER- positive MCF7 cell proliferation (342). Synthetic resveratrol (5- 40J-tg/ml, 24- 144 
hours) tested in an estrogen receptor- positive breast cancer cell line (MCF- 7), an 
immortal estrogen receptor- negative breast epithelial cell line (MCF- 1 OF), and a 
malignant estrogen receptor- negative breast ·epithelial cell line (MDA- MB- 231), 
reduced the number of viable cells and prevented proliferation of each cell line. 
In a study by Gehm et aL (1997) (340), resveratrol behaved as a superagonist in 
human breast adenocarcinoma cells (MCF-7) that expressed the estrogen receptor (ER+). 
Resveratrol (10IlM) prevented estradiol from binding to the estrogen receptor and also 
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activated transcription. In addition, the proliferation of T47D breast cancer cells, which 
are estrogen- dependent, was promoted. It is also noteworthy that the combination of both 
resveratrol (5f!M) and estradiol (lOOpM) demonstrated a synergistic effect in MCF-7 
cells, which suggests that both compounds bind and activate the same receptor. 
In contrast to the evidence of an agonistic effect of resveratrol, Turner et al. 
(1999) (343) found that resveratrol demonstrated antagonistic activity in a rat in vivo 
model. When uterine wet weight, epithelial cell height, and mRNA levels for IGF-I was 
examined after resveratrol administration, a statistically significant increase was not 
observed, which indicated that resveratrol is not an estrogen agonist. In addition, 
resveratrol (lOOOf!g/ day) did not express any effect on serum cholesterol levels, unlike 
17~- estradiol (100f!g/ day), which initiated a significant decrease after six days. These in 
vivo results suggest that resveratrol does not exhibit estrogen agonism when compared 
with previous in vitro studies. 
Further uncertainty was added to this controversy in both in vitro and in vivo 
tumour models (300). MCF-7, T47D, LY2, and S30 mammary cancer cells were treated 
with resveratrol (1- 15f!M) for 24 hours. A mild estrogenic response was observed in 
MCF-7 cells but changed to an antagonistic effect when combined with 17~- estradiol. In 
the S30 cell line similar effects were seen, however in the T47D and LY2 cells a strong 
estrogen antagonistic effect was demonstrated. Up- regulation of estrogen- inducible 
genes is a classic agonistic effect, therefore expression of the estrogen- responsive 
proteins including the progesterone receptor (PR) and pS2 were also examined. In MCF-
7 cells, resveratrol induced PR expression but a combination of resveratrol and estradiol 
inhibited PR expression. No change was seen in T47D cells but there was suppression of 
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the pS2 protein in L Y2 and S30 cells regardless of estradiol presence. Similar results 
were observed in a mouse mammary organ culture model. 
Bhat et al. (2001) (300) also studied this effect in mammary tumour- induced 
Sprague- Dawley rats at doses of 10 and 100mg/ kg ofresveratrol (5 days/ week for 111 
days). It was reported that resveratrol suppressed tumour multiplicity, reduced tumour 
incidence (50%), and increased the latency period by 27 days. These findings propose 
that resveratrol's activity, whether agonistic or antagonistic, is dependent on estradiol. 
Henry and Witt (2002) (344) support the in vitro findings that resveratrol acts as a 
mixed agonist/ antagonist. Resveratrol (lOOJ.lM, 7 days) significantly affected estrus 
cyclicity in female Sprague- Dawley rats. Only 41 % of females exhibited the normal 
cycle (4-5 days), while 42% remained in constant estrus and 17% experienced a 
shortened 3-day cycle. In a second experiment, 1000J.lg subcutaneous injections of 
resveratrol in ovariectomized females decreased sexual receptivity to the male stimulus. 
Resveratrol did not have any other effects alone but did stimulate lordosis and increased 
plasma estrogen levels (238 vs. 37.8pg/ml in peanut oil) when combined with 1713-
estradiol benzoate (EB) (10J.lg). This study also showed that when the ovaries were 
removed, pre- exposure to resveratrol did not change lordosis behaviour when EB and 
progesterone were administered. Although in sexually receptive females, resveratrol pre-
exposure caused a significant delay in rejection behaviour and decreased the number of 
interactions with the male stimulus (16.75 vs. 32 in water group). Hence, results from this 
study provide additional evidence that resveratrol is a mixed agonist! antagonist of the 
estrogen receptor. 
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Additional studies suggested that the effect of resveratrol was unrelated to 
estrogen receptor status in Wistar rats (345). Scarlatti et al. (2003) (346) demonstrated 
growth inhibition and apoptosis in MDA- MB- 231 metastatic breast cancer cells. This 
cell line is ER- negative so it does not respond to estrogen or similar structures like 
resveratrol. A 24% increase in apoptosis was discovered with resveratrol (16JlM) 
treatment after two days but the underlying mechanism was determined to be de novo 
ceramide synthesis and not p53 activation. 
The alteration of autocrine growth modulators and their receptors is an additional 
mechanism through which resveratrol is capable of inhibiting breast cancer cell 
proliferation. Resveratrol was administered to ER- positive cells (MCF- 7) and ER-
negative human breast carcinoma cells (MDA- MB- 468) for three days at 10-5 M and 
altered autocrine growth modulator pathways in breast cancer cells in order to inhibit 
proliferation. Autocrine growth stimulators transforming growth factor- alpha, PC cell-
derived growth factor, and insulin- like growth factor I receptor mRNA reduction was 
determined as the mechanism (347). 
In summary, resveratrol has been shown to have exceptional anti- oxidant, anti-
thrombotic, and anti- cancer properties in several different cell lines. Resveratrol also has 
potential for treating other diseases. For example, resveratrol mimics calorie restriction in 
yeast by extending their lifespan by approximately 70% (348). However, even though 
resveratrol has been extensively examined in these critical health- related fields, studies 
investigating the possible anti- diabetic properties of resveratrol are lacking. 
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1.10.7 Resveratrol and Signal Transduction. 
Resveratrol has been extensively studied in a variety of cell lines concerning its 
anti- cardiovascular disease properties, role as an anti- cancer agent, and an anti- oxidant. 
Several signalling molecules are affected by resveratrol, some of which are also involved 
in insulin signalling and glucose transport. However, resveratrol- stimulated signal 
transduction seems to be very much cell specific and concentration- dependent, as 
evidenced by both activation and inhibition of certain key signalling molecules and its 
< biphasic effects in various cell lines, which is extensively reviewed in Aggarwal et al. 
(2004) (274). 
Growth inhibition demonstrated by resveratrol is mediated through upregulation 
of p53, Bax, and p21CipllWAFl, downregulation of cyelin Dl, cyelin E, Bcl-2, Bel-XL, 
caspase activation, and cell cyele arrest. Resveratrol also inhibits the activation of 
transcription factors such as NFkB and AP-l, and protein kinases like IkBa kinase, 
ERKII2, JNK, Akt, PKC, and PKD, and downregulates gene products such as COX-2, 
VEGF, and IL-l. Generally resveratrol inhibits the MAPK and NFkB pathway and 
activates the p53, Fas, and cerami de signalling pathways. 
For example, DMBA- induced (7, 12- dimethylbenz (a) anthracene) protein 
synthesis of both COX2 and MMP- 9 is down- regulated by resveratrol (50JlM) in MCF-
7 cells. Resveratrol (50JlM, 4 h) also suppresses NF- kB activation, which is implicated 
in carcinogenesis and responsible for COX2 and MMP- 9 regulation. COX2 induction 
was not exhibited in any other cancer cell lines examined, which included Bic-l, HCE7, 
SW480, and HL60 cells (349). However, resveratrol (300JlM, 48 h) did cause an 
increase in COX2 expression in Seg-l cancer cells. 
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Phorbol ester- stimulated COX2 activity was inhibited by resveratrol (15JlM, 30 
min) in 184B5! HER cells. Resveratrol inhibited COX2 through protein kinase C (PKC) 
inhibition where its translocation from the cytosol to the membrane was reduced. PKC is 
well established as a regulator in cell signalling and tumour promotion. As a result, 
suppression of prostaglandin synthesis, involved in the inflammatory response, was 
suppressed in addition to tumour progression (350). 
Garcia- Garcia et al. (1999) (351) also found that resveratrol (30JlM) inhibited 
PKC u enzymatic activity in vitro where membrane effects exerted near the lipid- water 
interface in the model membrane improved PKCu inhibition. It is possible that resveratrol 
action either directly inhibited PKC or disrupted the protein- phospholipid bilayer 
interaction. A summary of the effects of resveratrol on key signalling molecules is shown 
in Table 2. 
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Table 2: Effects of resveratrol on key signalling molecules. 
U937 cells 
HL-60 cells 
CHO cells 
Ins-l cell assay 
(rat ~ pancreatic 
cells derived 
from parental 
RINm5f' 
PI3KANDAkt 
MCF-7 human 
breast epithelial 
cells 
Human 
embryonic lung 
fibroblasts 
infected with 
human cyto~ 
VSMC 
COS-7 cells 
Autophosphoryl 
ation reaction 
mixture 
PC-3 prostate 
cancer cells 
73uM 
75uM 
100uM 
100ug/ml 
(60 min) 
10uM (36 h) 
>50uM 
10- 20uM 
(10 min- 2h) 
5- 25uM 
50uM 
(30 min) 
100- 300uM 
(60 min) 
800uM 
5-100uM 
(5 min) 
50% inhibition of glucose and dehydroascorbic acid uptake since sodium 
independent transport blocked and R accumulated in cells (20- 1000pM) 
Glucose and dehydroascorbic acid uptake abolished with R in GLUTl/3 
overexpressed cell (352) 
inflammation) 
No effect on insulin secretion by INS-l cells (353) 
Biphasic effect. 10uM R increased ERa- associated activity and 
Akt phoshorylation whereas >50uM R showed a decrease. There was no 
effect on the PI3K p85 subunit, >50uM R decreased ERa protein 
expression and phospho-Akt activity whereas 10uM resulted in increases 
Decreased viral activity (replication) by blocking viral activation of 
phospho-Akt and phospho-PI3Kp85, and decreasing NFkB transcription 
factor activation, and decreasing EGFR activation (355) 
Limits cell proliferation and differentiation involved in cardiac fibrosis 
by downregulating ERK1I2 activation, however Akt was unaffected 
and inhibition of Akt, PI3K, and 
inhibiting angiotensin II induced 
Inhibition of Ca2+-dependent PKCa activity stimulated by phorbol esters 
or DAG. Additional inhibition of PKC~1 but no effect on PKCE and 
Possible mechanism to enhance endothelium 
Inhibition of PMA- stimulated PKD activity. 800uM R inhibited PKD 
phosphorylation (358) 
80% PKD autophosphorylation inhibition. <20% inhibition on 
cPKCa,~I,y, nPKCo,E, and aPKCI:;. Possible contribution to cancer 
action ofR 
Inhibits cell growth through downregulation ofERKl/2 and PKCa (360) 
Cardioprotection by R exerted from arterial shear stress by suppression 
of cell growth and induction of cell elongation found to be dependent on 
intracellular Ca2+ kinase actin microfilament and 
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endothelial cells microtubule assembly. No effect on PKC and R treated cells adhered 
(BPAEC) more strongly to cover slips during arterial flow. ERK1I2 
phosphorylation and NO synthase expression (6h- 4 days) were also 
increased (361) 
NFkB/TNF/p53 
. , 
" 
Endothelial </= luM Overnight stimulation increased pSONFkB and p6SNFkB nuclear 
cells (30 mm or appearance. Acute stimulation increased IkBa tyrosine phosphorylation 
overnight) of NFkB. No change in cellular p21 or peroxisome proliferators-
activated receptor a activity (311) 
JB6 cells IS and Radicals produced by cell exposure to metal (Cr(VI)) showed a decrease 
20uM with R treatment indicated by a decrease in luciferase receptor activity 
indicating inhibition ofNFkB signalling (362) 
Murine 0.01- Decreased LPS- stimulated NO production (37.6- 81.2%), TNFa 
microglial cells lOug/ml production, iNOS expression (possible mechanism), degradation of Hilla, 
(N9) (48 h) and phosphorylation of p38 MAPK. Therefore NFkB role in resveratrol 
Primary rat suppression of NO and TNFa release. 
microglia Decreased LPS- stimulated NO production in primary cells (S9.6-
71.2%) (363) 
MCF-7 cells 10, 2S and Cell growth and proliferation suppressed (cell accumulation in S phase). 
SOflM (72h) NF-kB activation suppressed (330) 
Splenic 2S- SOuM Inhibits proliferation of mitogen-, IL-2, or alloantigen- induced splenic 
lymphocytes lymphocytes through inhibition ofNFkB, IL-2, and TNF (364) 
Rat PC12 2S- 100uM Induces apoptosis by increasing DNA fragmentation and decreasing 
pheochromocyt 30 min pre- NFkB (297) 
oma cells incubation 
MAPKFAMILY (ERK1I2, JNK1I2,P38MAPK) ,',' " 
Mouse JB6 20uM R activated ERk1l2, JNK1I2, p38 MAPK, and senne IS pS3 
epidermal cells (30 min, 2- phosphorylation. Dominant negative mutant ofERK1I2 or p38 MAPK or 
4h) addition ofPD980S9/ SB202190 repressed pS3 phosphorylation at ser IS 
and repressed pS3- dependent transcriptional activity and apoptosis. 
Overexpression of dominant negative mutant of JNKl had no effect 
(334) 
Porcine 10- 200uM Basal and ET-l stimulation of ERK 112 , JNKl, and p38 MAPK 
coronary (20 min) phosphorylation inhibited. ERKl!2 activity and nuclear translocation also 
arteries inhibited by R (SOuM). No effect on cAMPIPKA (involved in MAPK 
inhibition). Estrogen receptor blockers (tamoxifen) did not block MAPK 
inhibition. ET -1 stimulation of protein tyrosine phosphorylation also 
decreased (319) 
HL- 60 cells 20uM Increased FasL expression (involved in apoptosis induction) and JNK 
(30 mm- and p38 MAPK activity with no effect on ERk1l2. Dominant negative 
24h) constitutively expressed JNK blocked R- stimulation of JNK and FasL 
upregulation (7S%), DNA fragmentation, and reduced apoptosis, without 
p38 MAPK involvement. Kinase- inactive ASKI mutant transfected cells 
showed ASKI as an upstream regulator of R- induced apoptosis. Cdc42 
also activated (30 min) and translocated in response to R. 
Cdc42/ASKlIJNK cascade (36S) 
HeLa cells 2S, SOuM PMA and UVC- stimulated AP-l reporter gene transcription (involved in 
(human cervical (60 min) tumour formation) inhibited. ERK2, JNKl, and p38 MAPK activation 
squamous inhibited but with no effect on Raf-l, MEKKl, or MKK6. Inhibition of 
carcinoma) c-Src tyrosine kinase activity and PKC activation (366) 
HUVEC I-SuM VEGF- mediated HUVEC migration and tube formation inhibited with 
(human (12,24h) no effect on cell proliferation (role in angiogenesis). No effect on VEGF 
umbilical vein receptor, ERK1I2,p38 MAPK or Akt. Tyrosine phosphorylation of VE-
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endothelial cadherin and f3-catenin abolished. ROS- dependent Src kinase activation 
cells) also inhibited (367) 
SK-me128 and 30, 60 or Increased phos of ERK1I2 in A375 cells to contribute to apoptosis and 
A375 human 100f.1M inhibit cell proliferation. No effect in ERK1I2 (SK-mel28), p38 MAPK 
melanoma cells (24-72 h) or JNK (335) 
JB6 mouse 2Of.1M R activated JNKs phos p53 and are required for R-induced p53 
epidermal cell (2, 16, 24h) dependent transcription and subsequent apoptosis induction (336) 
line C14I, 
stable 
transfectants 
CMV-neo and 
dominant 
negative 
mutant-JNKI 
SH-SY5Y IpM-IOuM Apoptosis induction and increase in ERK1I2 and reduction in caspase-7 
neuroblastoma 30 min (368) 
cells 
COXllCOX2 ',',' , . .' . ','" ........ 
...... " .. ,; .' .... 
'. " .," 
Human 0.01, 0.10, Inhibition of DMBA-induced preneoplastic lesions by decreasing 
promyelocytic 1, 10, and COX1I2 activity in HL-60 cells (273) 
leukemia cells, IOOf.1M 
carcinogen- (24 days) 
treated mouse 
mammary 
glands (HL-60) 
MCF7, SW480, 30-300uM Growth inhibition except in Bic-I cells. Induction of apoptosis in all cell 
HCE7, Seg-I, (2- 48h) lines (only 19% in Bic-l) with S phase arrest. Cox-2 expressed in Seg-l 
Bic-l, and only after 48h. f3-catechin decrease after 24/48h in SW480 (349) 
HL60 human 
cancer cell lines 
1 84B5/HER 2.5-100f.1M R suppresses prostaglandin synthesis via inhibition of COX-2 isoform of 
human (30 min- COX. R inhibits COX-2 induction by phorbol esters through inhibition of 
mammary, 4.5h) PKC translocation from cytosol to the membrane (350) 
MSK Leukl 
oral epithelial 
cells 
Female 100f.1g/rat Reduced incidence (45%), multiplicity (55%) and extended latency 
Sprague- (12- period of tumour development (mammary). Suppressed DMBA induced 
Dawley rats 15g/ratlday) ductal carcinoma. R suppressed DMBA- induced COX2 and matrix 
(120 days) metalloprotease- 9 expression in breast tumour. R suppressed DMBA-
induced NF-kB activation (NF-kB regulates COX2)(330) 
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1.11 HYPOTHESIS/ RATIONALE 
Skeletal muscle is responsible for more than 75% of glucose disposal in the 
postprandial state and is therefore quantitatively, the most important insulin target tissue 
(369). Defects in the muscle glucose transport system may lead to reduced insulin 
sensitivity or insulin resistance, which characterize type 2 diabetes (369;370). An in 
depth understanding of the glucose transport mechanism in skeletal muscle cells and the 
action of different compounds that stimulate glucose transport may provide new 
therapeutic approaches to overcome insulin resistance and type 2 diabetes mellitus. 
Substantial epidemiological data have shown that dietary sources containing 
resveratrol, including red wine, may protect against cardiovascular disease and cancer. 
Epidemiological evidence indicates that the French have the . lowest incidence of 
cardiovascular disease compared to the Western world despite diets high in saturated fat. 
This is termed the French Paradox. Further study associated this phenomenon with 
increased red wine consumption (371-373). According to the WHO, the prevalence of 
type 2 diabetes in Canada and the United States in 2002 was approximately 6.41 % 
whereas the prevalence in France was significantly lower at 2.86% (374). For these 
reasons resveratrol may have potential as an anti- diabetic compound. 
Numerous studies have linked enhanced production of ROS and its subsequent 
oxidative stress, to certain vascular diseases. ROS may also contribute to type 2 diabetes. 
Several antioxidants, including tempo I and alpha lipoic acid, have previously 
demonstrated an increased rate of glucose transport in vascular endothelial! smooth 
muscle cells (375) and L6 skeletal muscle cells (376) respectively_ Green tea polyphenols 
also increase glucose transport in adipocytes (377). Antioxidants have demonstrated a 
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positive effect on glucose homeostasis. For example, lipoic acid releases the IL-lbeta-
induced inhibition of glucose- stimulated insulin secretion from islet cells (378). 
Antioxidants are valuable in reducing insulin resistance. The antioxidant tempol 
improved angiotensin II - induced insulin resistance as shown by decreased glucose 
infusion in the hyperinsulinemic- euglycemic clamp and enhanced insulin- stimulated 
PI3K activation in rat liver and adipose tissue (379). Another antioxidant, tranilast, also 
exhibits effects against insulin resistance through inhibition of inflammatory cytokines 
such as TGFp, IL- 2, and monocyte chemoattractant protein 1 (MCP-l) that are involved 
in pathogenesis of insulin resistance by preventing TGFp release from fibroblasts and 
monocytes (380;381) and suppressing NFlcB in rat mesangial cells (382). Several studies 
show that resveratrol has exceptional anti-oxidant (278;279;291;292;323), anti-
thrombotic (305;306;310;321;383), and anti-cancer (273;324;328;384-386) properties 
both in vitro and in vivo. In the present study it is hypothesized that, similar to 
insulin, (1) resveratrol increases glucose transport into skeletal muscle cells and (2) 
employs signalling molecules that are involved in insulin- stimulated glucose uptake. 
1.12 OBJECTIVES 
An in vitro skeletal muscle model was used. The primary objectives of this study 
were (1) to examine the direct effects of resveratrol on basal and insulin- stimulated 
glucose transport, (2) to examine the effects of resveratrol on GLUT4 glucose transporter 
translocation, and (3) to attempt to elucidate the resveratrol signalling pathway and its 
mechanism of action. The secondary objectives of this study were (1) to examine the 
effects of resveratrol on basal and insulin- stimulated amino acid transport and (2) on 
basal and insulin- stimulated mitogenesis. 
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To address the primary objectives, the effect of resveratrol on glucose uptake, 
transporter distribution, and the employment of key signalling molecules involved in the 
insulin signalling pathway, such as PI3K, AktIPKB, and PKC, were examined. 
Furthermore, the amino acid analogue methyl-aminoisobutyric acid (MeAIB) was used to 
examine amino add transport while thymidine incorporation was used to study cell 
proliferation. This study provides the basis for understanding the biological effects of 
resveratrol on the glucose transport system of skeletal muscle cells. The knowledge 
gained from these studies may be used to design in vivo experiments to understand the 
resveratrol effects on glucose homeostasis. It also provides evidence of the effects of 
resveratrol on amino acid transport and cell proliferation. 
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CHAPTER 2: METHODOLOGY 
2.1 MATERIALS 
Minimum essential medium (a-MEM), fetal bovine serum (FBS), goat serum, 
trypsin, and antibiotic were purchased from GIBCO Life Technologies (Burlington, ON, 
Canada). HRP- conjugated anti- rabbit secondary antibody, Akt, ERK1I2, JNKll2, p38 
MAPK, and tyrosine antibodies (Total and Phospho- specific) and LumiGLO reagents 
were purchased from New England Biolabs (Mississauga, ON, Canada). 9EIO anti-myc 
monoclonal antibody was purchased from Santa Cruz (Santa Cruz, CA) and HRP-
conjugated donkey anti- mouse IgG was purchased from Jackson ImmunoResearch 
Laboratories (West Grove, PA). LY294002, wortmannin, cycloheximide (CHX), 
phorbol-12-myristate-13-acetate (PMA), and bovine serum albumin were purchased from 
Calbiochem. Polyvinylidene difluoride (PVDF) membranes, molecular weight protein 
standards, and electrophoresis reagents were purchased from BioRad. eH]2- deoxy-D-
glucose, [14C]methylaminoisobutyric acid, and eH]thymidine were purchased from 
PerkinElmer (Boston, MA). Paraformaldehyde was purchased from Canemco (St. 
Laurent, Quebec). All other chemicals, including cytochalasin D (CD), Go6983, 
bisindolylmaleimide 1 (BIMl), cytochalasin B (CB), cold methylaminoisobutyric acid, 
cold 2-deoxy-D-glucose, ammonium chloride, trichloroacetic acid (TCA) , and 
orthophenyldiene reagent (OPD), were purchased from Sigma Chemicals (St. Louis, 
MO). Both the parental and GLUT4myc overexpressing L6 cells were a kind gift from 
Dr. A. Klip (Hospital for Sick Children, Toronto, ON). 
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. 2.2.1 PARENTAL L6 SKELETAL MUSCLE CELLS 
L6 cells, which are derived from 3- day old rat hindlimb skeletal muscle, 
proliferate as mononucleated myoblasts in high serum (10% FBS) and spontaneously 
differentiate in low serum (2% FBS) through cellular fusion from myoblasts into 
multinucleated primary myotubes (387;388). The myotubes express the insulin receptor 
and insulin- like growth factor-I receptor (lGF-I) and several other proteins that are 
typical of skeletal muscle including the GLUT4 glucose transporter (389). As L6 
myoblasts differentiate, the number of insulin receptors, GLUT4 transporter expression, 
and insulin responsiveness increases. 
This cell line also expresses GLUT3 that is found in fetal muscle and neuronal 
tissue (390) and GLUTI that is ubiquitously expressed in mature skeletal muscle but are 
not as abundant as the GLUT4 transporter (391). The ratio of GLUTI to GLUT4 in the 
plasma membrane at rest is 1 :0.8 (392;393). In this cell line, insulin treatment results in a 
two- fold increase in glucose transport within 15 minutes of exposure (394) and the 
translocation of glucose transporters from an intracellular pool to the plasma membrane 
(395-398). 
Cultured cells have been used extensively to examine both hormonal and 
metabolic processes. The cell culture system has many advantages when studying 
molecular mechanisms of hormone action and transport function! regulation. For 
example, it is a homogeneous population of muscle cells with limited intracellular space, 
unlike intact tissue preparation. Another advantage is that this model allows for isolated 
treatment, where the external environment is very tightly controlled and not influenced 
by other hormonesl factors found in in vivo studies. In addition, cell cultures have an 
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extended viability and may be used to examine acute as well as more chronic effects of a 
substance! chemical under study. 
Human studies are very invasive and the isolation of skeletal muscle strips is 
possible only during a surgical procedure, therefore greatly limiting availability. During 
removal of the muscle, there is a risk of compromising membrane integrity (399). Whole 
tissue cultures have limited viability (2-3 hrs) and significant diffusional limitations may 
influence hormone action or the effects of experimental chemicals! drugs (400). 
Furthermore, physiological concentrations of insulin have been ineffective in stimulating 
glucose transport in primary cell culture and cultures of diverse origin (401;402). Primary 
muscle cell culture is not widely used and is difficult to establish. 
Apart from L6 cells, rat pheochrorriocytoma cells (PC12) have also been used as a 
model of muscle in a limited number of studies, however these cells are derived from 
neural tissue and are not a good representation of skeletal muscle. PC12 cells are 
primarily used as a neuronal cell model system to study GLUT3 regulation (403). Mouse 
C2C12 cells are another model of skeletal muscle but these cells predominantly express 
the GLUTI glucose transporter with low expression of GLUT4 (404;405) and most 
importantly lack insulin- stimulated glucose uptake (406). 
Although L6 cells express higher ratios of GLUTI and GLUT3 transporters and 
less GLUT4 than adult rat muscles, which is not an absolute representation of adult 
skeletal muscle (399;407), these cells have many skeletal muscle morphological and 
functional characteristics. The L6 cell line is one of few cell lines that differentiate in 
culture and is the only cell line that expresses GLUTl, GLUT3, and GLUT4 (389;408). 
L6 cells are widely used and the best available system representing skeletal muscle (387). 
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The cells grow in monolayers, which makes them readily and .easily accessible to 
substrates and therefore a good model for transport studies. 
2.2.2 GLUT4 OVEREXPRESSING L6 SKELETAL MUSCLE CELLS 
The L6 GLUT4myc overexpressing cell line was constructed by inserting a 
human cmyc epitope tag within the first exofacialloop of the GLUT4 transporter (409). 
The cmyc tag does not interfere with GLUT4 activity (410) (Figure 11). These cells 
differentiate normally from myoblasts to fused myotubes, at which stage they respond to 
insulin with a two- fold stimulation of glucose uptake and a two- fold translocation of 
GLUT4myc (409). The Km of glucose uptake is similar in L6 GLUT4myc cells to that of 
the parental L6 cells (156;394). Similar to L6 parental cells, L6 GLUT4myc cells respond 
to insulin by IRS-l phosphorylation and subsequent PI3K and AktlPKB activation, which 
are necessary for stimulation of glucose uptake (411). 
GLUTI expression is the same in L6 GLUT4myc cells as in parental L6 cells 
(392), however it is in low abundance compared to GLUT4myc. The ratio of GLUT4myc 
to GLUT4 and GLUTI is 124:1:1.2 (392;412;413). GLUT4myc mediates both basal and 
insulin- stimulated glucose uptake predominantly, where the ratio of surface GLUT4myc 
to total cellular GLUT4myc is 1: 2.6 (409). This was established by almost complete 
inhibition of basal and insulin- stimulate glucose transport with indinavir, a selective 
inhibitor of GLUT4 mediated glucose influx (392;414). However, the possibility that 
GLUT1 may also contribute to glucose uptake cannot be fully eliminated. In the basal 
state, 90% of GLUT4myc is sequestered intracellularly and a significant portion is 
translocated to the cell surface in response to insulin (415). GLUT4myc recycling is the 
same as that of endogenous GLUT4 (416). 
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. 2.3 CELL CULTURE TECHNIQUE 
L6 rat skeletal muscle cells (parental and GLUT4cmyc overexpressing) were 
grown in a-MEM (PH 7.4) containing 5mM glucose, 2% (v/v) FBS, and 1% (v/v) 
antibiotic- antimycotic solution (100 Ulmi penicillin, 1 00 ~g/ml streptomycin, and 250 
ng/ml amphotericin B) in a humidified atmosphere of 5% CO2- 95% air at 37°C as 
previously described (417). Cells were grown in flasks and seeded to 12- well plates for 
glucose uptake measurements. The cells were allowed to reach confluence, align, and 
fuse into myotubes before being used for glucose and amino acid experiments. 
Undifferentiated myoblasts were used for the thymidine incorporation experiments. Prior 
to experiments, the cells were growth- arrested by incubation with serum- free a-MEM 
for 5 h. Serum deprivation decreases the rate of basal transport so that the cells are not at 
maximum capacity before stimulation, thereby making an increase more visible (418). 
2.4 CELL TREATMENT 
Resveratrol, CHX, PMA, and CD stock solutions were prepared using 100% 
ethanol, insulin stock solution, which was used as a positive control, was prepared in 2% 
FBS- containing media, while LY294002, wortmannin, BIMI, and G06983 were all 
prepared in DMSO. The final concentration and the time of incubation for each 
compound are indicated in each figure. A vehicle- treated control group was used in 
parallel with the treated groups. 
2.5 DETERMINATION OF 2- deoxy-D-glucose (2DG) UPTAKE. 
At the end of the incubation period, the medium was removed, the cells were 
rinsed three times with HEPES- buffered saline solution (HBS; I40mM NaCl, 5mM KCl, 
20mM HEPES, 2.5mM MgS04, and ImM CaC12, pH 7.4), and subsequently, 2- deoxy-
D-glucose uptake measurements were carried out for 10 minutes in HEPES- buffered 
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saline containing I011M 2-eH]deoxy-D-glucose (417). Nonspecific uptake of glucose 
was detennined in the presence of l011M cytochalasin B and subtracted from total uptake 
(absence of CB) to detennine specific carrier-mediated glucose transport. The transport 
assay was tenninated by washing the cells three times with Iml ice- cold 0.9% NaCI 
solution, followed by solubilization of the cells with 0.05N NaOH and radioactivity 
counting. All experiments were assayed in triplicate and perfonned 4- 8 times. Cellular 
protein content was measured by the BioRad Protein Assay method. Because of the 
structure of 2DG, it is not metabolized by the cell and remains intact for scintillation 
counting. The first 10 minutes of 2DG transport has been shown to be limited by 
transport alone. 
2.6 DETERMINATION OF METHYLAMINOISOBUTYRIC ACID (MeAIB) 
UPTAKE. 
At the end of the incubation period, the medium was removed, the cells were 
rinsed three times with HEPES- buffered saline solution (HBS; 140mM NaCl, 5mM KCI, 
20mM HEPES, 2.5mM MgS04, and ImM CaCI2, pH 7.4), and subsequently, 
methylaminoisobutyric acid uptake measurements were carried out for 10 minutes in 
HEPES- buffered saline containing IOflM [14C]methylaminoisobutyric acid. Nonspecific 
uptake of MeAIB was detennined in the presence of 10mM cold MeAIB and subtracted 
from total uptake to detennine specific carrier-mediated amino acid transport. The 
transport assay was tenninated by washing the cells three times with Iml ice- cold 0.9% 
NaCI solution, followed by solubilization of the cells with 0.05N NaOH and radioactivity 
counting. All experiments were assayed in triplicate and perfonned 4- 8 times. Cellular 
protein content was measured by the Bio Rad Protein Assay method. 
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2.7 WESTERN BLOT ANALYSIS 
At the end of the treatment period, the cells were rinsed three times with HBS and 
then lysis buffer (20mM Tris (pH 7.5), 150mM NaCI, ImM EDTA, 1mM EGTA, 1% 
Triton X-lOO, 2.5mM N~07P2, 1mM ~-glycerolphosphate, ImM Na3V04, If!glml 
leupeptin, 1mM PMSF) was added and the lysate was scraped off and solubilized in 
electrophoresis sample buffer, followed by separation by sodium dodecyl sulfate-
polyacrylamide gel (10%) electrophoresis. The samples were subsequently transferred 
electrophoretically to PVDF membranes. 
The membranes were incubated for 1 h at room temperature with 5% (w/v) nonfat 
dry milk in Tris- buffered saline and then overnight at 4°C with the primary antibody. 
The following primary antibodies were used: Phospho- Akt (Ser473) polyclonal antibody 
(1 :1000), Total- Akt polyclonal antibody (1 :1000), Phospho- p38 MAPK polyclonal 
antibody (1:1000), Total- p38 MAPK polyclonal antibody (1:1000), Phospho ERK1I2 
polyclonal antibody (1:1000), Total- ERK1I2 polyclonal antibody (1:1000), Phospho-
SAPKlJNK polyclonal antibody (1 :1000), Total- SAPKlJNK polyclonal antibody 
(1 : 1 000), and Phospho- Tyrosine monoclonal antibody (1 :2000). The primary antibody 
was detected with either the HRP- conjugated anti- rabbit secondary antibody (1 :2000) or 
the HRP- conjugated anti- mouse secondary antibody (1 :2000), and LumiGLO reagent 
(NEB) and visualized by autoradiography using Kodak XAR-5 film. 
2.8 MEASUREMENT OF GLUT4myc TRANSLOCATION 
The amount ofmyc-tagged GLUT4 at the surface of intact cells was measured by 
an antibody- coupled colorimetric assay as previously described (409) (Figure 11). 
Following the treatment period, the monolayer of myotubes was fixed with 3% 
paraformaldehyde for 3 min at room temperature, incubated with ~ % glycine for 10 min 
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to reduce the remaining paraformaldehyde, blocked with 10% goat serum and 3% bovine 
serum albumin in PBS, and then exposed to anti-myc antibody (1:100) for 60 min, and 
followed by incubation with peroxidase- conjugated donkey anti- mouse IgG (1: 1 000) for 
30 min, all at 4°C. Cells were washed extensively, and 1 ml of OPD reagent was added 
for 30 min at room temperature. The reaction was stopped by 0.25 ml of 3N HC!. The 
supernatant was collected, and the absorbance was measured at 492 nm. Nonspecific IgG 
binding, as measured by a peroxidase- conjugated anti- mouse IgG, was subtracted from 
experimental values. 
Resveratrol 101 
Cmyc-GLUT4 
Figure 11: The GLUT4myc transfected L6 cell. 
2.9 MEASUREMENT OF THYMIDINE INCORPORATION 
L6 myoblasts were used for experimentation. Sub confluent myoblasts (-50%) 
were serum deprived (0.1 % FBS in a-MEM) for 24 h in order to bring the cells to a 
quiescent state. This was followed by cell treatment for 12 h in 0.1 % FBS. 10JlM 
eH]thymidine was then added to each well in parallel for an additional 12 hours. 
eH]thymidine is incorporated into the cell and remains intact. Total incubation time for 
all compounds was 24 hours. 
At the end of the incubation period, the media was removed, the cells were rinsed 
three times with ice- cold HBS, and subsequently, the unincorporated eH]thymidine was 
precipitated out of the cells with 10% trichloro- acetic acid (TCA) for 10 minutes at 4°C 
(317;356;360;419). The 10% TCA was aspirated and the cells were rinsed twice with ice-
cold HBS, followed by solubilization of the cells with 0.05N NaOH and radioactivity 
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counting. All experiments were assayed in triplicate and performed 4- 6 times. Cellular 
protein content was measured by the BioRad Protein Assay method. 
2.10 STATISTICAL ANALYSIS 
Statistical analysis was performed using the Statistical Package for the Social 
Sciences (SPSS). All data from several experiments were pooled and then presented as 
mean ± SEM. The means of the groups were compared with either the student's 
independent samples t- test or the one- way analysis of variance (ANOVA). 
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CHAPTER 3: Section 1: RESULTS 
3.1.1 Concentration and time- dependent effects of resveratrol on glucose uptake. 
Antioxidants, such as tempol and alpha lipoic acid, and green tea polyphenols 
have previously demonstrated increased rates of glucose transport in various cell lines 
(375-377). Furthermore, resveratrol is a polyphenol with exceptional anti-oxidant 
(278;279;291;292;323) properties both in vitro and in vivo. We hypothesized that 
resveratrol may stimulate glucose transport in L6 skeletal muscle cells. To examine this 
hypothesis, L6 myotubes were incubated with resveratrol 10, 25, 50, 100, and 125JlM for 
120 min as indicated in Figure 12A and followed by glucose transport measurements. 
Significant increases in glucose uptake were seen with 25uM resveratrol (l39 ± 
5.61 % of control, p<0.05). Maximum stimulation by resveratrol (201 ± 8.90% of control, 
p<O.OOI) was reached at a concentration of 100uM. Higher concentrations, 125JlM (200 
± 12.61 % of control, p<0.001) and 150uM (data not shown), did not result in any greater 
stimulation of glucose uptake. Cell morphology was observed microscopically and was 
not affected by treatment. It is important to note that noncarrier- mediated glucose 
uptake, as determined by CB administration, was approximately 5% of the total uptake 
and was not significantly affected by cell treatment in all experiments presented in the 
results section. 
To examine whether the response of the cells to resveratrol is tiine- dependent, the 
cells were incubated with 100J..LM resveratrol for 15, 30, 60, 90, and 120 minutes (Figure 
12B). Resveratrol increased glucose uptake in L6 cells to significant levels within 30 
minutes of incubation (141 ± 6.50% of control, p<0.05). Maximum stimulation by 
resveratrol was observed by 120 min (201 ± 8.90% of control, p<O.OOI), and in all 
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subsequent experiments 120 min incubation was used. In parallel experiments, insulin 
(10-7M, 30 min) increased glucose transport by 208 ± 10.87% compared to control 
(p<0.00l), which is similar to that seen with the maximal resveratrol response (Figure 
12C). These results suggest that resveratrol significantly stimulates glucose uptake in a 
dose- and time- dependent manner independent of insulin. 
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Figure 12: (A) Effects of resveratrol on 2DG uptake in L6 myotubes: dose response. L6 
myotubes were incubated with the indicated concentrations of resveratrol for 120 min at 37°C. 
(B) Effects of resveratrol on 2DG uptake in L6 myotubes: time course. L6myotubes were 
incubated for the indicated time periods with resveratrol (100~M) at 37°C. After treatment the 
cells were washed and eH]2DG uptake was measured. The results are the mean ± SE of 4-7 
independent experiments each performed in triplicate and expressed as a percent of control, 
*p<0.05, ***p<O.OOl, NS = not significant compared to untreated control. 
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Figure 12: (C) Effects of insulin and resveratrol on 2DG uptake in L6 myotubes. 
L6 myotubes were incubated with either 100nM insulin (30 min) or lOOIlM 
resveratrol (120 min) at 37°C. Cells were washed and eH]2DG uptake was 
measured. The results are the mean ± SE of 4-7 independent experiments each 
performed in triplicate and expressed as a percent of control, ***p<O.OOI 
compared to untreated control. 
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3.1.2 Effect of resveratrol treatment on insulin~ stimulated glucose uptake. 
Several anti- diabetic agents, including metfonnin, result in an additivity III 
glucose transport when combined with insulin (420). To investigate whether the action of 
resveratrol to increase glucose uptake affects the acute insulin- induced increase in 
glucose transport, we examined the interaction between acute insulin exposure and 
resveratrol treatment (Figure 13). Insulin was added to the cells for 30 min before the 
measurement of glucose uptake in the control and resveratrol- pretreated cells. Insulin 
concentrations of lO-1O, lO-9, lO-8, and lO-7M were used. Resveratrol treatment was 
continued in parallel with insulin treatment. 
Insulin alone at lO-8 M and lO-7 M for 30 min resulted in a significant increase in 
glucose uptake (209 ± 9.96%; 227 ± 12.52% of control; p<O.OOI). Treatment of 
myotubes for 120 min with resveratrol (lOOuM) and insulin added for the final 30 min, 
resulted in a significant increase in glucose uptake above basal values at all insulin 
concentrations used. No significant differences (p>0.05) were observed between 
resveratrol- treated and non- treated cells at maximal insulin concentrations. However, a 
statistically significant difference (p<0.01) was observed between the responses of the 
cells treated with insulin alone and those treated with both compounds at submaximal 
insulin levels (Figure 13). Thus, there is an apparent additivity of resveratrol with 
submaximal insulin concentrations. 
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Figure 13: Effects of resveratrol treatment on insulin- stimulated 2DG uptake. L6 
myotubes were incubated without (_) or with 100J.1M resveratrol (90 min) (e), 
followed by the addition of insulin in parallel for 30 min at the indicated 
concentrations. This was followed by the eH]2DG uptake assay. The results are the 
mean ± SE of 6-8 independent experiments performed in triplicate and expressed as a 
percent of control, **p<O.Ol, NS = not significant compared to control (resveratrol 
untreated cells). 
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3.1.3 Effect of cycloheximide (CHX) on resveratrol"- stimulated glucose uptake. 
Acute insulin stimulation in L6 myotubes is independent of protein synthesis and 
is CHX insensitive (394). The slightly increased response time observed with resveratrol 
treatment compared to insulin suggested that resveratrol action might induce the 
synthesis of a protein relevant for the stimulation of glucose uptake. In order to test this 
hypothesis, we examined the effects of resveratrol on glucose uptake in the presence of 
l/lglml CHX. CHX inhibits translational elongation by competitively inhibiting peptidyl 
transferase, resulting in inhibition of protein synthesis. This concentration of CHX has 
previously been demonstrated to effectively block protein synthesis over 24 h in L6 cells, 
as measured by e5S]methionine incorporation into protein (393). 
Myotubes were incubated with l/lglml CHX followed by resveratrol (IOO/lM, 120 
min) or insulin (10-7M, 30 min) treatment. Total incubation with CHX was 130 min in all 
groups. CHX did not demonstrate any significant effects on basal glucose uptake (101 ± 
6.38% of untreated control,p>0.05). Acute insulin treatment stimulated glucose uptake to 
205 ± 9.70% (p<0.001) of control and was not affected by CHX (211 ± 7.04% of control, 
p<O.OOl). The stimulation of glucose uptake was 182 ± 7.55% (p<0.001) of the control 
value in the presence of resveratrol alone (100uM, 120 min) and stimulations of similar 
magnitude were observed with resveratrol in the presence of CHX (172 ± 8.54% of 
control, p<O.001) (Figure 14). The increase in glucose uptake induced by resveratrol was 
not prevented. These results suggest that resveratrol- induced glucose uptake is not 
dependent on protein synthesis. 
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Figure 14: Effect of cycloheximide on resveratrol- and insulin- stimulated glucose 
transport. L6 myotubes incubated without (0) or with IJlg/ml CHX (_) were 
stimulated with 100JlM resveratrol (l20 min) or insulin (l0·7M, 30 min). Total 
treatment with CHX was 130 min. Results are the mean ± SE of 7-8 independent 
experiments performed in triplicate and expressed as a percent of control, 
***p<O.OOI compared to untreated control. 
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3.1.4 Effect of PI3K inhibitors on resveratrol- stimulated glucose uptake. 
It is well known that stimulation of glucose uptake by insulin requires PI3K. 
Since resveratrol demonstrated a similar action to that of insulin, we hypothesized that 
PI3K may also contribute to the elevated levels of glucose uptake observed. To examine 
our hypothesis, we used specific PI3K inhibitors. L Y294002 (100uM), a quercetin 
derivative that acts as a competitive inhibitor of the A TP binding site of PI3 K (41), and 
wortmannin (111M), a fungal metabolite that exerts its inhibition by binding to the plIO 
catalytic subunit of PI3K (38;39), were added to the cells 15 min prior to the addition of 
resveratrol (lOOuM, 60 min). Figure 15A shows that both insulin- (221 ± 7.24% of 
control, p<O.OOl) and resveratrol- (167 ± 14.13% of control, p<0.001) stimulated glucose 
uptake were abolished by LY294002 to 103 ± 7.44% and 69 ± 17.39% of control 
respectively. Similar results were obtained with wortmannin for both insulin and 
resveratrol, 126 ± 9.93% and 113 ± 7.34% of control. 
To examine the effectiveness of wortmannin to inhibit PI3K, we analyzed 
Akt/PKB phosphorylation of insulin- stimulated cells pretreated with wortmannin 
through Western blot analysis. Under our experimental conditions, wortmannin 
effectively blocked insulin- stimulated AktlPKB phosphorylation (C = 1.0; 1= 5.5; W = 
1.2; W + I = 1.2 arbitrary densitometry units compared to control) (Figure 15B), 
indicating an effective inhibition ofPI3K activity. These data (FigureI5A, B) suggest that 
PI3K is involved in the regulation of glucose uptake by resveratrol. 
Resveratrol 112 
A 
250 
*** 
Q) 
..lI::: 200 
*** m 
.... 
a. 
::1::::-
Q) 0 (f)!:; 150 o c 
o 0 
::I 0 
0,-
• 0 100 c 
.::$:! >-~ 
>< 0 
Q) 50 c 
• N 
0 
Basal Insulin Resveratrol 
Figure 15A: Effect of L Y294002 and wortmannin on insulin- and resveratrol-stimulated 
glucose transport. L6 cells were pre-incubated without (D) or with lOOJlM LY294002 (_) or 
1 JlM wortmannin • ), followed by the addition of resveratrol (100JlM, 60 min) or insulin (10-
7M, 30 min). Total incubation with LY294002 and wortmannin was 75 minutes. The results are 
the mean ± SE of 4 to 7 independent experiments performed in triplicate and expressed as a 
percent of control, ***p<0.001 compared to untreated control. 
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Figure 15B: AktlPKB phosphorylation by insulin. Total celllysates were prepared 
from L6 muscle cells that were treated for the indicated time with or without lO-7M 
insulin or pre-treated with luM (15 min) wortmannin. Lysates (12.5Jlg) were 
resolved by lO% SDS-PAGE and immunoblotted with anti-phospho-AktlPKB. 
Representative immunoblot of 1 experiment. Immunoblot was scanned to 
quantitate the density of the bands where all values are arbitrary densitometric units 
expressed relative to untreated control cells. Note: Data is from the same original 
blot, which was m'odified to exclude extraneous information. 
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3.1.5 Effect of resveratrol on AktIPKB phosphorylation. 
In order to further delineate the mechanism by which resveratrol raises the rate of 
glucose uptake into the cell, we examined elements involved in the insulin- signalling 
pathway further downstream. AktIPKB phosphorylation and subsequent activation· has 
been shown in several studies to be a step downstream of PI3K in insulin- stimulated 
glucose transport (92;421), so we tested whether resveratrol employs AktIPKB. We 
examined the effect of insulin and! or resveratrol on AktIPKB phosphorylation at the 
Ser473 residue. Western blot analysis revealed that stimulation of the cells with insulin 
for 5, 15 or 30 min resulted in significant AktIPKB phosphorylation (5.84 ± 1.36; 5.36 ± 
1.41; 5.14 ± 1.18 arbitrary densitometry units relative to untreated control, p<0.05). 
Unlike insulin, stimulation of the cells with resveratrol (100~M) for 5, 15, 30, 60, and 
120 min did not phosphorylate AktlPKB (p>O.05) (Figure 16A upper blot). In addition, 
resveratrol did not significantly affect insulin- induced AktIPKB phosphorylation (4.31 ± 
0.77 arbitrary densitometry units relative to untreated control,p<0.05). The total levels of 
AktIPKB were not affected by any treatment (Figure 16A lower blot). From the results 
presented here, it appears that the mechanism of action of resveratrol is PI3K- dependent 
but AktIPKB- independent. 
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Figure 16: (A) Akt/PKB phosphorylation by insulin and/or resveratrol. Total cell 
lysates were prepared from L6 muscle cells that were treated for the indicated time 
(min) with or without 10-7M insulin or 100J.tM resveratrol or insulin and resveratrol 
combined. Lysates (12.5J.tg) were resolved by 10% SDS-PAGE and immunoblotted 
with anti-phospho-Akt or anti-total-Akt antibody. Representative immunoblot of 3 
independent experiments. (B, C) Immunoblots were scanned to quantitate the density 
of the bands. Results are the mean ± SE of 3 independent experiments. All values are 
arbitrary densitometric units expressed relative to untreated control cells, *p<0.05 
compared to untreated control. 
Resveratrol 115 
3.1.6 Effect of PKC inhibitors on resveratrol- stimulated glucose transport. 
Several PKC isofonns have been identified as downstream targets of PI3K 
activation, including PKCA and PKCs, which have been shown to be involved in insulin-
stimulated glucose transport (223-225). It has also been documented in skeletal muscle 
cells that acute activation of PKC by PMA, a DAG analogue, leads to increased glucose 
uptake (422;423). Since resveratrol employs PI3K but does not involve AktIPKB 
activation, it was important to examine a possible alternative pathway that may involve 
PI3K and PKC to affect glucose transport. We hypothesized that members of the PKC 
family may be involved in resveratrol- stimulated glucose transport. To examine this 
hypothesis, we used the PKC inhibitors BIMI (I~M, 60 min) and G06983 (500nM, 20 
min), followed by stimulation with PMA (1~M, 30 min) or resveratrol (100~M, 60 min). 
BIMI and G06983 are known inhibitors of the conventional, novel, and atypical isofonns 
of PKC. Both BIM1 and G06983 act as competitive inhibitors for the ATP- binding site 
ofPKC. BIM1 and G06983 show high selectivity for different PKC isofonns, however at 
the concentrations used in this study they both effectively inhibit all PKC isofonns (423-
426). 
Acute exposure to PMA resulted in stimulation of glucose transport (159 ± 6.47% 
of control, p<O.OOl) to levels similar to those of resveratrol (169 ± 8.00% of control, 
p<O.OOl). BIM and G06983 did not have a significant effect on basal glucose transport 
(99 ± 4.00%; 104 ± 3.31 % of untreated control, p>0.05). Both compounds significantly 
abolished the PMA- stimulated glucose transport (109 ± 3.99%; 106 ± 2.65% of control, 
p>0.05), indicating that they are effective inhibitors of PKC. However resveratrol-
stimulated glucose transport was not inhibited by BIM or G06983 (169 ± 6.71%; 159 ± 
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9.63% of control (p<0.001)). The PKC inhibitors did not affect glucose transport 
stimulation by resveratrol (Figure 17) and these data indicate that PKC does not have a 
significant role in resveratrol- stimulated glucose transport. 
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Figure 17: Effects of BIMI and G06983 on PMA- and resveratrol- stimulated glucose 
transport. L6 cells were pre- incubated without (0) or with 1/lM BIMI (til) or 500nM 
G06983 (_), followed by the addition ofresveratrol (lOO/lM, 60 min) or PMA (1/lM, 30 
min). Total incubation with BIM1 and G06983 was 120 and 80 minutes respectively. 
The results are the mean ± SE of 4- 8 independent experiments performed in triplicate 
and expressed as a percent of control, ***p<O.OOl compared to untreated control. 
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3.1.7 Effect of resveratrol on glucose transporter translocation- GLUT4. 
Insulin- stimulated glucose transport requires GLUT4 translocation. To elucidate 
the mechanism by which resveratrol altered glucose uptake, we measured surface GLUT4 
levels under the various treatments. L6 GLUTmyc cells stably express GLUT4 tagged 
with an exofacial myc epitope (GLUTmyc) (409). GLUT4myc segregates, cycles, and 
responds to insulin in a manner similar to endogenous GLUT4. The amount of GLUTmyc 
incorporated into the plasma membrane was quantitated by immunologically labelling the 
myc epitope at the surface of intact cells. 
Acute maximal insulin (10-7M, 30 min) stimulation in the absence of resveratrol 
increased the amount of GLUT4myc epitope at the surface of intact cells to 194 ± 11.66% 
of untreated control cells (p<0.001) (Figure 18A). However, unlike that of insulin, 
resveratrol treatment (100uM, 120 min) did not cause a significant increase in 
recruitment of GLUT4myc to the plasma membrane (78 ± 9.81 % of control, p>0.05). In 
addition, resveratrol did not have any significant effect on insulin- stimulated GLUT4 
translocation at both maximal and submaximal hormone concentrations (Figure 18B). 
These results suggest that resveratrol- stimulated glucose uptake is not due to GLUT4 
translocation. 
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Figure 18A: Effect of insulin or resveratrol on plasma membrane GLUT4 levels in 
GLUT4cmyc overexpressing myotubes. Cells were treated with resveratrol (lOOJlM, 120 
min) (_) or insulin (l0-7M, 30 min) Gi). GLUT4 transporter translocation was 
determined following incubation. The results are the mean ± SE of 4-5 independent 
experiments performed in triplicate and expressed as a percent of control, ***p<O.OOl, 
NS = not significant compared to untreated control. 
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Figure 18B: Effect of resveratrol on insulin- mediated GLUT4 translocation in 
GLUT4cmyc overexpressing myotubes. Cells were treated with resveratrol (lOOJlM, 
120 min) (_), followed by treatment with insulin (30 min) at the indicated 
concentrations. GLUT4 transporter translocation was determined following 
incubation. The results are the mean ± SE of 4 experiments performed in triplicate and 
expressed as a percent of control, **p<O.Ol, ***p<O.OOl compared to untreated 
control. 
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3.1.8 Effect ofresveratrol on glucose uptake in GLUT4myc overexpressing cells. 
Since resveratrol- stimulated glucose transport was observed in parental L6 cells 
and GLUT4 translocation was examined in GLUT4myc overexpressing cells, it was 
important to ensure that resveratrol also significantly stimulated glucose uptake in a 
similar fashion in the GLUT4myc tagged cell line. We measured insulin- and resveratrol-
stimulated glucose transport in overexpressing GLUT4myc tagged cells. As previously 
seen in the parental L6 cell line, insulin (10-7M, 30 min) induced a 2- fold increase in 
glucose transport (192 ± 9.43% of control, p<O.OOl) in GLUT4myc overexpressing L6 
cells. Treatment with resveratrol (lOOf.lM, 120 min) did result in a significant increase in 
glucose uptake (141 ± 6.42% of control, p<0.01) (Figure 19) as well. Together these 
results (Figure 19 and Figure 18A) indicate that resveratrol significantly stimulates 
glucose uptake in L6 GLUT4myc cells by a mechanism that is independent of GLUT4 
translocation. 
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Figure 19: Effects of resveratrol on 2DG uptake in L6 GLUT4myc tagged 
myotubes. Myotubes were incubated with either resveratrol (lOOIlM, 120 min) or 
insulin (1O-7M, 30 min) at 37°C. Cells were washed and eH]2DG uptake was 
measured. The results are the mean ± SE of 4-5 independent experiments 
perfonned in triplicate and expressed as a percent of control, **p<0.01, 
***p<O.OOl compared to untreated control. 
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3.1.9 Effect of actin network disassembly on resveratrol- stimulated glucose 
transport. 
Previous studies have shown that an intact actin cytoskeleton is required for 
insulin- stimulated glucose transport and glucose transporter translocation (232). 
Cytochalasin D (CD) is a fungal metabolite that disassembles the actin network and is 
widely used (427-430). The primary site of action of CD is actin where it binds to the 
barbed end of the actin monomer and filament and affects actin polymerization to 
decrease actin filament formation (429). Similar analogues such as cytochalasin B (CB) 
have a high affinity for facilitated diffussional glucose transporters (GLUTs) and inhibit 
glucose transport. However CD, at concentrations used to disassemble the actin 
cytoskeleton, has a very low affinity for the GLUTs and does not significantly affect 
basal glucose uptake (232;429;431). 
An intact actin network may be required for transporter translocation (exocytosis) 
as well as for early insulin signalling. In bovine pulmonary artery endothelial cells, it was 
shown that resveratrol (100)lM)- induced cell elongation was abolished by CD, indicating 
that an intact actin cytoskeleton is required for this response (361). In light of these data, 
we hypothesized that an intact actin network is required for resveratrol- stimulated 
glucose transport. Therefore, we treated L6 myotubes with CD (I)lM) for 2 h, followed 
by stimulation with resveratrol (100)lM, 120 min) or insulin (l0-7M, 30 min). 
Exposure of the cells to insulin for 30 min or resveratrol for 60 or 120 min 
resulted in a significant increase in glucose uptake (223 ± 13.06; 163 ± 4.73%,p<0.001; 
137 ± 4.59%, p<O.OI) compared to control. Treatment with CD did not significantly 
affect basal glucose transport (77 ± 3.04% of untreated control, p>0.05). However, CD 
significantly reduced glucose transport stimulation by both insulin (114 ± 7.46% of 
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control) and resveratrol at 120 min (109 ± 7.31% of control) and 60 min (87 ± 4.58% of 
control) (Figure 20). After approximately 10 minutes of exposure to cytochalasin D, the 
cells had undergone morphological changes (a star like appearance). The same 
morphological changes have been reported by others and are indicative of the 
effectiveness of CD to disassemble the actin network (232). These data indicate that the 
actin cytoskeleton appears to be required in resveratrol- stimulated glucose transport. 
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Figure 20: Effect of cytochalasin D (CD) on insulin- and resveratrol- stimulated 
glucose transport. L6 cells were pre- incubated in the absense (D) or presence of IJ!M 
CD (_), followed by the addition ofresveratrol (100J!M, 120 or 60 min) or insulin (10-
7M, 30 min). Total incubation with CD was 120 minutes except for resveratrol (120 
min), which was pre- incubated with CD for 30 minutes (150 min total CD treatment). 
The results are the mean ± SE of 5 independent experiments performed in triplicate 
and expressed as a percent of control, **p<O.Ol, ***p<O.OOl compared to untreated 
control. 
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3.2.1 Effect of resveratrol on ERK1I2 MAPK phosphorylation. 
Resveratrol has been shown to activate ERK1I2 in different cell lines 
(334;335;368). Insulin has been demonstrated to activate the Ras- signalling pathway 
(96) and induce ERK1I2 activation, promoting cell proliferation, in several studies. In L6 
cells, insulin rapidly activates ERK1I2 (111; 112). Although the insulin- induced ERK1I2 
activation is not required for insulin- stimulated glucose transport, the possibility that 
resveratrol acts via ERK1I2 exists. To examine this possibility we tested whether 
resveratrol, like insulin, would also have an effect on ERK1I2 phosphorylation. Insulin 
treated (5, 15, and 30 minutes at 1O-7M) cells were used as positive controls. Cells were 
exposed to 100~M resveratrol for 5, 15,30,60, or 120 minutes. 
Western blot analysis revealed that insulin rapidly (within 5 min) stimulated 
ERK1I2 phosphorylation to significant levels (4.84 ± 1 arbitrary densitometry units 
relative to untreated control, p<O.OOl) and the increased ERK1I2 phosphorylation was 
sustained after 30 min of exposure to the hormone. Resveratrol, in contrast to insulin, did 
not stimulate ERK1I2 phosphorylation at any time point (120 min = 0.68 ± 0.05 arbitrary 
densitometry units relative to untreated control, p>0.05), as shown in Figure 21A (upper 
blot). The total levels of ERKII2 expression were not significantly changed by any 
treatment (Figure 21A lower blot). These data indicate that the mechanism of action of 
resveratrol on glucose transport is ERK1I2- independent. 
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Figure 21: (A) ERK1I2 phosphorylation by insulin or resveratrol. Total cell lysates 
were prepared from L6 muscle cells that were treated for the indicated time (min) with 
or without 1O-7M insulin or 100j.!M resveratrol. Lysates (12.5j.!g) were resolved by 
10% SDS-PAGE and immunoblotted with anti-phospho-ERK112 or anti-total-ERK112 
antibody. Representative immunoblot of 3 independent experiments. (B, C) 
Immunoblots were scanned to quantitate the density of the bands. Results are the mean 
± SE of 3 independent experiments. All values are arbitrary densitometric units 
expressed relative to untreated control, ***p<O.OOl compared to untreated controL 
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3.2.2 Effect of resveratrol on JNKl/2 MAPK phosphorylation. 
JNK1I2 is another member of the MAPK superfamily that is activated by insulin 
in L6 myotubes (l96). Previously, it was postulated that insulin- induced activation of 
glycogen synthase involved JNK phosphorylation in skeletal muscle (195), however 
further investigation demonstrated that insulin activation of glycogen synthase is JNK-
independent in L6 myotubes (l96). It is not clear whether JNK activation is required for 
. insulin- stimulated glucose transport. Since resveratrol has been previously reported to 
activate JNK1I2 (334;336;365) we tested whether tesveratrol, like insulin, would also 
phosphorylate JNK1I2 in the L6 cell line. 
Figure 22A shows strong JNK1I2 phosphorylation with 5, 15, and 30 min insulin 
(l0-7M) treatment (3.91 ± 0.83; 3.82 ± 0.56; 3.37 ± 0.65 arbitrary densitometry units 
relative to untreated control, p<0.05). Resveratrol (100JlM) did not phosphorylate 
JNK1I2 at any time point (5- 120 min = 0.83 ± 0.32 arbitrary densitometry units relative 
to untreated control, p>0.05). These data suggest that resveratrol- stimulated glucose 
transport does not include JNK1I2 activation. 
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Figure 22: (A) JNKll2 phosphorylation by insulin or resveratrol. Total cell 
lysates were prepared from L6 muscle cells that were treated for the indicated 
time (min) with or without 1O-7M insulin or 100~M resveratrol. Lysates (12.5~g) 
were resolved by 10% SDS-P AGE and immunoblotted with anti-phospho-
JNK1I2 antibody. Representative immunoblot of 3 independent experiments. (B) 
Immunoblots were scanned to quantitate the density of the bands. Results are the 
mean ± SE of 3 independent experiments. All values are arbitrary densitometric 
units expressed relative to untreated control, *p<0.05 compared to untreated 
control. 
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3.2.3 Effect of resveratrol on p38 MAPK phosphorylation. 
p38 MAPK is a member of the MAPK family and is rapidly activated by insulin 
(10) through MKK3 and MKK6 activation in L6 myotubes (157). Inhibition of p38 
MAPK with SB203580, a specific p38 MAPK inhibitor that does not affect other MAPK 
family members, reduced insulin- stimulated glucose transport by approximately 60%, 
suggesting that p38 MAPK phosphorylation is required for activation of the GLUT4 
glucose transporter in order to achieve maximal glucose uptake (153). In addition, 
resveratrol has been reported to activate p38 MAPK in various cell lines (334;365). 
Therefore we tested whether resveratrol, like insulin, would also phosphorylate p38 
MAPK in the L6 cell line. 
Western blot analysis revealed that basal p38 MAPK phosphorylation levels were 
significantly elevated compared to ERK1I2 and JNK1I2 phosphorylation (Figure 21A and 
Figure 22A). Since the cells were serum deprived for 5h before treatment and cell lysis, 
we reasoned that the lack of serum may be acting as a stressor activating p38 MAPK 
phosphorylation. We therefore took a number of approaches to reduce basal p38 MAPK 
phosphorylation such as incubating the cells in media containing. different FBS 
concentrations (0.1 %, 2%) for different periods of time (data not shown). Unfortunately 
despite all efforts and approaches, we were not able to reduce basal p38 MAPK 
phosphorylation (Figure 29A), which is consistent with the data published by others 
(432-434). Insulin (l0-7M) stimulated p38 MAPK phosphorylation to maximum within 5 
minutes (1.97 ± 0.20 arbitrary densitometry units relative to untreated control, p<0.05) 
and began to decline at 15 (1.46 ± 0.08 arbitrary densitometry units relative to untreated 
control) and 30 (l.11 ± 0.05 arbitrary densitometry units relative to untreated control) 
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minutes. These results are in agreement with a previously published study (156) (Figure 
23A). Unlike insulin, 100ilM resveratrol for 5, 15, 30, 60, or 120 min did not increase 
p38 MAPK phosphorylation (120 min = 0.55 ± 0.12 arbitrary densitometry units relative 
to untreated control,p>0.05). Total levels ofp38 MAPK were not significantly altered by 
any treatment (Figure 23A lower blot). These data indicate that the mechanism of action 
ofresveratrol on basal glucose transport is p38 MAPK- independent. 
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Figure 23: (A) p38 MAPK phosphorylation by insulin andlor resveratrol. Total 
cell lysates were prepared from L6 muscle cells that were treated for the 
indicated time (min) with or without 10-7M insulin or 100pM resveratrol. 
Lysates (12.5J!g) were resolved by 10% SDS-PAGE and immunoblotted with 
anti-phospho-p38 MAPK or anti- total- p38 MAPK antibody. Representative 
immunoblot of 3 independent experiments. (B, C) Immunoblots were scanned 
to quantitate the density of the bands. Results are the mean ± SE of 3 
independent experiments. All values are arbitrary densitometric units 
expressed relative to untreated control, *p<0.05 compared to untreated control. 
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3.2.4 Effect of quercetin, rutin, and alpha-tocopherol on glucose transport. 
Resveratrol is a polyphenol that has demonstrated significant antioxidant activity. 
The question arose ifresveratrols' effect is dependent upon its structure or antioxidant 
capability. Since resveratrol stimulates glucose transport independent of insulin, we 
examined whether this is a general effect of antioxidants and/or polyphenols or an effect 
specific to resveratroL Therefore, we incubated L6 myotubes with the polyphenols 
quercetin (IOOJlM, 120 min) and rutin (lOOJlM, 120 min), which possess antioxidant 
activity (435), and the antioxidant a-tocopherol (lOOJlM, 120 min), alone and in 
combination with insulin (10-7M, 30 min), followed by glucose transport measurements 
(Figure 24). 
No significant increases in basal glucose uptake were observed with any of the 
compounds. In addition, quercetin and a-tocopherol did not affect insulin- stimulated 
glucose transport (186%; 215% of control), while rutin did show a considerable decrease 
(130% of control). These data show that antioxidants and polyphenols with structural 
similarity to resveratrol do not increase or potentiate glucose transport and suggest that 
resveratrol- stimulated glucose transport is specific for trans- resveratroL 
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Figure 24: Effect of quercetin, rutin, and a-tocopherol on 2DG uptake in L6 
myotubes. L6 myotubes were}.!lcubated with either quercetin (lOOIlM, 120 min) 
(_), rutin (lOOIlM, 120 min) Cf.~) or a-tocopherol (lOOIlM, 120 min) ( ) in the 
absence or presence of 10-7M insulin (30 min) at 37°C. Cells were washed and 
eH]2DG uptake was measured. The results are the mean ± SE of 2 independent 
experiments, each performed in triplicate and expressed as a percent of control. 
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3.3.1 Effect of resveratrol on amino acid uptake. 
Insulin is a pleiotropic hormone. In skeletal muscle cells, apart from glucose 
transport, insulin also stimulates amino acid transport through the System A amino acid 
transport system. Since resveratrol stimulated glucose transport, we asked the question 
whether it also stimulated amino acid transport. MeAIB, the non- metabolizable amino 
acid analogue, is specifically transported by System A, which makes it ideal for transport 
studies (253). Myotubes were incubated with 10, 25, 50, 100, and 1251lM concentrations 
ofresveratrol as indicated (Figure 25A), followed by amino acid transport measurements. 
In contrast to the stimulatory effect seen with resveratrol for glucose transport, 
amino acid transport was inhibited. Significant reduction of MeAIB uptake was seen only 
with 100uM resveratrol (74.2 ± 6.55% of control, p<0.05), which appeared to be 
maximum. Cell morphology was observed microscopically and was not affected by any 
treatment. In parallel experiments, insulin (10-7M, 30 min) increased MeAIB transport by 
147 ± 5.77% (p<0.001) compared to control, which is in agreement to previously 
published data by other investigators (436). It is important to note that noncarrier-
mediated MeAIB uptake, as determined by 10mM cold MeAIB administration, was 
approximately 5% of the total uptake and was not significantly affected by cell treatment. 
Incubation of L6 myotubes with 100uM resveratrol (Figure 25B) for different 
periods of time resulted in a time- dependent inhibition of amino acid transport. 
Maximum inhibition by resveratrol was observed at 120 min (74 ± 6.55% of control, 
p<0.05). 
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Figure 25: (A) Effects of resveratrol on MeAIB uptake in L6 myotubes: dose 
response. L6 myotubes were incubated with the indicated concentrations of 
resveratrol for 120 min at 37°C. (B) Effects of resveratrol on MeAIB uptake in L6 
myotubes: time course. L6 myotubes were incubated for the indicated time periods 
with resveratrol (lOOIlM) at 37°C. Cells were washed and e4C]MeAIB uptake was 
measured as discussed in the methods. The results are the mean ± SE of 3-5 
independent experiments each performed in triplicate and expressed as a percent of 
control, *p<0.05 compared to untreated control. 
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3.3.2 Effect of resveratrol on insulin- stimulated amino acid uptake. 
To investigate whether, apart from inhibiting basal amino acid uptake, resveratrol 
affects the acute insulin- induced increase in amino acid transport, we examined the 
interaction between acute insulin exposure and resveratrol treatment (Figure 26). Insulin 
was added to the cells for 30 min before the measurement of MeAIB uptake in control-
untreated and resveratrol- pretreated cells. Resveratrol treatment was continued in 
parallel with insulin treatment. Insulin alone at 10-7 M for 30 min resulted in a significant 
increase in MeAIB uptake (147 ± 5.77% of control,p<O.OOl). Treatment ofmyotubes for 
120 min with resveratrol (100uM) alone resulted in a significant inhibition of basal amino 
acid uptake (74 ± 6.55% of control, p<0.05), which is in agreement with the previous 
dose- response and time- course experiments (Figure 25). Importantly, resveratrol 
completely abolished the insulin- stimulated amino acid transport (103 ± 7.35% of 
control, p>0.05). 
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Figure 26: Effect of resveratrol on basal- and insulin- stimulated MeAIB uptake in 
L6 myotubes. L6 myotubes were incubated with resveratrol (lOOJlM, 120 min), 
insulin (l0-7M, 30 min), or a combination ofresveratrol and insulin at 37°C. Cells 
were washed and [14C]MeAIB uptake was measured as indicated in the methods. 
The results are the mean ± SE of 3-5 independent experiments performed in 
triplicate and expressed as a percent of control, *p<0.05, ***p<O.OOI compared to 
untreated control. 
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3.4.1 Effect of resveratrol on thymidine incorporation in L6 myoblasts. 
Insulin has a mitogenic effect and stimulates thymidine incorporation in L6 
myoblasts (112;437). On the other hand, resveratrol has been shown to inhibit cell 
proliferation and thymidine incorporation in numerous cell lines (317;438;439). We 
wanted to determine whether resveratrol mimicked insulin's mitogenic effect. 
Subconfluent myoblasts (40- 55% confluent) were growth arrested by incubating them in 
medium without any serum for 24 h. The cells were then treated with 0.1, 1, 10, 50, or 
IOOIlM resveratrol and after 24h, thymidine incorporation was measured as indicated in 
the methods section (Figure 27 A). 
Resveratrol at 0.1 and 111M did not have a significant effect on thymidine 
incorporation (97 ± 4.89% and 100 ± 2.72% of control, p>0.05 respectively). However, 
resveratrol at IOIlM significantly inhibited thymidine incorporation (36 ± 8.04% of 
control, p<0.05). Maximum inhibition was observed at 50llM (8 ± 1.59% of control, 
p<O.OOI). The same resveratrol concentration (50IlM) effectively inhibits thymidine 
incorporation in vascular smooth muscle cells and several cancer cell lines as reported by 
others (317;438;439). Visual microscopic inspection of all experimental groups revealed 
that resveratrol- treated cells were less confluent than control, indicating an inhibition of 
cell proliferation. Cell morphology, which was also observed microscopically, was not 
affected by any treatment. 
We also examined the effect of resveratrol on the insulin- and FBS- stimulated 
mitogenic response (Figure 27B). Insulin (10-7M, 24 h) significantly increased thymidine 
incorporation (280 ± 9.92% of control,p<O.OOl). Media containing 10% FBS resulted in 
stimulation of thymidine incorporation to 691 ± 36.92% of control, p<O.OOl. Resveratrol 
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(50/lM) completely abolished both insulin- (11 ± 1.26% of control, p<O.001) and FBS-
stimulated (36 ± 5.16% of control, p<O.05) cell proliferation. 
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Figure 27 A: Effects of resveratrol on thymidine incorporation in L6 myotubes: dose 
response. L6 myotubes were incubated with the indicated concentrations of 
resveratrol for 24 hours at 37°C. Cells were washed and eH]thymidine 
incorporation was measured as discussed in the methods. The results are the mean ± 
SE of 4 independent experiments performed in triplicate and expressed as a percent 
of control, *p<0.05, ***p<O.OOl, NS = not significant compared to untreated 
control. 
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Figure 27B: Effects of resveratrol on insulin- and fetal bovine serum (FBS)-
stimulated thymidine incorporation. L6 cells were incubated without (.) or with 
50!lM resveratrol (0), immediately followed by the addition of insulin (10-7M) or 
10% FBS for 24 h at 37°C. Cells were washed and eH]thymidine incorporation 
was measured as indicated in the methods. Results are the mean ± SE of 4 
independent experiments performed in triplicate and expressed· as a percent of 
control, *p<0.05, ***p<O.OOl compared to untreated control. 
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3.4.2 Effect of chronic resveratrol treatment on ERKl12 phosphorylation. 
ERK1I2 activation leads to cell proliferation (114). Several studies have shown 
that resveratrol inhibits ERKII2 activation and cell proliferation (319;321;356;440). 
However, resveratrol has also been shown to activate ERK1I2 in many different cell lines 
while maintaining its inhibition of mitogenesis (334;335;368). Insulin also stimulates 
mitogenesis through the activation of the Ras- Raf- ERK1I2 pathway (96), to promote 
cell proliferation and differentiation. For example, L6 myoblasts exhibit a proliferative 
response when stimulated with either insulin or insulin- like growth factor- 1 (IGF-l) 
(111;112). We hypothesized that ERKII2 activation may be involved in resveratrol 
inhibited thymidine incorporation. To examine this possibility we measured total and 
phosphorylated ERK1I2. 
Acute treatment with insulin (10-7M, 30 min) increased ERK1I2 phosphorylation 
as shown previously (Figure 21 and Figure 28A) (4.84 ± 1.00 arbitrary densitometry units 
relative to untreated control,p>O.OOI). Resveratrol (1 00 11M, 120 min) had no effect (0.68 
± 0.05 arbitrary densitometry units relative to untreated control, p>0.05) but did 
completely abolish the insulin response (0.51 ± 0.09 arbitrary densitometry units relative 
to untreated control, p>0.05). This data shows that resveratrol very effectively blocks 
phosphorylation of ERK1I2 by insulin and suggests that the inhibitory effect of 
resveratrol on insulin- stimulated thymidine incorporation may be due to inhibition of 
ERK1I2 phosphorylation. All of the data presented up to now involve acute treatment and 
we also examined whether the same applies for chronic stimulation. 
As shown in Figure 28D (upper blot), chronic (24 h) insulin (lO-7M) and lO% 
FBS treatment resulted in a significant phosphorylation of ERK1I2 (1.96 and 1.91 
arbitrary densitometry units relative to untreated control). The chronic. effect of insulin is 
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similar to that observed with acute (5- 30 min) treatment (Figure 21). In addition, chronic 
resveratrol treatment (50JlM), which was maximum inhibition of thymidine incorporation 
(Figure 27 A), did not affect ERK1I2 phosphorylation, which is also similar to the result 
seen with acute (5- 120 min) resveratrol treatment (0.85 arbitrary densitometry units 
relative to untreated control). Furthermore, resveratrol did not inhibit the insulin- or FBS-
stimulated ERK1I2 phosphorylation (2.03 and 2.24 arbitrary densitometry units relative 
to untreated control). This effect with resveratrol is in opposition to that observed with 
acute treatment where preincubation with resveratrol completely abolished insulin-
stimulated ERK1I2 phosphorylation (Figure 28). 
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Figure 28: ERKII2 phosphorylation by insulin, FBS or resveratrol. Total celllysates 
(12.5~g) were prepared from treated L6 muscle cells, resolved by 10% SDS-PAGE, 
and immunoblotted with anti-phospho-ERK1I2 or anti-total-ERK1I2 antibody. (A) 
Cells were treated for the indicated time (min) with or without 1O-7M insulin or 
1 OO~M resveratrol or resveratrol + insulin. Representative immunoblot of 3 
independent experiments. (D) Cells were treated for 24 h without or with either 10-7M 
insulin, 10% FBS, or 50~M resveratrol or in combination with resveratrol. 
Representative immunoblot of 1 independent experiment. (B, C, E, F) Immunoblots 
were scanned to quantitate the density of the bands. Results are the mean ± SE of 3 (B, 
C) and 1 (E, F) independent experiment. All values are arbitrary densitometric units 
expressed relative to untreated control cells, ***p<O.OOl compared to untreated 
control. 
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3.4.3 Effect of chronic resveratrol treatment on p38 MAPK phosphorylation. 
p38 MAPK activation has been shown to have biological importance in regulating 
cellular processes such as cell proliferation and differentiation (151). Resveratrol has 
been reported to activate p38 MAPK in various cell lines affecting mitogenesis 
(334;365). p38 MAPK can also be activated by acute insulin (30 min) stimulation in L6 
myotubes (441), a process that involves MKK3 and MKK6 activation (157). 
Furthermore, chronic insulin treatment has been demonstrated to increase mitogenesis 
involving p38 MAPK activation in C2C12 cells (442). Therefore we hypothesized that p38 
MAPK phosphorylation may be involved in FBS- and insulin- stimulated cell 
proliferation and that the inhibitory effect observed with resveratrol· (Figure 27) could be 
due to inhibition of p3 8 MAPK. 
Acute treatment with insulin (10-7M, 5 min) rapidly increased p38 MAPK 
phosphorylation as previously shown (Figure 23A) (1.97 ± 0.20 arbitrary densitometry 
units relative to untreated control, p<0.05). In contrast to insulin, resveratrol (lOOIlM, 5-
120 min) did not have any significant effect alone (120 min = 0.55 ± 0.12 arbitrary 
densitometry units relative to untreated control, p>0.05) but did inhibit the insulin 
response (0.61 ± 0.10 arbitrary densitometry units relative to untreated control, p>0.05) at 
100llM (120 min) (Figure 29A). This data indicates that resveratrol is an effective 
inhibitor of insulin- stimulated p38 MAPK phosphorylation and suggests that perhaps the 
inhibitory effect of resveratrol on insulin- stimulated thymidine incorporation may be 
attributed to the acute inhibition of p38 MAPK phosphorylation. These data involve acute 
treatment only, so we also examined the chronic effect of resveratrol. 
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To address this question we treated L6 myoblasts in the exact same conditions as 
for thymidine incorporation experiments and after preparing a cell lysate we examined 
phosphorylated p38 MAPK. As shown in Figure 29C, chronic (24 h) insulin (10-7M) and 
10% FBS treatment resulted in increased phosphorylation of p38 MAPK (1.74 arbitrary 
densitometry units relative to untreated control). The chronic effect of insulin is similar to 
that seen with acute (5- 30 min) insulin treatment of the cells (Figure 23). Chronic 
resveratrol treatment (50/lM) did not affect p38 MAPK phosphorylation (0.91 arbitrary 
densitometry units relative to untreated control). This result is similar to the effect 
observed with acute (5- 120 min) resveratrol treatment. Furthermore, resveratrol did not 
abolish the insulin or FBS stimulation of p38 MAPK phosphorylation (1.42 and 2.09 
arbitrary densitometry units relative to untreated control). This effect of resveratrol is 
opposite to that seen with acute treatment where preincubation with resveratrol abolished 
insulin- stimulated p38 MAPK phosphorylation (Figure 29A). 
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Figure 29: (A) p38 MAPK phosphorylation by insulin, FBS or resveratrol. Total cell 
lysates (12.S)!g) were prepared from treated L6 muscle cells, resolved by 10% SDS-
PAGE, and immunoblotted with anti-phospho-p38 MAPK. (A) Cells were treated for the 
indicated time (min) with or without 1O-7M insulin or 100)!M resveratrol or resveratrol + 
insulin. Representative immunoblot of 3 independent experiments. (C) Cells were treated 
for 24 h without or with either 1O-7M insulin, 10% FBS, or 50)!M resveratrol or in 
combination with resveratrol. Representative immunoblot of 1 independent experiment. 
(B, D) Immunoblots were scanned to quantitate the density of the bands. Results are the 
mean ± SE of 3 (B) and 1 (D) independent experiment. All values are arbitrary 
densitometric units expressed relative to untreated control cells, *p<O.OS compared to 
untreated control. 
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3.4.4 Effect of chronic resveratrol treatment on JNK1I2 phosphorylation. 
JNK1I2 activation is involved in the regulation of cell growth and mitogenesis 
(443) and is phosphorylated by acute insulin stimulation in L6 myotubes (196). 
Resveratrol also activates JNKll2 in different cell lines leading to apoptosis (334;336), 
however resveratrol also inhibits JNKll2 phosphorylation to decrease cell proliferation 
(319;444). We reasoned that JNK1I2 may be involved in resveratrol's inhibition of 
mitogenesis. To examine this possibility we used Western blot analysis to measure total 
and phosphorylated JNK1I2. 
Acute treatment with insulin (l0-7M, 30 min) increased JNKll2 phosphorylation 
as shown previously (Figure 22 and Figure 30A) (3.37 ± 0.65 arbitrary densitometry units 
relative to untreated control, p<0.05). In contrast to insulin, resveratrol (lOOf.lM, 5- 120 
min) did not have any effect alone (0.83 ± 0.32 arbitrary densitometry units relative to 
untreated control, p>0.05) but did completely abolish the insulin response (1.12 ± 0.21 
arbitrary densitometry units relative to untreated control, p>0.05) at lOOf.lM (120 min). 
This data demonstrates that resveratrol is an effective inhibitor of insulin- stimulated 
JNK1I2 phosphorylation and suggests that the inhibitory effect of resveratrol on insulin-
stimulated thymidine incorporation may be attributed to the inhibition of JNK1I2 
phosphorylation. These data involve acute treatment and whether the same effect is 
observed with chronic treatment was also examined. 
As shown in Figure 30e, chronic (24 h) insulin (l0-7M) and 10% FBS treatment 
resulted in a significant phosphorylation of JNK1I2 (2.96 and 2.76 arbitrary densitometry 
units relative to untreated control). The chronic effect of insulin is similar to that 
observed with acute (5- 30 min) treatment (Figure 22). In addition, chronic resveratrol 
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treatment (50,...,M) did not affect JNKl/2 phosphorylation, which is also similar to acute 
(5- 120 min) resveratrol treatment (0.98 arbitrary densitometry units relative to untreated 
control). Furthermore, resveratrol did not inhibit the insulin- or FBS- stimulated JNK1I2 
phosphorylation (2.33 and 2.75 arbitrary densitometry units relative to untreated control). 
This effect observed with resveratrol is opposite to that observed with acute treatment 
where preincubation with resveratrol completely abolished insulin- stimulated JNK1I2 
phosphorylation (Figure 30). 
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Figure 30: JNK1I2 phosphorylation by insulin, FBS or resveratrol. Total cell lysates 
(12.5flg) were prepared from treated L6 muscle cells, resolved by 10% SDS-P AGE, and 
immunoblotted with anti-phospho-JNK1I2. (A) Cells were treated for the indicated time 
(min) with or without 1O-7M insulin or 100flM resveratrol or resveratrol + insulin. 
Representative immunoblot of 3 independent experiments. (C) Cells were treated for 24 
h without or with either 10-7M insulin, 10% FBS, or 50flM resveratrol or in combination 
with resveratrol. Representative immunoblot of 1 independent experiment. (B, D) 
Immunoblots were scanned to quantitate the density of the bands. Results are the mean 
± SE of 3 (B) and 1 (D) independent experiment. All values are arbitrary densitometric 
units expressed relative to untreated control cells, *p<0.05 compared to untreated 
control. 
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CHAPTER 4: Section 1: DISCUSSION 
4.1 Resveratrol and glucose transport. 
4.1.1 Resveratrol significantly increases glucose uptake. 
The incidence of type 2 diabetes is rapidly increasing on a global scale and has a 
significant impact on the Canadian health care system as a major cause of death in North 
America. A reduction in peripheral glucose uptake is observed in type 2 diabetic 
individuals (237). Although a number of different pharmacological agents are available 
and are clinically used to improve glycemic control in type 2 diabetes, a better 
understanding of glucose transport regulation is needed in order to develop new and more 
effective interventions. 
Since skeletal muscle is the primary site for glucose disposal in the post- prandial 
state and is the major target of insulin action controlling glycaemia, it is expected that 
new interventions improving glucose transport in this tissue specifically would be 
beneficial. Resveratrol has beneficial effects as an anti-oxidant, anti-cardiovascular 
disease, and anti-cancer agent. Here we examined the effects of resveratrol on basal- and 
insulin- stimulated glucose transport. 
The L6 skeletal muscle cell line is the most widely used and well- established 
model of skeletal muscle and is most suitable for studying glucose transport in vitro. In 
these cells, insulin causes a two- fold increase in glucose transport within 15 minutes of 
exposure, which is protein synthesis independent (394). L6 cells are currently the only 
cell line that expresses both the GLUT 1 and GLUT4 glucose transporters (391). 
Therefore, we chose L6 muscle cells to examine the effects of resveratrol on glucose 
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transport. Currently, there are no previous studies examining the effects of resveratrol on 
glucose uptake in skeletal muscle cell lines, skeletal muscle in vitro or in vivo. 
The results of the present study demonstrate for the first time that resveratrol 
stimulates glucose uptake in cultured L6 skeletal muscle cells, which confirms our initial 
hypothesis that resveratrol has insulin- like effects on skeletal muscle cells. This appears 
to be a specific property of resveratrol that is not shared by all antioxidants and 
structurally similar compounds since quercetin, rutin, and alpha- tocopherol did not have 
any effect. It is important to note that resveratrol- stimulated glucose transport is entirely 
independent of insulin since insulin was not present in the medium and the cells were 
serum deprived for 5 hours before treatment. This effect is time- dependent, requiring a 
relatively long time of exposure compared to insulin, for the development of the full 
response. Insulin (100nM) rapidly stimulates glucose transport activity to maximum 
within 15 minutes in L6 skeletal muscle cells (394). 
In addition to the insulin receptor, L6 rat skeletal muscle cells also express 
functional estrogen receptors (a and ~), which was demonstrated by increased myoblast 
proliferation and strong c-fos and egr gene induction after estrone or 17~- estradiol 
treatment (445). In addition, estrogens such as 17~- estradiol have been shown to 
promote insulin- mediated glucose uptake in mouse soleus skeletal muscle (446). 
Resveratrol has been shown in numerous studies to behave as both an estrogen receptor 
agonist and antagonist (292;340-343). Therefore we acknowledge the possibility that 
resveratrol- stimulated glucose uptake may be mediated by the estrogen receptors present 
in L6 cells. In the future this theory could be examined with specific estrogen receptor 
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inhibitors such as ICI- 182780 and tamoxifen or estrogen receptor knockouts, followed 
by glucose transport measurements after resveratrol treatment. 
The delay in resveratrol action may be due to its permeation to an intracellular site 
and/or subsequent generation of a specific intracellular signal. Studies in both 
hepatocytes (281) and intestinal cells (282) have shown that resveratrol (30- 150JlM) 
enters the cell by simple diffusion to significant levels within 5 minutes, suggesting that 
the delayed response observed in our study may be due to specific signalling events. 
Currently, resveratrol transport into· skeletal muscle has not been examined, however 
future studies could use radioactive e4qresveratrol to study this mechanism. This study 
focused on the acute effects of resveratrol and insulin on glucose transport, however it is 
well known that chronic insulin treatment (24 h) also enhances glucose transport through 
a modification of protein synthesis. Therefore, future studies could focus on the chronic 
effects of resveratrol on glucose transport and glucose transporter expression. 
The relatively long incubation period required to observe an effect with 
resveratrol suggested that there may be a need for synthesis of specific proteins, however 
experiments with cycloheximide showed that protein synthesis was not required for 
resveratrol- stimulated glucose uptake. It is well established by others that CHX at 
1 Jlglml, which is the concentration used in the present study, blocks protein synthesis. 
Although protein synthesis was not directly measured, to assess the effectiveness of 
CHX, eH]leucine incorporation into protein could be measured (447). 
The dose of resveratrol required to achieve maximum stimulation is 100J.LM. This 
concentration of resveratrol is in accordance with previous studies where concentrations 
of less than 10JlM generally do not result in any significant biological effect in various in 
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vitro systems (276;319;328;331;448). In addition, concentrations ofresveratrol used in in 
vitro studies are usually 10- 1000 times greater than peak plasma concentrations found in 
humans after oral administration. For example, plasma resveratrol concentrations in 
humans after oral administration of resveratrol dissolved in either grape juice, vegetable 
juice or white wine, are approximately 2/!M and may be as low as 20nM depending on 
the rate of metabolism, which is approximately 1000 times less than the concentrations 
used in our in vitro study (449). Lower plasma concentrations of a compound compared 
to in vitro studies does not indicate that the in vitro studies are irrelevant. Similar 
discrepancies between in vivo and in vitro concentrations have been observed for 
different agents used in the treatment of diabetes such as metformin, glyburide, and even 
insulin. Metformin is not metabolized in humans or rats (450) and its plasma 
concentration is approximately 537nM (451), which is 1000 times less than the 
commonly used 400/!M concentration in in vitro studies (393). In addition, glyburide is 
frequently used in vitro at approximately 100/!M (417) while the concentration found in 
human plasma is in the nanomolar range (105nM) (452). Similarly, the circulating human 
plasma insulin levels are lOpM (453) while the insulin concentration used in in vitro 
studies in cell cultures are 100nM. Therefore, the relatively high concentration of 
resveratrol required to see a biological effect in our in vitro system does not exclude in 
vivo relevance. 
As a polyphenolic compound, resveratrol is structurally similar to several other 
compounds also found in red wine, including quercetin and rutin (454). Currently there 
are no studies concerning the effects of quercetin or rutin on glucose transport in skeletal 
muscle. However, quercetin (100/!M) does inhibit insulin- stimulated glucose transport in 
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a dose- dependent manner in rat adipocytes (455).· We found that at similar 
concentrations (100IlM), quercetin did not affect basal or insulin- stimulated glucose 
transport in L6 myotubes whereas rutin showed a decrease. These data suggest that 
resveratrol- stimulated glucose uptake is specific to this compound. There are numerous 
other polyphenols present in red wine and future studies could examine their effects on 
glucose transport separately or in combination. 
Alpha- tocopherol, which is a compound found in Vitamin E, contains only a 
single phenolic group and is an established antioxidant (456). Its antioxidant activity is 
similar to that of resveratrol, depending on the free radical stressor (457). Alpha-
tocopherol has been shown to stimulate glucose transport in rat- hemidiaphragrn in vivo 
(458) but did not increase glucose uptake in L6 myotubes in the present study (100IlM, 
120 min) or after 24 h (lOIlM) incubation (459). In our study, alpha- tocopherol did not 
alter basal or insulin- stimulated glucose transport, suggesting that only particular 
antioxidants are capable of stimulating glucose transport and that resveratrol- stimulated 
glucose uptake is specific. 
It is not clear whether the effects of resveratrol are due to its antioxidant activity 
as ROS levels have not been measured. Generally ROS production is thought to decrease 
insulin sensitivity and inhibit glucose transport. However ROS, although diverse, also 
stimulate glucose transport in L6 cells and 3T3-Ll adipocytes through increased GLUTl 
mRNA and protein expression (460). Antioxidants have also been shown to generate free 
radicals, for example the pro- oxidant role of antioxidants is supported by 4- hydroxyl 
tempol (375). Tempol (5mM, 12 h) increased the rate of glucose transport in both 
vascular endothelial and smooth muscle cells through an increase in GLUTI mRNA and 
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protein content and plasma membrane abundance. These effects were related to ROS 
generation. Other antioxidants, such as alpha- lipoic acid (376), also stimulated glucose 
transport in L6 myotubes and 3T3-L1 adipocytes. Therefore, it is possible that resveratrol 
may stimulate glucose transport through modification ofROS levels. Future studies could 
focus on measuring the levels of ROS and the free radical scavenging activity of 
resveratrol in L6 myotubes. 
Significant conjugation of trans- resveratrol has been demonstrated in vivo, which 
raises a question concerning the physiological relevance of unconjugated trans-
resveratrol. The vast majority of in vitro studies pertaining to resveratrol also employ 
trans- resveratrol and despite substantial conjugation of resveratrol, studies on the 
bioavailability of orally ingested resveratrol demonstrate that a measurable portion of 
trans- resveratrol remains intact. This indicates that the present in vivo studies may have 
a significant in vivo relevance. 
Several hypoglycaemic agents, including gliclazide, glyburide (417), troglitazone 
(459), vanadate, and pervanadate (436), enhance basal glucose transport but do not 
enhance the maximum insulin response. In our study, resveratrol did not potentiate 
maximal insulin but had a significant effect on the cell response to submaximal insulin 
levels, which is similar to the above-mentioned compounds. This finding indicates that 
resveratrol and submaximal insulin concentrations are additive. Our data suggest that 
resveratrol may be useful in states of insulin resistance and could enhance insulin action. 
Currently, several anti- diabetic agents used clinically, such as the thiazolidinediones 
rosiglitazone (461), and pioglitazone, and metformin (462), have been shown to playa 
role in reducing insulin resistance. 
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The lack of a significant change in maximal insulin responSIveness III the 
presence of resveratrol may be because resveratrol alone may nearly reach maximum 
before insulin is added, thereby reducing the requirement for insulin- stimulated glucose 
transport. A shorter incubation period (10- 15 min) with resveratrol combined with 
insulin may be sufficient to potentiate the submaximal insulin response and should be 
examined in the future. 
4.1.2 Elucidating the mechanism of action of resveratrol. 
Furthennore, the present study suggests that the signalling molecules involved in 
resveratrol action may be different than that of insulin. These findings are very important 
because certain signalling events or molecules involved in insulin action may be 
defective, leading to insulin resistance, and resveratrol may provide a tool of bypassing 
these defective-signalling events. PI3K is a downstream effector protein in the insulin-
signalling cascade (23) that is composed of a 1l0kDa catalytic subunit and an 85kDa 
regulatory subunit. PI3K activation is necessary but not sufficient for insulin- stimulated 
glucose transport since mutant Llp85, which lacks a binding site for the p 110 catalytic 
subunit, greatly inhibited insulin- stimulated glucose uptake in eRO cells (42) but 
active- PI3K overexpression required insulin to achieve maximal glucose uptake (44;45). 
In this study PI3K involvement was examined with the phannacological 
inhibitors, L Y294002 and wortmannin. Wortmannin is a fungal metabolite that binds to 
the pllO catalytic subunit of type 1 PI3K to exert potent inhibition (38;39;463). 
Alternatively, L Y294002, a quercetin derivative, acts as a competitive inhibitor of the 
ATP binding site of PI3K (41). Both of these inhibitors are widely used and shown to 
effectively inhibit PI3K in several different cell lines (37;268;423;432;464-467). 
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Specifically the insulin- induced PI3K activation is abolished by both L Y294002 and 
wortmannin (468;469). In the present study, resveratrol- stimulated glucose transport was 
inhibited by both L Y294002 and wortmannin as was the insulin- stimulated response. 
These data suggest that like insulin, the resveratrol response is PI3K- dependent. 
Although in the present study the activity of PI3K was not directly measured, insulin-
dependent Akt/PKB phosphorylation in the presence of wortmannin was strongly 
inhibited, indicating that under our experimental design PI3K activity was effectively 
blocked by L Y294002 and wortmannin. In the future, a direct approach to measure PI3K 
activation could be taken which is the measurement of the lipid products synthesized by 
PI3K, PIP2 and PIP3-
AktlPKB exists as three different isoforms; PKBa, PKB~, and PKBy, all of which 
are expressed in L6 skeletal muscle cells (470). Akt/PKB is located downstream ofPI3K 
and is one of its major targets contributing to insulin- stimulated glucose transport (471). 
All three Akt/PKB isoforms are activated by insulin stimulation, however in L6 
myotubes PKBa is the dominant isoform involved in insulin- stimulated glucose transport 
(269;470). Resveratrol has been reported previously to Increase AktIPKB 
phosphorylation in MCF-7 human breast epithelial cells (354). Activation of AktlPKBa 
involves phosphorylation of two residues, Thr308 and Ser473. In order for full activation 
to occur the Ser473 residue must be phosphorylated. Akt/PKB may also be 
phosphorylated on Serl24 and Thr450 residues but these sites do not regulate AktlPKB 
activity and their phosphorylation is unchanged after stimulation with insulin (71). 
To determine the role of Akt/PKB activation in resveratrol- stimulated glucose 
transport, we examined AktIPKB phosphorylation at Ser473 through Western blot 
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. analysis (472-474). The antibody that recognizes Ser473 is the most widely used. It is 
generally accepted that phosphorylation of AktlPKB represents activation and this 
technique has been employed in numerous studies. Although each Akt/PKB isoform was 
not examined separately in the present study, the antibody used recognizes all three 
isoforms when they are phosphorylated on their corresponding serine residues. This 
antibody does not recognize the Thr308 phosphorylation site. 
The present results showing an increase in glucose transport by resveratrol 
without an effect on Akt/PKB phosphorylation! activation, suggest a mechanism that is 
independent of AktIPKB. Nitric oxide- stimulated glucose transport in 3T3- Ll 
adipocytes is also Akt/PKB independent (475). Similarly to our resveratrol data, 
neureglilin- stimulated glucose transport in L6E9 myotubes is PI3K- dependent but 
Akt/PKB- independent (476). The use of small interference RNA (siRNA) to silence 
proteins has been widely used in recent years. In siRNA knockouts, protein expression is 
inhibited via RNA interference where gene expression is selectively silenced through the 
transfection of double-stranded RNA molecules. Akt/PKB siRNA technology could be 
employed to further examine the involvement of AktlPKB in resveratrol- stimulated 
transport. Additionally, an AktlPKB activity assay could provide more information. 
Insulin- stimulated GLUT4 glucose transporter translocation has been 
documented in several fat and muscle cell lines (9-11) and is well- established. Since 
resveratrol stimulated glucose transport to significant levels similar to insulin we 
reasoned that GLUT4 translocation may be involved. We measured surface GLUT4 
levels with L6 GLUTmyc cells that stably express GLUT4 tagged with an exofacial myc 
epitope (GLUTmyc) (409). The amount of GLUTmyc incorporated into the plasma 
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membrane was quantitated by immunologically labelling the myc epitope at the surface 
of intact cells. Resveratrol- mediated glucose transport appears to be independent of 
GLUT4 translocation, despite a significant increase in glucose transport by resveratrol in 
the GLUT4 overexpressing cells. The non- involvement of GLUT4 translocation could 
suggest that resveratrol may have an effect or combined effect on 1) the intrinsic activity 
of the GLUT4 transporters, 2) the intrinsic activity of other glucose transporters 
expressed in the L6 cell line (GLUT1 or GLUT3), or 3) the translocation of GLUTl 
and/or GLUT3. Interestingly, metformin action in L6 muscle cells had no effect on 
GLUT4 translocation but did significantly increase GLUT 1 glucose transporter 
redistribution to the plasma membrane (420). 
GLUTl and GLUT3 glucose transporters are in low abundance compared to 
GLUT4 in L6- GLUTmyc cells, where the ratio of GLUT4myc to GLUT4 and GLUTl is 
124:1:1.2 (392;412;413). GLUTI expression is the same in GLUT4myc cells as in 
. parental L6 cells (392). GLUT 1 expression is the same in the parental and L6-
GLUT4myc cells but the ratio of GLUTl to GLUT4myc is significantly altered. 
Therefore, the overabundance of GLUT4myc may interfere with the GLUTI transporter 
translocation. It is possible that resveratrol- stimulated glucose uptake involves the 
GLUTl transporter, which could explain why we observed slightly decreased glucose 
uptake with resveratrol in the L6- GLUT4myc cells. Alternatively, resveratrol may 
prolong the half- life of glucose transporters by reducing degradation and stabilizing 
GLUTs at the plasma membrane. 
Subcellular fractionation studies to examine the effect of resveratrol on GLUT1, 
3, and 4 in both the intracellular and plasma membranes could be employed in the future 
Resveratrol 159 
to gain a better understanding of the action of resveratrol on the -different L6 glucose 
transporters. Translocation would be indicated if an increase in plasma membrane 
glucose transporters corresponded with a decrease in the intracellular membrane content 
of the transporters. Alternative methods of examining translocation include 
photo labelling and immunofluorescence but they are not as widely used. 
p38 MAPK is rapidly activated by insulin (10) through MKK3 and MKK6 
activation in L6 myotubes (157). Changes in the intrinsic activity of glucose transporters 
by insulin have been previously suggested through activation of p38 MAPK in both L6 
myotubes (153) and 3T3-Ll adipocytes (153;155). Resveratrol has been reported to 
activate p38 MAPK in various cell lines as well (334;365). We tested whether 
resveratrol, like insulin, would also phosphorylate p38 MAPK in L6 myotubes through 
Western blot analysis. 
We found that resveratrol did not phosphorylate p38 MAPK and even reduced 
acute insulin- stimulated p38 MAPK phosphorylation. These data suggest that 
resveratrol- stimulated glucose transport does not require p38 MAPK phosphorylation. 
Assuming that p38 MAPK is a major regulator of GLUT4 activity, since resveratrol did 
not phosphorylate p38 MAPK (Figure 23) it is likely that resveratrol- stimulated glucose 
transport does not involve an increase in p38 MAPK- mediated GLUT4 activity but could 
possibly stimulate an alternative regulator to increase GLUT4 activity. 
Maximum insulin- stimulated glucose transport requires an increase in GLUT4 
activity through p38 MAPK activation (153;155). The inhibition of insulin- stimulated 
p38 MAPK phosphorylation seen in our studies might explain the lack of additivity in 
glucose transport when maximum concentrations of resveratrol and insulin were 
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combined (Figure 13). Although in our studies p38 MAPK activity was not directly 
measured, p38 MAPK phosphorylation (Thr180 and Tyr182) correlates very highly with 
activation and is widely accepted as an indicator of activation (153;155;157). Basal p38 
MAPK activity, as mentioned before (Section 3.2.3), was somehow elevated in our 
experiments. Although p38 MAPK is not phosphorylated! activated by resveratrol, one 
may argue that the existing activated p38 MAPK may be sufficient for resveratrol 
signalling. The p38 MAPK inhibitor SB203580 or p38 MAPK siRNA approach could be 
employed to further examine the role of p38 MAPK in resveratrol- stimulated glucose 
transport. These approaches are widely used and accepted to effectively inhibit p38 
MAPK activation (156;432;477). 
Insulin activates ERK1I2, which is another member of the MAPK family, through 
the RaslRaflMEK pathway in L6 cells to stimulate mitogenesis, however this activation 
is not required for insulin- stimulated glucose transport (478). Still ERKl!2 activation 
may be involved in resveratrol- induced glucose uptake. Resveratrol has been shown to 
activate ERK1!2 in several cancer celllines (334;335) and we used Western blot analysis 
to examine if resveratrol would also phosphorylate ERK1I2 in L6 myotubes. We 
discovered that, unlike insulin, resveratrol did not phosphorylate ERK1!2. These data 
indicate that resveratrol- induced glucose uptake does not involve ERK1I2 
phosphorylation. 
Insulin has been found to activate the MAPK JNK1I2 in L6 myotubes (196), 
however its' function is undefined and it is unclear whether it is required for insulin-
stimulated glucose transport. Similar to the findings reported for the other MAPK family 
members, ERKII2 and p38 MAPK, resveratrol has been reported to activate JNK1!2 in 
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various cell lines (334;336). We took the same approach as for p38 MAPK and ERKll2 
and examined if resveratrol induced JNK1I2 phosphorylation in L6 myotubes. Our results 
showed that insulin stimulated JNK1I2 phosphorylation as reported previously, however 
resveratrol did not have any effect. These results suggest that since resveratrol does not 
phosphorylate JNK1I2, it is unlikely that this kinase is required for resveratrol- stimulated 
glucose uptake. 
An ERKll2 and JNKll2 activity assay was not used since phosphorylation is 
generally accepted as an indicator of activation of these kinases. Pharmacologic 
inhibition of MEKll2, an upstream regulator of ERK1I2, with PD98059, a specific 
inhibitor ofMEK1I2, and SP600125, a competitive inhibitor for the ATP- binding site of 
JNK1I2, would have provided additional information. However since we have no 
indication that resveratrol phosphorylates either ERK1I2 or JNK1I2, it is unlikely that the 
inhibitors would have any significant effect on resveratrol- stimulated glucose transport. 
As with AktlPKB and p38 MAPK, ERK1I2 and JNK1I2 siRNAs could be employed to 
further examine their role in resveratrol- stimulated glucose uptake. 
The role of PKC in insulin- stimulated glucose uptake is highly debated. Insulin 
increased the activity of PKCs, which was blocked by both wortmannin and L Y294002. 
In addition, expression of inactive PKCS inhibited both basal and insulin- stimulated 
glucose transport in L6 myotubes (223), suggesting that PKC (A, s) activation is required 
for insulin- stimulated glucose transport and is independent of AktlPKB but requires 
PI3K (221-224). It has also been documented that acute activation of PKC by PMA, a 
DAG analogue, leads to increased glucose uptake (422). Since resveratrol employs PI3K 
but does not involve AktlPKB activation, it was important to examine a possible 
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alternative pathway that involves PI3K and affects glucose transport. One of the 
difficulties in studying PKC is the large number of isoforms, which are divided into the 
conventional, novel, and atypical isoforms. Therefore, in our study we applied two 
inhibitors that are widely used in order to inhibit all isoforms ofPKC, BIMI and G06983 
and measured glucose transport after PMA or resveratrol treatment. BIMI and G06983 
are selective inhibitors of all PKC isoforms that act as competitive inhibitors for the ATP-
binding site ofPKC. 
Resveratrol- stimulated glucose uptake was not affected by either inhibitor, 
suggesting that resveratrol action is PKC- independent. If we had an indication of PKC 
involvement in resveratrol action, we could have taken a multiple approach to elucidate 
the isoforms employed and their roles. For example, additional inhibitors could have been 
used, siRNA knockouts, and even dominant negative mutants for specific PKC isoforms 
could have been employed. 
It was shown previously that an intact actin cytoskeleton is required for the 
translocation of glucose transporters (GLUT 1 , 3, and 4) and early signalling steps 
activated by insulin (232). In bovine pulmonary artery endothelial cells, it was shown that 
resveratrol (lOOflM)- induced cell elongation was abolished by cytochalasin D (CD), 
indicating that an intact actin cytoskeleton is required (361). As mentioned previously 
(Section 3.1.9), the fungal metabolite CD binds to the barbed end of the actin monomer 
or filament and affects actin polymerization to decrease actin filament formation (429). 
We used CD to examine the role of an intact actin network in resveratrol- stimulated 
glucose transport. CD treatment effectively inhibited both insulin- and resveratrol-
stimulated glucose transport, indicating that an intact actin network is required for both 
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stimuli. The fact that the response of the cells to resveratrol is sensitive to CD and the 
lack of potentiation of the maximal insulin response by resveratrol suggest that the 
resveratrol signalling pathway may converge with that of insulin. 
4.2 Resveratrol and amino acid transport. 
Insulin is a pleiotropic hormone and apart from stimulating glucose transport, it 
also stimulates amino acid transport in skeletal muscle (261). Amino acid transport is 
essential for protein synthesis and adaptive regulation in response to chronic amino acid 
deprivation (479) and is most commonly measured with the amino acid analogue MeAIB, 
which is specifically transported by the insulin- sensitive System A amino acid carrier 
(253). Currently the effect of resveratrol on amino acid uptake in skeletal muscle has not 
been examined. Since resveratrol stimulates glucose uptake similar to that of insulin, we 
wanted to examine whether resveratrol would mimic additional metabolic effects of 
insulin and examined MeAIB uptake in L6 myotubes. 
Insulin significantly increased MeAIB uptake, however resveratrol reduced both 
basal- and insulin- stimulated MeAIB transport. These results are similar to the vanadium 
compounds sodium orthovanadate and pervanadate, all of which increased glucose 
transport but decreased amino acid uptake (436). Future studies could focus on the 
mechanism of inhibition of amino acid transport by resveratrol, the mechanism may 
involve the reduction of the rate of amino acid transport through a decrease in the number 
of SNAT2 transporters (Vrnax) and subsequently decreasing SNAT2 translocation or 
activity and! or an increase in Km indicating a lower affinity for the amino acids to be 
transported into the cell. The reduction in insulin- stimulated amino acid transport by 
resveratrol may be due to inhibition of key signalling molecules required for insulin-
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stimulated amino acid transport, which would most likely occur downstream of PI3K and 
AktlPKB since insulin- stimulated Akt/PKB phosphorylation was not modified by 
resveratrol, suggesting that the PI3K1 AktlPKB pathway is not influenced. 
4.3 Resveratrol and mitogenesis. 
Insulin is well known for its metabolic effects, however it also has mitogenic 
properties. More specifically, insulin stimulates cell proliferation and differentiation 
(111; 112). FBS contains many growth factors (480) and it is widely used to stimulate cell 
growth. Numerous studies have shown that resveratrol has an inhibitory effect on cell 
growth and proliferation (328;331 ;335;346). Therefore we wanted to examine if 
resveratrol mimicked insulin action beyond its metabolic effects. We studied the effect of 
resveratrol on mitogenesis through measurement of tritiated thymidine incorporation into 
L6 myoblasts. We found that resveratrol inhibited mitogenesis as demonstrated by a 
decrease in thymidine incorporation, which is consistent with previous studies with 
resveratrol in various cancer cell lines (317;438;439). In addition, resveratrol completely 
abolished insulin- and FBS- stimulated cell proliferation. In the current study we used 
thymidine incorporation to measure cell proliferation but if we used bromodeoxyuridine 
(BrdU) staining where BrdU incorporation in cells in the S phase causes fluorescence 
(328), we would expect a similar result. Although cell viability was not directly 
measured, cell morphology was assessed with microscopic observation and was 
unaffected after chronic resveratrol treatment. 
Insulin stimulates ERK1I2 phosphorylation through the Ras- signalling pathway 
in order to promote cell proliferation and mitogenesis (96). Studies in several cancer and 
vascular smooth muscle cell lines have demonstrated that chronic resveratrol treatment 
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decreases ERK1I2 phosphorylation! activation and subsequently inhibits cell proliferation 
and mitogenesis (319;321 ;356;440). However resveratrol has also been shown to activate 
ERK1I2 (334;335;368). We previously found that acute resveratrol treatment did not 
phosphorylate ERK1I2 (Figure 21). Therefore, we attempted to elucidate the mechanism 
of resveratrol- inhibited mitogenesis by examining ERK1I2 phosphorylation through 
Western blot analysis. 
Our data show that acute resveratrol treatment abolished insulin- stimulated 
ERK1I2 phosphorylation but chronic resveratrol (24 h) did not affect ERK1I2 
phosphorylation and had no effect on insulin- or FBS- induced ERKl/2 phosphorylation. 
Perhaps the acute inhibition of insulin- and FBS- stimulated ERK1I2 phosphorylation by 
resveratrol is sufficient to block mitogenesis and ERK1I2 inhibition is reversed as a 
compensatory mechanism. In addition, even though the cell compensates by increasing 
ERK1I2 phosphorylation, this may not result in increased cell proliferation if resveratrol 
inhibits alternate signalling pathways involved in the regulation of cell proliferation. 
Alternatively, it is possible that resveratrol may restrict the phase of the cell cycle. Future 
experiments could address these possibilities by flow cytometry analysis or Western blot 
analysis ofthecyclins and cdks responsible for regulating cell cycle progression. 
p38 MAPK and JNK1I2 are also activated by growth factors such as insulin and 
although they are primarily involved in the mediation of apoptosis and inflammation, 
recent evidence has shown biological importance in regulating cell proliferation 
(151;201-203). Resveratrol has been shown to activate both p38 MAPK and JNK1I2 in 
different cell lines (334;336;365). Insulin also stimulates p38 MAPK activation in L6 
myotubes (441) through MKK3 and MKK6 activation (157) where prolonged insulin 
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treatment has been demonstrated to increase mitogenesis involving p38 MAPK activation 
in C2CI2 cells (442). Insulin stimulates JNKll2 activation in L6 myotubes as well, 
however its exact role is unknown (196). 
We examined the effect of acute and chronic (24 h) insulin, FBS, and resveratrol 
treatment on p38 MAPK and JNK1I2 phosphorylation through Western blot analysis. Our 
results indicate that acute resveratrol treatment did not increase p38 MAPK or JNK1I2 
phosphorylation but inhibited insulin- stimulated phosphorylation of the two kinases. 
Chronic resveratrol treatment did not affect insulin- or FBS- induced p38 MAPK or 
JNK1I2 phosphorylation. These data suggest that p38 MAPK and JNKll2 
phosphorylation is present after chronic resveratrol treatment even though it is inhibited 
during acute stimulation. Similar to ERKl/2 activation, it is possible that acute inhibition 
of insulin- and FBS- stimulated p38 MAPK and JNK1I2 phosphorylation by resveratrol is 
sufficient to block mitogenesis and inhibition of these MAPK members is reversed as a 
compensatory mechanism to promote cell survival. This compensation does not appear to 
be sufficient to increase cell proliferation, which may be explained if resveratrol inhibits 
additional signalling pathways involved in mitogenic regulation. JNK1I2 and p38 MAPK 
activation is often associated with apoptosis induction (334;336). The lack of inhibition 
of insulin- and FBS- mediated MAPK phosphorylation by resveratrol may be an indicator 
of apoptosis induction. Apoptosis was not examined in this study however future 
experiments could explore this possibility. 
In summary, the present study provides important insights into the role of 
resveratrol in glucose transport regulation in L6 skeletal muscle cells. Our results showed 
that resveratrol increases glucose uptake in a dose- and time- dependent fashion that is 
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independent of protein synthesis and does not require the presence of insulin. Resveratrol 
may act as an insulin sensitizer, however further studies are needed to establish this 
concept. Investigation into the mechanism of resveratrol- stimulated glucose uptake 
revealed that PI3K and an intact actin network are involved in signalling. However, 
AktlPKB, PKC, ERK1/2, p38 MAPK or JNK1I2 activation and GLUT4 translocation 
cannot explain the increase in glucose transport. Further investigation of this novel action 
is required. 
4.4 Significance of the Present Study 
Type 2 diabetes has a high prevalence worldwide. The increasing prevalence of 
type 2 diabetes may also increase the frequency of cardiovascular disease and other 
complications of diabetes. Insulin resistance or insulin insensitivity characterizes the 
disease where defects in the skeletal muscle glucose transport system are present 
(369;370). Therefore an in depth understanding of the glucose transport mechanism in 
skeletal muscle cells and the action of different compounds that stimulate glucose 
transport may provide new therapeutic approaches to overcome insulin resistance and 
type 2 diabetes mellitus. As previously mentioned, resveratrol has demonstrated 
significant positive health benefits as an antioxidant and anti- cardiovascular disease and 
anti- cancer agent. Recent studies have shown that resveratrol activates sirtuins, which 
have been implicated in longevity and improving insulin sensitivity in 3T3-Ll adipocytes 
(481 ). 
This study is the first study to examine the effects of resveratrol on glucose 
transport in one of the major insulin target tissues. Furthermore, our findings are novel 
since we discovered that resveratrol did in fact stimulate glucose uptake into L6 skeletal 
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muscle cells to levels similar to that of insulin independent of protein synthesis and the 
presence of insulin. The mechanism of resveratrol- stimulated glucose uptake is PI3K-
dependent and requires an intact actin network. However AktIPKB, PKC, ERK 112 , 
JNKI12, p38 MAPK, and GLUT4 translocation do not appear to be employed in 
resveratrol's action. Our results suggest that resveratrol may have potential for use 
against insulin resistance. Currently, several oral anti- diabetic drugs are used to manage 
type 2 diabetes, however it would be beneficial if this drugs had a positive pleiotropic 
effect on health. Resveratrol has demonstrated positive health benefits in several major 
diseases, including cancer and cardiovascular disease. In addition, our study is the first 
step in this exciting new area of research and indicates that resveratrol's actions/ effects 
should be considered for further studies in animal models as a possible anti- diabetic 
drug. 
4.5 Future Directions 
Our research concentrated on the in vitro effects of resveratrol in L6 skeletal 
muscle cells and therefore may be extended to new in vitro models examining alternate 
insulin target tissues and in vivo models to study glucose transport. Furthermore, 
significant study is still required to further delineate the mechanism of action of 
resveratrol- stimulated glucose uptake in L6 skeletal muscle cells. This analysis could 
include examination of the GLUTI and GLUT3 glucose transporters or the AMPK and 
cbl- signalling pathways. Future studies could also examine: 
1) The effects of resveratrol on glucose transport in intact skeletal muscle. 
2) The effects of resveratrol on glucose transport and glucose homeostasis in a rat in 
vivo model of insulin resistance. 
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3) The effects of resveratrol on glucose transport in adipocytes. 
4) The effects of resveratrol on gluconeogenesis, glycogenolysis, and glucose release 
in hepatocytes, another insulin target tissue. 
5) The effects of resveratrol on insulin secretion in pancreatic beta cells. 
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